##### Table of Contents





UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549





FORM 10-Q





(Mark One)

|x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ---------------------------------------------------------------------------------------

For the quarterly period ending March 31, 2011



| ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ----------------------------------------------------------------------------------------

For the transition period from  to

Commission File Number:
000-29101





SEQUENOM, INC.

(Exact name of registrant as specified in its charter)







|                                                               |  |                                        
|-------------------------------------------------------------- |  | ---------------------------------------
|DELAWARE                                                       |  | 77-0365889                             
|(State or other jurisdiction of
incorporation or organization) |  | (I.R.S. Employer Identification Number)



|                                              |  |           
|--------------------------------------------- |  | ----------
|3595 John Hopkins Court San Diego, California |  | 92121     
|(Address of principal executive offices)      |  | (Zip Code)

Registrants telephone number, including area code: (858) 202-9000





Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.    x  Yes     ̈  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files).     ̈  Yes     ̈  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller
reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.



|                        |  |                                                  |  |                                 |  |  
|----------------------- |  | ------------------------------------------------ |  | ------------------------------- |  | -
|Large accelerated filer |  |  ̈                                                |  | Accelerated filer               |  | x
|                        |  |                                                  | 
|Non-accelerated filer   |  |  ̈  (Do not check if a smaller reporting company) |  | Smaller reporting company filer |  |  ̈

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).    Yes   ̈    No  x

The number of shares of the Registrants Common Stock outstanding as of April 29, 2011, was 99,057,011.









---

##### Table of Contents

SEQUENOM, INC.

INDEX



|                               |  |                                                                                                                |  |          |    | 
|------------------------------ |  | -------------------------------------------------------------------------------------------------------------- |  | -------- | -- | 
|                               |  |                                                                                                                |  | Page No. |   
|                              
|PART I - FINANCIAL INFORMATION | 
|                               |  |                                                                                                               
|Item 1.                        |  | Financial Statements                                                                                           |  |          | 3  | 
|                               |  |                                                                                                               
|                               |  | Condensed Consolidated Balance Sheets  as of March 31, 2011 (unaudited) and December 31, 2010                 |  |          | 3  | 
|                               |  |                                                                                                               
|                               |  | Condensed Consolidated Statements of Operations for the three months ended March 31, 2011 and 2010 (unaudited) |  |          | 4  | 
|                               |  |                                                                                                               
|                               |  | Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2011 and 2010 (unaudited) |  |          | 5  | 
|                               |  |                                                                                                               
|                               |  | Notes to Unaudited Condensed Consolidated Financial Statements                                                 |  |          | 6  | 
|                               |  |                                                                                                               
|Item 2.                        |  | Managements Discussion and Analysis of Financial Condition and Results of Operations                          |  |          | 18 | 
|                               |  |                                                                                                               
|Item 3.                        |  | Quantitative and Qualitative Disclosures About Market Risk                                                     |  |          | 27 | 
|                               |  |                                                                                                               
|Item 4.                        |  | Controls and Procedures                                                                                        |  |          | 28 | 
|                              
|PART II  OTHER INFORMATION    | 
|                               |  |                                                                                                               
|Item 1.                        |  | Legal Proceedings                                                                                              |  |          | 29 | 
|                               |  |                                                                                                               
|Item 1A.                       |  | Risk Factors                                                                                                   |  |          | 32 | 
|                               |  |                                                                                                               
|Item 5.                        |  | Other Information                                                                                              |  |          | 52 | 
|                               |  |                                                                                                               
|Item 6.                        |  | Exhibits                                                                                                       |  |          | 54 | 



2



---

##### Table of Contents

PART I - FINANCIAL INFORMATION



|Item 1. | Financial Statements
|------- | --------------------

SEQUENOM, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value and share information)



|                                                                                                                                                                             |  |               |          |   |                  |   |          |  
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | ------------- | -------- | - | ---------------- | - | -------- | -
|                                                                                                                                                                             |  | March 31,2011 |          |   | December 31,2010 |  
|                                                                                                                                                                             |  | (Unaudited)   |          |   |                  |  
|Assets                                                                                                                                                                       |  |               |          |   |                  |   |          |  
|Current assets:                                                                                                                                                              |  |               |          |   |                  |   |          |  
|Cash and cash equivalents                                                                                                                                                    |  | $             | 35,035   |   |                  | $ | 116,647  |  
|Marketable securities                                                                                                                                                        |  |               | 90,233   |   |                  |   | 18,833   |  
|Restricted cash                                                                                                                                                              |  |               | 76       |   |                  |   | 1,404    |  
|Accounts receivable, net                                                                                                                                                     |  |               | 6,827    |   |                  |   | 6,911    |  
|Inventories                                                                                                                                                                  |  |               | 5,380    |   |                  |   | 5,605    |  
|Other current assets and prepaid expenses                                                                                                                                    |  |               | 2,576    |   |                  |   | 2,387    |  
|                                                                                                                                                                             |  |               |          |   |                  |   |          |  
|Total current assets                                                                                                                                                         |  |               | 140,127  |   |                  |   | 151,787  |  
|Equipment and leasehold improvements, net                                                                                                                                    |  |               | 11,108   |   |                  |   | 11,038   |  
|Intangible assets, net                                                                                                                                                       |  |               | 682      |   |                  |   | 773      |  
|Goodwill                                                                                                                                                                     |  |               | 10,007   |   |                  |   | 10,007   |  
|Other assets                                                                                                                                                                 |  |               | 676      |   |                  |   | 674      |  
|                                                                                                                                                                             |  |               |          |   |                  |   |          |  
|Total assets                                                                                                                                                                 |  | $             | 162,600  |   |                  | $ | 174,279  |  
|                                                                                                                                                                             |  |               |          |   |                  |   |          |  
|Liabilities and stockholders equity                                                                                                                                         |  |               |          |   |                  |   |          |  
|Current liabilities:                                                                                                                                                         |  |               |          |   |                  |   |          |  
|Accounts payable                                                                                                                                                             |  | $             | 5,500    |   |                  | $ | 5,958    |  
|Accrued expenses                                                                                                                                                             |  |               | 7,752    |   |                  |   | 9,947    |  
|Deferred revenue                                                                                                                                                             |  |               | 3,121    |   |                  |   | 2,624    |  
|Current portion of debt and obligations                                                                                                                                      |  |               | 906      |   |                  |   | 938      |  
|                                                                                                                                                                             |  |               |          |   |                  |   |          |  
|Total current liabilities                                                                                                                                                    |  |               | 17,279   |   |                  |   | 19,467   |  
|Deferred revenue, less current portion                                                                                                                                       |  |               | 668      |   |                  |   | 518      |  
|Other long-term liabilities                                                                                                                                                  |  |               | 2,459    |   |                  |   | 2,660    |  
|Long-term portion of debt and obligations                                                                                                                                    |  |               | 675      |   |                  |   | 902      |  
|Commitments and contingencies                                                                                                                                                |  |               |          |   |                  |   |          |  
|Stockholders equity:                                                                                                                                                        |  |               |          |   |                  |   |          |  
|Convertible preferred stock, par value $0.001; 5,000,000 shares authorized, no shares issued or outstanding at March 31,
2011 and December 31, 2010, respectively            |  |               |         |   |                  |   |         |  
|Common stock, par value $0.001; 185,000,000 shares authorized, 98,986,440 and 98,849,381 shares issued and outstanding at
March 31, 2011 and December 31, 2010, respectively |  |               | 99       |   |                  |   | 99       |  
|Additional paid-in capital                                                                                                                                                   |  |               | 871,156  |   |                  |   | 867,977  |  
|Accumulated other comprehensive income                                                                                                                                       |  |               | 1,065    |   |                  |   | 786      |  
|Accumulated deficit                                                                                                                                                          |  |               | (730,801 | ) |                  |   | (718,130 | )
|                                                                                                                                                                             |  |               |          |   |                  |   |          |  
|Total stockholders equity                                                                                                                                                   |  |               | 141,519  |   |                  |   | 150,732  |  
|                                                                                                                                                                             |  |               |          |   |                  |   |          |  
|Total liabilities and stockholders equity                                                                                                                                   |  | $             | 162,600  |   |                  | $ | 174,279  |  
|                                                                                                                                                                             |  |               |          |   |                  |   |          |  

See accompanying notes.



3



---

##### Table of Contents

SEQUENOM, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share information)



|                                                                                  |  |                             |         |   |      |   |         |  
|--------------------------------------------------------------------------------- |  | --------------------------- | ------- | - | ---- | - | ------- | -
|                                                                                  |  | Three months endedMarch 31, |        
|                                                                                  |  | 2011                        |         |   | 2010 |  
|                                                                                  |  | (Unaudited)                 |        
|Revenues:                                                                         |  |                             |         |   |      |   |         |  
|Consumables                                                                       |  | $                           | 5,303   |   |      | $ | 5,143   |  
|MassARRAY systems and other product related                                       |  |                             | 5,843   |   |      |   | 4,776   |  
|Contract research services                                                        |  |                             | 698     |   |      |   | 481     |  
|Diagnostic                                                                        |  |                             | 1,666   |   |      |   | 204     |  
|Research and other                                                                |  |                             |        |   |      |   | 6       |  
|                                                                                  |  |                             |         |   |      |   |         |  
|Total revenues                                                                    |  |                             | 13,510  |   |      |   | 10,610  |  
|                                                                                  |  |                             |         |   |      |   |         |  
|Cost of revenues:                                                                 |  |                             |         |   |      |   |         |  
|Cost of consumables and products revenue                                          |  |                             | 3,318   |   |      |   | 3,962   |  
|Cost of contract research services revenue                                        |  |                             | 140     |   |      |   | 114     |  
|Cost of diagnostic revenue (excludes amortization of purchased intangible assets) |  |                             | 1,555   |   |      |   | 1,181   |  
|                                                                                  |  |                             |         |   |      |   |         |  
|Total cost of revenues                                                            |  |                             | 5,013   |   |      |   | 5,257   |  
|                                                                                  |  |                             |         |   |      |   |         |  
|Gross margin                                                                      |  |                             | 8,497   |   |      |   | 5,353   |  
|                                                                                  |  |                             |         |   |      |   |         |  
|Operating expenses:                                                               |  |                             |         |   |      |   |         |  
|Research and development                                                          |  |                             | 10,722  |   |      |   | 11,191  |  
|Selling and marketing                                                             |  |                             | 6,060   |   |      |   | 6,188   |  
|General and administrative                                                        |  |                             | 4,838   |   |      |   | 4,894   |  
|                                                                                  |  |                             |         |   |      |   |         |  
|Total operating expenses                                                          |  |                             | 21,620  |   |      |   | 22,273  |  
|                                                                                  |  |                             |         |   |      |   |         |  
|Loss from operations                                                              |  |                             | (13,123 | ) |      |   | (16,920 | )
|Other income, net                                                                 |  |                             | 404     |   |      |   | 5       |  
|                                                                                  |  |                             |         |   |      |   |         |  
|Loss before income taxes                                                          |  |                             | (12,719 | ) |      |   | (16,915 | )
|Income tax benefit (expense)                                                      |  |                             | 49      |   |      |   | (33     | )
|                                                                                  |  |                             |         |   |      |   |         |  
|Net loss                                                                          |  | $                           | (12,670 | ) |      | $ | (16,948 | )
|                                                                                  |  |                             |         |   |      |   |         |  
|Net loss per common share, basic and diluted                                      |  | $                           | (0.13   | ) |      | $ | (0.27   | )
|                                                                                  |  |                             |         |   |      |   |         |  
|Weighted average shares outstanding, basic and diluted                            |  |                             | 98,929  |   |      |   | 62,085  |  
|                                                                                  |  |                             |         |   |      |   |         |  

See accompanying notes.



4



---

##### Table of Contents

SEQUENOM, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)



|                                                                            |  |                             |         |   |      |   |         |  
|--------------------------------------------------------------------------- |  | --------------------------- | ------- | - | ---- | - | ------- | -
|                                                                            |  | Three months endedMarch 31, |        
|                                                                            |  | 2011                        |         |   | 2010 |  
|                                                                            |  | (Unaudited)                 |        
|Operating activities                                                        |  |                             |         |   |      |   |         |  
|Net loss                                                                    |  | $                           | (12,670 | ) |      | $ | (16,948 | )
|Adjustments to reconcile net loss to net cash used in operating activities: |  |                             |         |   |      |   |         |  
|Stock-based compensation                                                    |  |                             | 2,263   |   |      |   | 2,422   |  
|Restricted stock                                                            |  |                             | 339     |   |      |   | 595     |  
|Depreciation and amortization                                               |  |                             | 1,410   |   |      |   | 1,361   |  
|Deferred rent                                                               |  |                             | (200    | ) |      |   | (167    | )
|Other non-cash items                                                        |  |                             | (51     | ) |      |   | 3       |  
|Changes in operating assets and liabilities:                                |  |                             |         |   |      |   |         |  
|Accounts receivable, net                                                    |  |                             | 207     |   |      |   | (302    | )
|Inventories                                                                 |  |                             | 274     |   |      |   | 1,530   |  
|Prepaid expenses and other assets                                           |  |                             | (170    | ) |      |   | (210    | )
|Accounts payable and accrued expenses                                       |  |                             | (2,687  | ) |      |   | (1,846  | )
|Deferred revenue                                                            |  |                             | 547     |   |      |   | 276     |  
|Other liabilities                                                           |  |                             | (15     | ) |      |   | (139    | )
|                                                                            |  |                             |         |   |      |   |         |  
|Net cash used in operating activities                                       |  |                             | (10,753 | ) |      |   | (13,425 | )
|Investing activities                                                        |  |                             |         |   |      |   |         |  
|Purchases of equipment and leasehold improvements                           |  |                             | (1,368  | ) |      |   | (223    | )
|Purchases of marketable securities                                          |  |                             | (76,166 | ) |      |   | (19     | )
|Proceeds from sales of marketable securities                                |  |                             |        |   |      |   | 471     |  
|Maturities of marketable securities                                         |  |                             | 4,880   |   |      |   | 15,000  |  
|Release of (increase in) restricted cash                                    |  |                             | 1,330   |   |      |   | (3      | )
|                                                                            |  |                             |         |   |      |   |         |  
|Net cash (used in) provided by investing activities                         |  |                             | (71,324 | ) |      |   | 15,226  |  
|Financing activities                                                        |  |                             |         |   |      |   |         |  
|Proceeds from exercise of stock options and ESPP purchases                  |  |                             | 575     |   |      |   | 570     |  
|Payments on debt                                                            |  |                             | (229    | ) |      |   | (342    | )
|Payments on capital lease obligation                                        |  |                             | (30     | ) |      |   | (28     | )
|                                                                            |  |                             |         |   |      |   |         |  
|Net cash provided by financing activities                                   |  |                             | 316     |   |      |   | 200     |  
|                                                                            |  |                             |         |   |      |   |         |  
|Net (decrease) increase in cash and cash equivalents                        |  |                             | (81,761 | ) |      |   | 2,001   |  
|Effect of exchange rate changes on cash and cash equivalents                |  |                             | 149     |   |      |   | (83     | )
|Cash and cash equivalents at beginning of period                            |  |                             | 116,647 |   |      |   | 26,919  |  
|                                                                            |  |                             |         |   |      |   |         |  
|Cash and cash equivalents at end of period                                  |  | $                           | 35,035  |   |      | $ | 28,837  |  
|                                                                            |  |                             |         |   |      |   |         |  

See accompanying notes.



5



---

##### Table of Contents

SEQUENOM, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(1) Summary of Significant
Accounting Policies and Significant Accounts

Nature of the Business

We are a molecular diagnostic testing and genetics analysis company committed to providing products, services, applications, and genetic analysis products that translate the results of genomic science
into solutions for biomedical research, translational research, molecular medicine applications, and agricultural, livestock, and other areas of research. Our development and commercialization efforts in various diagnostic areas include noninvasive
womens health-related and prenatal diagnostics, ophthalmology, oncology, infectious diseases, and other medical conditions, disorders and diseases.

Basis of Presentation

The accompanying unaudited condensed consolidated financial
statements of Sequenom, Inc. have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) with the instructions to Form 10-Q and Article 10 of Regulation S-X and include the accounts of Sequenom, Inc. and our
wholly-owned subsidiaries located in the United States, Germany, the United Kingdom, Japan, India and Hong Kong. All significant intercompany accounts and transactions are eliminated in consolidation. These statements do not include all of the
information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments considered necessary for a fair presentation of the financial information have
been included. Interim results are not necessarily indicative of results for a full year or any other period(s). Certain reclassifications have been made to the prior period amounts in order to conform to the current presentation.

The condensed consolidated balance sheet at December 31, 2010 has been derived from the audited financial statements at that date, but does not
include all of the information and disclosures required by GAAP for complete financial statements. Subsequent events were evaluated by management through the date of filing of this Form 10-Q.

These financial statements should be read in conjunction with the audited financial statements and disclosures included in our Annual Report on Form 10-K for the year ended December 31, 2010, as
filed with the Securities and Exchange Commission (SEC) on March 8, 2011.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires us to make certain estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those
estimates.

Revenue Recognition

Revenues are recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed and determinable, and collectability is reasonably
assured. Revenue is deferred for fees received before earned. Revenues from sales of consumables are recognized generally upon shipment and transfer of title to the customer. Revenue from sales of MassARRAY systems with standard payment terms of net
90 days or less are recognized upon shipment and transfer of title to the customer and when all revenue recognition criteria are met. Our contracts do not contain refund or cancellation clauses. Revenues from the sale or licensing of our proprietary
software are recognized upon transfer of title to the customer. We recognize revenue on maintenance services for ongoing customer support over the maintenance period.

In October 2009, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2009-13, Multiple-Deliverable Revenue Arrangements. The new standard changes the
requirements for establishing separate units of accounting in a multiple element arrangement and requires the allocation of arrangement consideration to each deliverable to be based on the relative selling price. We adopted the standard and
effective as of January 1, 2011, when a sales arrangement contains multiple elements, such as hardware and software products, licenses and/or services, we allocate revenue to each element based on a selling price hierarchy. The selling price
for a deliverable is based on its vendor specific objective evidence (VSOE) if available, third party evidence (TPE) if VSOE is not available, or estimated selling price (ESP) if neither VSOE nor TPE is available. We limit the amount of revenue
recognition for delivered elements to the amount that is not contingent on the future delivery of products or services, future performance obligations or subject to customer-specified return or refund privileges.

We evaluate deliverables in an arrangement to determine whether each represents a separate unit of accounting. A deliverable constitutes a separate unit
of accounting when it has standalone value and there are no customer-negotiated refund or return rights for the delivered elements. If the arrangement includes a customer-negotiated refund or return right relative to the delivered item and the
delivery and performance of the undelivered item is considered probable and substantially in our control, the delivered element constitutes a separate unit of accounting. In instances when the aforementioned criteria are not met, the deliverable is
combined with the undelivered elements and the allocation of the arrangement consideration and revenue recognition is determined for the combined unit as a single unit. Allocation of the consideration is determined by management at the arrangement
inception on the basis of each units relative selling price.



6



---

##### Table of Contents

We establish VSOE of selling price using the price charged for a deliverable when sold separately and, in
rare instances, using the price established by management having the relevant authority. TPE of selling price is established by evaluating largely similar and interchangeable competitor products or services in standalone sales to similarly situated
customers. The best estimate of selling price is established considering internal factors such as margin objectives, pricing practices and controls, customer segment pricing strategies and the product lifecycle.

Revenues from genetic services are recognized at the completion of key stages in the performance of the service, which is generally delivery of single
nucleotide polymorphism (SNP) assay information. Grant revenue is recorded as the research expenses relating to the grants are incurred, provided that the amounts received are not refundable if the research is not successful. Amounts received that
are refundable if the research is not successful would be recorded as deferred revenue and recognized as revenue upon the grantors acceptance of the success of the research results.

Diagnostic revenues from Sequenom CMMs cystic fibrosis carrier screening and fetal Rhesus D genotyping laboratory developed tests, which were commercially launched in September 2009 and February
2010, respectively, have been recognized on a cash basis due to the limited number of contract or agreements with third-party payors and limited collections experience. We generally bill third-party payors upon generation and delivery of a report to
the physician. As such, we take assignment of benefits and risk of collection with the third-party payor. We usually bill the patient directly for amounts not covered by their insurance carrier in the form of co-pays and deductibles, but only after
multiple requests for full payment have been denied or only partially paid by the insurance carrier. Some payors may not cover our test as ordered by the physician under their reimbursement policies. Consequently, we pursue case-by-case
reimbursement where policies are not in place.

Collaboration, Development and Licensing Agreements

We enter into license agreements and collaborative research and development arrangements with partners that may involve multiple deliverables. Our
arrangements may contain one or more of the following elements: upfront fees, milestone payments, royalties and license fees. Each deliverable in the arrangement is evaluated to determine whether it meets the criteria to be accounted for as a
separate unit of accounting or whether it should be combined with other deliverables. Revenue is recognized for each element when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and
collection is reasonably assured.

Upfront fees received for license and collaborative agreements are recognized ratably over our expected
performance period under the arrangement. Management makes its best estimate of the period over which we expect to fulfill our performance obligations. Given the uncertainties of research and development collaborations, significant judgment is
required to determine the duration of the performance period.

In April 2010, the FASB issued ASU No. 2010-17, Revenue Recognition
 Milestone Method,which provides guidance on the criteria that should be met for determining whether the milestone method of revenue recognition is appropriate. We adopted the standard and, effective as of January 1, 2011, we can
recognize consideration that is contingent upon achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved if the milestone meets all the criteria to be considered substantive. If the milestone is not
substantive, the payment is generally recognized as revenue over the remaining service period. We do not expect to receive any milestone revenue from our current collaboration agreements.

Cash and Cash Equivalents

Cash equivalents consist of short-term, highly liquid
investments with original maturities of three months or less when purchased.

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard
describes three levels of inputs that may be used to measure fair value:

Level 1 - Quoted prices in active markets for identical
assets or liabilities.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or
liability, either directly or indirectly. These inputs include quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for
substantially the full term of the assets or liabilities.

Level 3 - Unobservable inputs that are supported by little or no market
activity and that are significant to the fair value of the assets or liabilities.



7



---

##### Table of Contents

The following table presents our fair value hierarchy for assets and liabilities, net of cash, measured at
fair value on a recurring basis at March 31, 2011 (in thousands):



|                                                 |  |       |         |  |         |   |        |         |  |   |         |  |  |   |   | 
|------------------------------------------------ |  | ----- | ------- |  | ------- | - | ------ | ------- |  | - | ------- |  |  | - | - | 
|Description                                      |  | Total |         |  | Level 1 |   |        | Level 2 |  |   | Level 3 | 
|Cash equivalents                                 |  | $     | 24,750  |  |         | $ | 24,750 |         |  | $ |        |  |  | $ |  | 
|Debt securities in government sponsored entities |  |       | 5,064   |  |         |   |       |         |  |   | 5,064   |  |  |   |  | 
|Corporate debt securities                        |  |       | 12,885  |  |         |   |       |         |  |   | 12,885  |  |  |   |  | 
|Mutual funds                                     |  |       | 382     |  |         |   | 382    |         |  |   |        |  |  |   |  | 
|Certificates of deposit                          |  |       | 6,991   |  |         |   |       |         |  |   | 6,991   |  |  |   |  | 
|U.S. treasury securities                         |  |       | 64,911  |  |         |   | 64,911 |         |  |   |        |  |  |   |  | 
|                                                 |  |       |         |  |         |   |        |         |  |   |         |  |  |   |   | 
|Total                                            |  | $     | 114,983 |  |         | $ | 90,043 |         |  | $ | 24,940  |  |  | $ |  | 
|                                                 |  |       |         |  |         |   |        |         |  |   |         |  |  |   |   | 

The following table sets forth our fair value hierarchy for assets and liabilities, net of cash, measured at fair value on a
recurring basis as of December 31, 2010 (in thousands):



|                                                 |  |       |         |  |         |   |         |         |  |   |         |  |  |   |   | 
|------------------------------------------------ |  | ----- | ------- |  | ------- | - | ------- | ------- |  | - | ------- |  |  | - | - | 
|Description                                      |  | Total |         |  | Level 1 |   |         | Level 2 |  |   | Level 3 | 
|Cash equivalents                                 |  | $     | 107,126 |  |         | $ | 107,126 |         |  | $ |        |  |  | $ |  | 
|Restricted cash                                  |  |       | 1,404   |  |         |   | 1,404   |         |  |   |        |  |  |   |  | 
|Debt securities in government sponsored entities |  |       | 5,060   |  |         |   |        |         |  |   | 5,060   |  |  |   |  | 
|Corporate debt securities                        |  |       | 3,021   |  |         |   |        |         |  |   | 3,021   |  |  |   |  | 
|Mutual funds                                     |  |       | 382     |  |         |   | 382     |         |  |   |        |  |  |   |  | 
|Certificates of deposit                          |  |       | 5,372   |  |         |   |        |         |  |   | 5,372   |  |  |   |  | 
|U.S. treasury securities                         |  |       | 4,998   |  |         |   | 4,998   |         |  |   |        |  |  |   |  | 
|                                                 |  |       |         |  |         |   |         |         |  |   |         |  |  |   |   | 
|Total                                            |  | $     | 127,363 |  |         | $ | 113,910 |         |  | $ | 13,453  |  |  | $ |  | 
|                                                 |  |       |         |  |         |   |         |         |  |   |         |  |  |   |   | 

Beginning in the first quarter of 2011, we began to classify debt securities and certificates of deposit in Level 2 of the
fair value hierarchy instead of Level 1 in order to be consistent with industry practice. There were no transfers in or out of Level 2 and Level 3 investments during the three months ended March 31, 2011 or during the year ended
December 31, 2010.

Marketable securities

The following is a summary of our marketable securities (in thousands):



|                                                 |  |               |        |  |                      |   |     |                       |  |   |                     |   |  |   |        | 
|------------------------------------------------ |  | ------------- | ------ |  | -------------------- | - | --- | --------------------- |  | - | ------------------- | - |  | - | ------ | 
|                                                 |  |               |        |  | March 31, 2011       |   |     |                       | 
|                                                 |  | AmortizedCost |        |  | GrossUnrealizedGains |   |     | GrossUnrealizedLosses |  |   | EstimatedFair Value |  
|Debt securities in government sponsored entities |  | $             | 5,062  |  |                      | $ | 2   |                       |  | $ |                    |   |  | $ | 5,064  | 
|Corporate debt securities                        |  |               | 12,883 |  |                      |   | 4   |                       |  |   | (2                  | ) |  |   | 12,885 | 
|Mutual funds                                     |  |               | 217    |  |                      |   | 165 |                       |  |   |                    |   |  |   | 382    | 
|Certificates of deposit                          |  |               | 6,996  |  |                      |   |    |                       |  |   | (5                  | ) |  |   | 6,991  | 
|U.S. treasury securities                         |  |               | 64,899 |  |                      |   | 15  |                       |  |   | (3                  | ) |  |   | 64,911 | 
|                                                 |  |               |        |  |                      |   |     |                       |  |   |                     |   |  |   |        | 
|Total available-for-sale securities              |  | $             | 90,057 |  |                      | $ | 186 |                       |  | $ | (10                 | ) |  | $ | 90,233 | 
|                                                 |  |               |        |  |                      |   |     |                       |  |   |                     |   |  |   |        | 



8



---

##### Table of Contents

|                                                 |  |               |        |  |                      |   |     |                       |  |   |                     |   |  |   |        | 
|------------------------------------------------ |  | ------------- | ------ |  | -------------------- | - | --- | --------------------- |  | - | ------------------- | - |  | - | ------ | 
|                                                 |  |               |        |  | December 31, 2010    |   |     |                       | 
|                                                 |  | AmortizedCost |        |  | GrossUnrealizedGains |   |     | GrossUnrealizedLosses |  |   | EstimatedFair Value |  
|Debt securities in government sponsored entities |  | $             | 5,056  |  |                      | $ | 4   |                       |  | $ |                    |   |  | $ | 5,060  | 
|Corporate debt securities                        |  |               | 3,021  |  |                      |   |    |                       |  |   |                    |   |  |   | 3,021  | 
|Mutual funds                                     |  |               | 237    |  |                      |   | 145 |                       |  |   |                    |   |  |   | 382    | 
|Certificates of deposit                          |  |               | 5,376  |  |                      |   |    |                       |  |   | (4                  | ) |  |   | 5,372  | 
|U.S. treasury securities                         |  |               | 4,994  |  |                      |   | 4   |                       |  |   |                    |   |  |   | 4,998  | 
|                                                 |  |               |        |  |                      |   |     |                       |  |   |                     |   |  |   |        | 
|Total available-for-sale securities              |  | $             | 18,684 |  |                      | $ | 153 |                       |  | $ | (4                  | ) |  | $ | 18,833 | 
|                                                 |  |               |        |  |                      |   |     |                       |  |   |                     |   |  |   |        | 

As of March 31, 2011, we had 34 available-for-sale securities in a gross unrealized loss position, which had been in
such position for less than twelve months. There were no unrealized losses due to credit issues for the periods presented. There were no impairments considered other-than-temporary as it is more likely than not we will hold the securities until
maturity or a recovery of the cost basis. The following table shows the fair values and the gross unrealized losses of our available-for-sale securities that were in an unrealized loss position as of March 31, 2011 and December 31, 2010
aggregated by investment category (in thousands):



|                          |  |                |        |  |                       |   |     |            |  |   |                       |  |  |   |    |  
|------------------------- |  | -------------- | ------ |  | --------------------- | - | --- | ---------- |  | - | --------------------- |  |  | - | -- | -
|                          |  | March 31, 2011 |        |  | December 31, 2010     |  
|                          |  | Fair Value     |        |  | GrossUnrealizedLosses |   |     | Fair Value |  |   | GrossUnrealizedLosses | 
|Corporate debt securities |  | $              | 5,525  |  |                       | $ | (2  | )          |  | $ |                      |  |  | $ |   |  
|Certificates of deposit   |  |                | 6,024  |  |                       |   | (5  | )          |  |   | 4,691                 |  |  |   | (4 | )
|U.S. treasury securities  |  |                | 19,970 |  |                       |   | (3  | )          |  |   |                      |  |  |   |   |  
|                          |  |                |        |  |                       |   |     |            |  |   |                       |  |  |   |    |  
|Total                     |  | $              | 31,519 |  |                       | $ | (10 | )          |  | $ | 4,691                 |  |  | $ | (4 | )
|                          |  |                |        |  |                       |   |     |            |  |   |                       |  |  |   |    |  

Realized gains and losses are determined based on the specific identification method and are reported in other income, net
in the condensed consolidated statements of operations. Gross realized gains and losses on sales of available-for-sale securities were immaterial for the three months ended March 31, 2011 and 2010. As of March 31, 2011, all of our
available-for-sale securities are due within one year.

Goodwill and Purchased Intangible Assets

Goodwill is recorded when the consideration paid for an acquisition exceeds the fair value of the identified net tangible and intangible assets of
acquired businesses. The allocation of purchase price for acquisitions requires extensive use of accounting estimates and judgments to allocate the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed
based on their respective fair values. Additionally, we must determine whether an acquired entity is considered to be a business or a set of net assets, because a portion of the purchase price can only be allocated to goodwill in a business
combination. Goodwill and intangible assets deemed to have indefinite lives are not amortized, but are subject to annual impairment tests. The amounts and useful lives assigned to other intangible assets, such as lab accreditations, patent rights
and licenses, requires the use of estimates and the exercise of judgment. These judgments can significantly affect our net operating results. As of March 31, 2011 and December 31, 2010, we had goodwill recorded of $10.0 million,
respectively.

We annually evaluate our goodwill and purchased intangible assets at the reporting unit level during the fourth quarter of each
fiscal year or more frequently if we believe indicators of impairment are present.

Accounts Receivable

Trade accounts receivable are recorded at net invoice values. We consider receivables past due based on the contractual payment terms. We review our
exposure to amounts receivable and reserve specific amounts if collectability is no longer reasonably assured. We also reserve a percentage of our trade receivable balance based on collection history. We re-evaluate such reserves on a regular basis
and adjust our reserves as needed. Amounts determined to be uncollectible are charged or written off against the reserve.



9



---

##### Table of Contents

Inventories

Inventories are stated at the lower of cost (first-in, first-out) or market value (net realizable value). The components of inventories were as follows (in thousands):



|                |  |               |       |  |                  |   |       | 
|--------------- |  | ------------- | ----- |  | ---------------- | - | ----- | 
|                |  | March 31,2011 |       |  | December 31,2010 |  
|Raw materials   |  | $             | 3,755 |  |                  | $ | 3,738 | 
|Work in process |  |               | 22    |  |                  |   | 45    | 
|Finished goods  |  |               | 1,603 |  |                  |   | 1,822 | 
|                |  |               |       |  |                  |   |       | 
|Total           |  | $             | 5,380 |  |                  | $ | 5,605 | 
|                |  |               |       |  |                  |   |       | 

Inventories are shown net of reserves of $1.9 million and $1.5 million at March 31, 2011 and December 31, 2010,
respectively.

Reserves for Obsolete and Slow-moving Inventory

We operate in an industry characterized by rapid improvements and changes to our technology and products. The introduction of new products by us or our competitors can result in our inventory being
rendered obsolete or requiring us to sell items at a discount. We estimate the recoverability of our inventory by reference to our internal estimates of future demands and product life cycles. If we incorrectly forecast demand for our products or
inadequately manage the introduction of new product lines, we could materially impact our consolidated financial statements by having excess inventory on hand. Our future estimates are subjective and could be incorrect. During the three months ended
March 31, 2011, slow-moving and obsolete inventory specific reserves of $0.3 million, net, were charged against cost of goods sold and the reserve was $1.3 million and $1.0 million at March 31, 2011 and December 31, 2010,
respectively.

Equipment and Leasehold Improvements

Equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally 3 to 5 years). Leasehold improvements are amortized using the
straight-line method over the estimated useful life of the improvement or the remaining term of the lease, whichever is shorter. The maximum estimated useful life of any leasehold improvement is 15 years from the completion of the improvement.
Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating expense.

Equipment and leasehold improvements and related accumulated depreciation and amortization were as follows (in thousands):



|                                               |  |               |         |   |                  |   |         |  
|---------------------------------------------- |  | ------------- | ------- | - | ---------------- | - | ------- | -
|                                               |  | March 31,2011 |         |   | December 31,2010 |  
|Laboratory equipment                           |  | $             | 24,223  |   |                  | $ | 23,562  |  
|Leasehold improvements                         |  |               | 5,330   |   |                  |   | 5,319   |  
|Office furniture and equipment                 |  |               | 12,405  |   |                  |   | 11,900  |  
|                                               |  |               |         |   |                  |   |         |  
|                                               |  |               | 41,958  |   |                  |   | 40,781  |  
|Less accumulated depreciation and amortization |  |               | (30,850 | ) |                  |   | (29,743 | )
|                                               |  |               |         |   |                  |   |         |  
|Equipment and leasehold improvements, net      |  | $             | 11,108  |   |                  | $ | 11,038  |  
|                                               |  |               |         |   |                  |   |         |  

Depreciation expense for the three months ended March 31, 2011 and 2010 was $1.3 million and $1.3 million,
respectively.

Warranty Cost and Reserves

We record a warranty provision related to the sales of our MassARRAY system based on our historical experience of returns and repairs required under the warranty period. We generally provide a one-year
warranty on our MassARRAY system. We establish an accrual for estimated warranty expenses associated with system sales based on historical amounts. This expense is recorded as a component of cost of product revenue. Changes in our warranty liability
during the three months ended March 31, 2011 were as follows (in thousands):



|                                      |  |   |     | 
|------------------------------------- |  | - | --- | 
|Balance as of December 31, 2010       |  | $ | 152 | 
|Additions charged to cost of revenues |  |   | 10  | 
|Repairs and replacements              |  |   |    | 
|                                      |  |   |     | 
|Balance as of March 31, 2011          |  | $ | 162 | 
|                                      |  |   |     | 



10



---

##### Table of Contents

Research and Development Costs

Research and development costs are expensed as incurred. These costs include personnel expenses, fees paid to collaborators, laboratory supplies, facilities, miscellaneous expenses, and allocation of
corporate costs. These expenses are incurred during proprietary research and development activities, as well as providing services under collaborative research agreements.

Foreign Currency Translation and Transactions

The financial statements of our
German, United Kingdom, India, and Japanese subsidiaries are measured using, respectively, the Euro (EUR), Great British pound (GBP), the Indian Rupee (INR), and the Japanese Yen (JPY), as the functional currency. Assets and liabilities of these
subsidiaries are translated at the rates of exchange in effect at the balance sheet date. Income and expense items are translated at the average daily rate of exchange during the reporting period. Resulting remeasurement gains or losses are
recognized as a component of other comprehensive income (loss). Transactions denominated in currencies other than the local currency are recorded based on exchange rates at the time such transactions arise. Subsequent changes in exchange rates
result in transaction gains and losses, which are reflected in income as unrealized (based on period-end translations) or realized upon settlement of the transaction. Transaction gains or losses were not material for the three months ended
March 31, 2011 and 2010.

Income Taxes

Our provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary
differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted
tax rates in effect for the years in which those tax assets are expected to be realized. A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved. The
evaluation of the need for a valuation allowance is performed on a jurisdiction by jurisdiction basis, and includes a review of all available positive and negative evidence. As of March 31, 2011 and December 31, 2010, we maintained a
valuation allowance against U.S. and foreign deferred tax assets that we concluded had not met the more likely than not threshold of being released. Changes in the valuation allowance are recognized in the provision for income taxes
are included as a component of the estimated annual effective tax rate.

We recognize excess tax benefits associated with stock-based
compensation to stockholders equity only when realized. When assessing whether excess tax benefits relating to stock-based compensation have been realized, we follow the with-and-without approach, excluding any indirect effects of the excess
tax deductions. Under this approach, excess tax benefits related to stock-based compensation are not deemed to be realized until after the utilization of all other tax benefits available to us.

We recognize the impact of a tax position in our financial statements only if that position is more likely than not to be sustained upon examination by
taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected in income tax expense.

Net Loss Per Share

Basic net loss per share is computed by dividing the net loss
for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of common and common equivalent shares
outstanding during the period. Common stock equivalents consisting of exercisable stock options of 4,016,092, warrants of 59,035 and restricted stock of 958,414 were not included in the computation of diluted net loss per share as their effect was
anti-dilutive for all periods presented.

Stock-Based Compensation

Stock-based compensation cost for all stock-based payment awards, including employee stock options, restricted stock units, and rights to purchase shares under our Employee Stock Purchase Plan, or ESPP,
is measured at the grant date based on the estimated fair value of the award using the Black-Scholes option pricing model. For stock options, restricted stock and restricted stock units, we recognize compensation cost on a straight-line basis over
the awards vesting periods for those awards that contain only a service vesting feature. For awards with a performance condition vesting feature, when achievement of the performance condition is deemed probable, we recognize compensation cost
on a graded-vesting basis over the awards expected vesting periods.



11



---

##### Table of Contents

Our net loss for the three months ended March 31, 2011 and 2010, included the following compensation
expense related to our stock-based compensation awards (in thousands):



|                           |  |                             |       |  |      |   |       | 
|-------------------------- |  | --------------------------- | ----- |  | ---- | - | ----- | 
|                           |  | Three months endedMarch 31, |      
|                           |  | 2011                        |       |  | 2010 |  
|Research and development   |  | $                           | 1,026 |  |      | $ | 1,156 | 
|Selling and marketing      |  |                             | 713   |  |      |   | 880   | 
|General and administrative |  |                             | 863   |  |      |   | 981   | 
|                           |  |                             |       |  |      |   |       | 
|Total                      |  | $                           | 2,602 |  |      | $ | 3,017 | 
|                           |  |                             |       |  |      |   |       | 

Cash flows resulting from tax deductions in excess of the cumulative compensation cost recognized for options exercised
(excess tax benefits) are classified as cash inflows from financing activities and cash outflows from operating activities. Due to our net loss position, no tax benefits have been recognized in the accompanying condensed consolidated statements of
cash flows.

We have not recognized, and do not expect to recognize in the near future, any tax benefit related to stock-based compensation
cost as a result of the full valuation allowance of our net deferred tax assets and our net operating loss carryforwards.

The fair value of
options granted to non-employees is estimated at the measurement date using the Black-Scholes option pricing model and remeasured at each reporting date to fair value, with changes recorded in the statement of operations in the current period. Total
stock-based compensation for options granted to non-employees for the three months ended March 31, 2011 and 2010, was $16,000 and $80,000, respectively.

As of March 31, 2011, total compensation cost related to non-vested stock options not yet recognized was $21.6 million, which is expected to be recognized over the next 2.9 years. As of
March 31, 2011, total compensation cost related to non-vested restricted stock not yet recognized was $6.1 million, which is expected to be recognized over the next 2.6 years.

Comprehensive Loss

Comprehensive loss and its components encompasses all changes in
equity other than those with stockholders and includes net loss, unrealized gains and losses on our available for sale marketable securities and foreign currency translation gains and losses, and are disclosed as a separate component of
stockholders equity. A summary of our comprehensive loss is as follows (in thousands):



|                                                            |  |                             |         |   |      |   |         |  
|----------------------------------------------------------- |  | --------------------------- | ------- | - | ---- | - | ------- | -
|                                                            |  | Three months endedMarch 31, |        
|                                                            |  | 2011                        |         |   | 2010 |  
|Net loss                                                    |  | $                           | (12,670 | ) |      | $ | (16,948 | )
|Unrealized gain on available-for-sale marketable securities |  |                             | 114     |   |      |   | 20      |  
|Foreign currency translation adjustments                    |  |                             | 236     |   |      |   | (284    | )
|Foreign income tax provision                                |  |                             | (71     | ) |      |   |        |  
|                                                            |  |                             |         |   |      |   |         |  
|Comprehensive loss                                          |  | $                           | (12,391 | ) |      | $ | (17,212 | )
|                                                            |  |                             |         |   |      |   |         |  

Recent Accounting Pronouncements

In 2010, the FASB issued an ASU related to Revenue Recognition that applies to arrangements with milestones relating to research or development deliverables. This guidance provides criteria that must be
met to recognize consideration that is contingent upon achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. The update was effective for us beginning January 1, 2011. The adoption of this
update did not have a material impact on our condensed consolidated financial statements.

In 2010, the FASB issued an ASU related to Fair
Value Measurements and Disclosures that requires reporting entities to make new disclosures about recurring or nonrecurring fair value measurements including significant transfers into and out of Level 1 and Level 2 fair value measurements and
information on purchases, sales, issuances, and settlements on a gross basis in the reconciliation of Level 3 fair value measurements. The FASB also clarified existing fair value measurement disclosure guidance about the level of disaggregation,
inputs, and valuation techniques. The new and revised disclosures are required to be implemented in interim or annual periods beginning after December 15, 2009, except for the gross presentation of the Level 3 rollforward, which was effective
for us beginning January 1, 2011. The adoption of this update did not have a material impact on our condensed consolidated financial statements.



12



---

##### Table of Contents

In 2009, the FASB issued an ASU related to Revenue Recognition that amends the previous guidance on
arrangements with multiple deliverables. This guidance provides principles and application guidance on whether multiple deliverables exist, how the arrangements should be separated, and how the consideration should be allocated. It also clarifies
the method to allocate revenue in an arrangement using the estimated selling price. The update was effective for us beginning January 1, 2011. The adoption of this update did not have a material impact on our condensed consolidated financial
statements.

New Accounting Standards Not Yet Adopted

There have been no new recent accounting pronouncements or changes in accounting pronouncements for the three months ended March 31, 2011, as compared to the recent accounting pronouncements
described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2010. We have adopted or will adopt, as applicable, accounting pronouncements that are effective for fiscal year 2011.

(2) Acquisition

SensiGen, LLC

In February 2009, we completed a taxable acquisition of certain assets and assumption of certain liabilities of SensiGen, LLC
(SensiGen). The acquisition of the SensiGen assets provided us with intellectual property related to certain molecular diagnostics for womens health and cancer. The acquisition resulted in the recognition of goodwill at the time of purchase of
approximately $7.0 million and is now part of our wholly-owned subsidiary, Sequenom CMM. Under the terms of the asset purchase agreement (the Agreement), we acquired certain assets related to SensiGens business in gene-based molecular
diagnostic tests relating to cervical cancer, head and neck cancer, chronic kidney disease and lupus. We paid SensiGen cash consideration of approximately $1.9 million, which included a loan advance of $340,000, and issued common stock valued at
$1.9 million (utilizing the minimum floor price of $20.94 per share in accordance with the Agreement). An additional $1.3 million was contingently payable to SensiGen upon the completion of certain triggering events with either cash or shares of our
common stock (priced at the average closing price of our common stock over the ten trading day period ending on the third trading day prior to the applicable triggering event for such payment). During 2009, we satisfied one of the triggering events
related to the Agreement with a cash payment of $130,000. The remaining contingent consideration was remeasured and the liability increased to $541,000 as of December 31, 2009. During 2010, we satisfied additional obligations with an aggregate
cash payment of $520,000. As of December 31, 2010, we measured the remaining contingent consideration and increased the remaining accrual balance to $53,000. During the three months ended March 31, 2011 there were no material changes
required in our contingent consideration. As of March 31, 2011, we have $53,000 recorded as our fair value estimate for the remaining contingent consideration associated with the SensiGen acquisition.

(3) Business Segment Information

Description of the types of products and services from which each reportable segment derives its revenues

We operate two primary business segments, Molecular Diagnostics and Genetic Analysis. Molecular Diagnostics researches, develops and commercializes
noninvasive molecular diagnostic tests for womens health-related and prenatal diagnostics, ophthalmology, and other medical conditions, disorders and diseases. Genetic Analysis designs, markets and provides maintenance services for our
proprietary MassARRAY system, comprised of hardware, software applications, and consumable chips and reagents, which are marketed to premier clinical research laboratories, bioagriculture, biotechnology and pharmaceutical companies.

Revenue for Molecular Diagnostics is generated from customers located within the United States. Revenue for Genetic Analysis is generated from customers
and/or distributors located in North America, Europe and Asia.

Measurement of segment profit or loss and segment assets

We evaluate performance and allocate resources based on total segment revenue, operating expenses and operating profit or loss
exclusive of general and administrative expenses and other indirect overhead costs, which are not allocated to our segments for performance assessment by our chief operating decision maker. No evaluation of segment performance or allocation of
resources is done in consideration of segment assets. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. Intersegment revenues and transfers are immaterial.

Unallocated expenses for research and development and sales and marketing expenses consist of stock-based compensation, indirect overhead
expenses and allocated and absorbed costs. Unallocated operating loss consists of general and administrative expenses, stock-based compensation, indirect overhead expenses and unabsorbed costs.



13



---

##### Table of Contents

Factors management used to identify our reportable segments

Our reportable segments are business units that offer different products and services and are each managed separately. Operating results for each segment
are reported separately to senior management to make decisions as to the allocation of resources and to assess performance. The following table sets forth our revenues and operating loss from our Molecular Diagnostic and Genetic Analysis segments
for the three months ended March 31, 2011 and 2010, respectively (in thousands):



|                      |  |                             |         |   |      |   |         |  
|--------------------- |  | --------------------------- | ------- | - | ---- | - | ------- | -
|                      |  | Three months endedMarch
31, |        
|                      |  | 2011                        |         |   | 2010 |  
|Revenues:             |  |                             |         |   |      |   |         |  
|Molecular Diagnostics |  | $                           | 1,666   |   |      | $ | 204     |  
|Genetic Analysis      |  |                             | 11,844  |   |      |   | 10,406  |  
|                      |  |                             |         |   |      |   |         |  
|Total revenues        |  | $                           | 13,510  |   |      | $ | 10,610  |  
|                      |  |                             |         |   |      |   |         |  
|Operating loss:       |  |                             |         |   |      |   |         |  
|Molecular Diagnostics |  | $                           | (7,390  | ) |      | $ | (8,958  | )
|Genetic Analysis      |  |                             | 3,906   |   |      |   | 2,107   |  
|Unallocated           |  |                             | (9,639  | ) |      |   | (10,069 | )
|                      |  |                             |         |   |      |   |         |  
|Total operating loss  |  | $                           | (13,123 | ) |      | $ | (16,920 | )
|                      |  |                             |         |   |      |   |         |  

(4) Debt and Obligations

Debt

In connection with our acquisition of SensiGen in February 2009, we assumed
two loans with an aggregate balance at the closing date of approximately $3.2 million. The first loan of approximately $0.3 million has a stated interest rate of 1% with all payments deferred until March 2013. Commencing March 2013, principal
payments of approximately $3,000 are due monthly through March 2018, at which time a final balloon payment of approximately $161,000 is due. The second loan of approximately $2.9 million has a stated interest rate of 7% with monthly principal
payments of approximately $68,000 through September 2012. As of March 31, 2011, we had an aggregate of $1.4 million outstanding on these loans. Both loans are collateralized by all of Sequenom CMMs tangible and intangible property and
rights in which a security interest or lien may be taken.

Capital Lease

In the second quarter of 2009, we entered into a 36 month capital lease arrangement for new phone equipment, which was capitalized with office furniture
and equipment at an aggregate balance of approximately $366,000. As of March 31, 2011, we had an aggregate of $126,000 outstanding on this capital lease.

(5) Litigation

IPO Litigation

In November 2001, we and certain of our current or former officers and directors were named as defendants in a class action shareholder complaint filed by
Collegeware USA in the U.S. District Court for the Southern District of New York (now captioned In re Sequenom, Inc. IPO Securities Litigation) Case No. 01-CV-10831. In the complaint, the plaintiffs allege that our underwriters, certain of our
officers and directors and we violated the federal securities laws because our registration statement and prospectus contained untrue statements of material fact or omitted material facts regarding the compensation to be received by and the stock
allocation practices of the underwriters. The plaintiffs seek unspecified monetary damages and other relief. Similar complaints were filed in the same District Court against hundreds of other public companies that conducted initial public offerings
of their common stock in the late 1990s and 2000 (the IPO Cases).

In October 2002, our officers and directors were dismissed without
prejudice pursuant to a stipulated dismissal and tolling agreement with the plaintiffs. In February 2003, the District Court dismissed the claim against us brought under Section 10(b) of the Exchange Act, without giving the plaintiffs leave to
amend the complaint with respect to that claim. The District Court declined to dismiss the claim against us brought under Section 11 of the Securities Act of 1933, as amended (the Securities Act).

In September 2003, pursuant to the authorization of a special litigation committee of our board of directors, we approved in principle a settlement offer
by the plaintiffs. In September 2004, we entered into a settlement agreement with the plaintiffs. In February 2005, the District Court issued a decision certifying a class action for settlement purposes and granting preliminary approval of the
settlement subject to modification of certain bar orders contemplated by the settlement. In August 2005, the District Court reaffirmed class



14



---

##### Table of Contents

certification and preliminary approval of the modified settlement. In December 2006, the U.S. Court of Appeals for the Second Circuit vacated the District Courts decision certifying as
class actions the six lawsuits designated as focus cases. Thereafter the District Court ordered a stay of all proceedings in all of the lawsuits pending the outcome of plaintiffs petition to the Second Circuit for rehearing en
banc. In April 2007, the Second Circuit denied plaintiffs rehearing petition, but clarified that the plaintiffs may seek to certify a more limited class in the District Court. Accordingly, the settlement as originally negotiated was terminated
pursuant to stipulation.

In February 2009, liaison counsel for plaintiffs informed the District Court that a new settlement of all IPO Cases
had been agreed to in principle, subject to formal approval by the parties and preliminary and final approval by the District Court. In April 2009, the parties submitted a tentative settlement agreement to the District Court and moved for
preliminary approval thereof. In June 2009, the District Court granted preliminary approval of the tentative settlement and ordered that notice of the settlement be published and mailed to class members. In September 2009, the District Court held a
final fairness hearing. In October 2009, the District Court certified the settlement class in each IPO Case and granted final approval to the settlement. Thereafter, three shareholders filed a Petition for Permission to Appeal Class Certification
Order, asserting that the District Courts certification of the settlement classes violates the Second Circuits earlier class certification decisions in the IPO Cases and a number of shareholders also filed direct appeals, objecting to
final approval of the settlement. If the settlement is affirmed on appeal, the settlement will result in the dismissal of all claims against us and our officers and directors with prejudice, and our pro rata share of the settlement fund will be
fully funded by insurance.

Securities and Shareholder Derivative Litigation

In April 2009, we announced that the expected launch of our a test for trisomy 21 then under development by Sequenom CMM had been delayed and that they
were no longer relying on the previously announced test data and results for that test, as a result of inadequately substantiated claims, inconsistencies and errors and inadequate protocols and controls, which included: the mischaracterization of
tests as having been conducted in a blinded manner (i.e., that the tests had been performed by scientists who did not know the true outcomes for the samples tested before the test results had been determined); the improper unblinding of true
outcomes for samples being tested; the use of the unblinded true outcomes to alter and improve reported test results; the unsubstantiated reporting of test results for low-risk samples (i.e., samples from expectant mothers who were less likely to be
carrying a fetus with trisomy 21) without knowing the true outcomes for such samples; the failure to perform testing on those low-risk samples; the inadequate storage of serum samples resulting in breakdown of nucleic acids; and other improper
practices. Following the April 2009 announcement, several complaints were filed in the U.S. District Court for the Southern District of California against us and certain of our current and former officers and directors on behalf of certain
purchasers of our common stock. The complaints included claims asserted under Sections 10 and 20(a) of the Exchange Act and Sections 11 and 12(a)(2) of the Securities Act and were brought as shareholder class actions. In general, the complaints
alleged that we and certain of our officers and directors violated federal securities laws by making materially false and misleading statements regarding our test, thereby artificially inflating the price of our common stock. In September 2009 the
complaints were consolidated under the caption In re Sequenom, Inc. Securities Litigation, Master File No. 3:09-cv-00921 LAB-WMC and a lead plaintiff was appointed. In December 2009 we entered into a stipulation of settlement with the lead
plaintiff on behalf of the plaintiffs class. Pursuant to the terms of the stipulation, we paid $14 million, which was funded by insurance proceeds. We also agreed to issue to the plaintiffs class approximately 6.8 million shares of
our common stock, and to adopt or continue our implementation of changes and additions to certain corporate governance policies, protocols and practices. The court held a final settlement approval hearing in May 2010, following which the court
approved the final settlement. The time for appeals lapsed without any appeal. Of the 6.8 million shares of common stock to be issued in the settlement, 409,005 shares were issued in June 2010 to counsel for the plaintiffs class in
accordance with the stipulation of settlement. Following completion of the class action claim procedures, we issued the balance of 6,407,738 shares as of December 31, 2010.

In May 2009, a shareholder derivative complaint was filed in the Superior Court of California for the County of San Diego against certain of our current and former directors and officers. Thereafter, a
number of similar actions, also styled as shareholder derivative suits, were filed in state court and were consolidated in a single court. In July 2009 the first of three shareholder derivative suits were filed in the U.S. District Court for the
Southern District of California. The federal shareholder derivative actions were consolidated before a single court under the caption In re Sequenom, Inc. Derivative Litigation, S.D. Cal. Case No. 09-CV-1341 LAB (WMc) and plaintiffs filed a
single consolidated complaint. A separate federal derivative compliant, Ries, et al. v. Stylli, et al, case no. 09-CV-2517 LAB (WMc), was filed thereafter and it was coordinated with the consolidated federal derivative action. The state and federal
shareholder derivative actions are hereinafter collectively referred to as the Derivative Actions. The complaints in the Derivative Actions allege breaches of fiduciary duties by the defendants and other violations of law. In general,
the complaints allege that our directors and certain of our officers caused or allowed for the dissemination of materially false and misleading statements regarding the trisomy 21 test then under development, thereby artificially inflating the price
of our common stock. In May 2010, we entered into a stipulation of settlement to resolve the Derivative Actions. The current and former directors and officers named as individual defendants in the Derivative Actions also entered into the stipulation
of settlement. In exchange for a release of all claims by the plaintiffs and a dismissal of the Derivative Actions, we agreed (i) to adopt or continue certain corporate governance measures and (ii) to pay the plaintiffs attorneys a
total of $2.5 million, of which $1.0 million has been funded by insurance proceeds. The U.S. District Court issued its final approval of the settlement in accordance with the terms of the stipulation of settlement in July 2010, and



15



---

##### Table of Contents

entered an order dismissing the federal shareholder derivative actions in July 2010. In accordance with the terms of the stipulation of settlement, the parties in the state shareholder derivative
actions filed a joint stipulation to dismiss the actions with prejudice in San Diego Superior Court in July 2010. In connection with the final approval of settlement, we remitted a cash payment of $338,000 and issued 200,000 shares of our common
stock at a fair value of $5.81 per share in payment of the portion of the plaintiffs attorneys fees not funded by insurance proceeds.

SEC Investigation

In June 2009, we received written notification that the
Enforcement staff of the SEC has initiated an investigation following our April 2009 announcement regarding the trisomy 21 test then under development. As part of this investigation, the SEC staff has also required us to produce information with
respect to our announcement relating to our offer to acquire EXACT Sciences, Inc. in January 2009. On March 7, 2011, the staff of the SEC advised us that it is considering recommending that the SEC bring a civil injunctive action against us
alleging that we violated Sections 10(b) and 13(a) of the Exchange Act of 1934 and Rules 10b-5, 12b-20, 13a-1 and 13a-11 thereunder. We have cooperated fully with the SEC in its investigation and will endeavor to negotiate an acceptable
resolution with the staff, but any resolution that we may negotiate with the staff will be subject to the approval of the SEC. There can be no assurance that such resolution will not have a material adverse effect on our business, results of
operation or financial condition.

In June 2010, the SEC filed a complaint against Elizabeth Dragon, who was formerly our Senior Vice
President, Research and Development. The complaint alleged that between June 2008 and January 2009 Dr. Dragon made or allowed for the dissemination of materially false and misleading statements regarding the trisomy 21 test then under
development, thereby inflating the price of our stock. The SEC sought a permanent injunction against any future violations of the federal securities laws by Dr. Dragon, civil penalties, and imposition of an officer and director bar against her.
On the same day, Dr. Dragon filed a consent to judgment of permanent injunction and other relief. In the consent to judgment, Dr. Dragon, without admitting or denying the allegations in the SECs complaint, agreed to the permanent
injunction against future violations of federal securities laws, the director and officer bar, and civil penalties to be determined by the court. Prior to sentencing, Dr. Dragon passed away in February 2011.

DOJ and FBI Investigation

Following our September 2009 announcement regarding the work and recommendations of a special committee of independent directors after it had completed
its independent investigation of activity related to the trisomy 21 test, representatives of the Office of the U.S. Attorney for the Southern District of California contacted us to inquire about the announcement. We intend to continue to cooperate
fully with the U.S. Attorney and the Federal Bureau of Investigation (FBI) in this matter.

In June 2010, the U.S. Attorney filed a criminal
information against Dr. Dragon. The criminal information charged Dr. Dragon with one count of conspiracy to commit securities fraud by conspiring to disseminate materially false and misleading statements regarding the trisomy 21 test then
under development. On the same day, Dr. Dragon pled guilty to the criminal information, and the magistrate judge assigned to this matter recommended that the district court judge accept Dr. Dragons guilty plea. Prior to sentencing,
Dr. Dragon passed away in February 2011.

Former Employee Litigation

In August 2010, Paul Hawran, our former chief financial officer, sued the three directors who comprised the special committee that conducted the
investigation of activity related to the trisomy 21 test, alleging that they had defamed him, invaded his privacy, negligently and intentionally interfered with his prospective economic advantage, and committed unfair business practices under
California Business and Professions Code Section 17200. Mr. Hawran alleged in his complaint that he was asked to resign because he had raised concerns about the conduct of certain of our directors. The lawsuit, Hawran v. Hixson et al, case
no. 37-2010-00058632-CU-DF-NC, was filed in the Superior Court of California for the North County of San Diego. In September 2010, we were served with an amended complaint in this lawsuit, in which Mr. Hawran named us as a defendant in addition
to the three individuals previously named and added claims of breach of contract and intentional and negligent misrepresentation. In October 2010, the defendants filed a motion to strike the complaint under California Code of Civil Procedure
Section 425.16 on the grounds that Mr. Hawrans claims arise from acts in furtherance of the defendants right of petition or free speech under the United States or California Constitution in connection with a public issue and
filed a demurrer to each and every cause of action in the complaint. On January 3, 2011, the court issued a minute order dismissing some, but not all, of the claims alleged in the amended complaint. The defendants filed a notice of appeal
regarding the minute order on January 11, 2011 and Mr. Hawran filed a cross-appeal regarding the same on January 31, 2011. The individual defendants and we intend to vigorously defend ourselves against the claims advanced.

In addition, from time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. These
other matters are, in the opinion of management, immaterial with respect to our consolidated financial position, liquidity, or results of operations.

Claim estimates that are probable and can be reasonably estimated are reflected as liabilities of the Company. Because of the uncertainties related to the incurrence, amount and range of loss on any
pending litigation, investigation, inquiry or claim, management is currently unable to predict the ultimate outcome of any litigation, investigation, inquiry or claim, determine whether a liability has been incurred or make an estimate of the
reasonably possible liability that could result from an unfavorable outcome. It is



16



---

##### Table of Contents

reasonably possible that some of the matters, which are pending or may be asserted, could be decided unfavorably to the Company. An adverse ruling or outcome in any lawsuit involving us could
materially affect our business, liquidity, consolidated financial position or results of operations ability to sell one or more of our products or could result in additional competition. In view of the unpredictable nature of such matters, we cannot
provide any assurances regarding the outcome of any litigation, investigation, inquiry or claim to which we are a party or the impact on us of an adverse ruling of such matters.

(6) Stockholders Equity

In December 2010, we issued 6,407,738 shares of our common
stock at a fair value of $8.03 per share, which represented the remaining portion of the court approved share settlement to the plaintiffs class in the class action securities lawsuits consolidated under the caption In re Sequenom, Inc.
Securities Litigation.

In December 2010, we closed an underwritten public offering of our common stock totaling 16,100,000 shares of our
common stock at $6.00 per share. The offering resulted in aggregate net proceeds of approximately $90.6 million after deducting underwriting commissions and transaction expenses.

In July 2010 we issued 200,000 shares of our common stock at a fair value of $5.81 per share, which represented the portion of the plaintiffs attorneys fees not covered by insurance to resolve
the various derivative actions filed in federal and state court. The shares were issued in accordance with the courts stipulation of settlement.

In June 2010 we issued 409,005 shares of our common stock at a fair value of $5.94 per share, which represented a portion of the court approved share settlement in the class action securities lawsuits
consolidated under the caption In re Sequenom, Inc. Securities Litigation. The shares were issued to counsel for the plaintiffs class in accordance with the courts order awarding attorneys fees.

In May 2010 we issued 12,435,000 shares of our common stock at $4.15 per share to certain investors in a private placement. The private placement
resulted in aggregate net proceeds of $47.8 million after deducting commissions and transaction expenses.

(7) Subsequent Events

On May 3, 2011 we entered into an additional License Agreement (the License Agreement) and a sponsored research agreement with The Chinese
University of Hong Kong (the University) pursuant to which the University granted us an exclusive, worldwide (excluding Hong Kong), royalty-bearing license to use, and to sublicense, certain intellectual property covered by patent applications owned
by the University for prenatal diagnostics, prognostics, and analysis for research and commercial purposes. The License Agreement covers intellectual property rights relating to size-based genomic analysis. Pursuant to the License Agreement we
agreed to pay the University $1,500,000 within 30 days and another $1,500,000 within one year. We are obligated to pay royalties on sales of products incorporating the licensed intellectual property and amounts we receive from any sublicensees.
We are also obligated to pay additional amounts to the University upon the accomplishment of certain commercialization and development milestones. If we fail to achieve certain commercialization and development milestones within specified
timeframes, the University may terminate the License Agreement. In accordance with the License Agreement, the University will prosecute, defend and maintain certain patent applications relating to the licensed intellectual property at our
expense. The License Agreement will expire on the later of 20 years or the expiration of the last patent, if any patent is issued, relating to the licensed intellectual property, unless terminated earlier pursuant to the terms of the License
Agreement. We may terminate the License Agreement at any time after one year on 30 days written notice to the University.

Pursuant to the
License Agreement, on May 3, 2011 we issued to the Chinese University of Hong Kong Foundation Limited (an affiliate of the University) a warrant to purchase up to 200,000 shares of our common stock at a price of $7.00 per share, the closing price of
our common stock on May 3, 2011 as reported by The Nasdaq Global Market (the Warrant). The Warrant is immediately exercisable and has a term of seven years.



17



---

##### Table of Contents

|Item 2. | Managements Discussion and Analysis of Financial Condition and Results of Operations
|------- | -------------------------------------------------------------------------------------

All statements in this report that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act. These forward-looking statements can generally
be identified as such because the context of the statement will include words such as may, will, intend, plans, believes, anticipates, expects,
estimates, predicts, potential, continue, opportunity, goals, or should, the negative of these words or words of similar import. Similarly, statements that describe
our future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. These forward-looking statements are or will be, as applicable, based largely on our expectations and projections about
future events and future trends affecting our business, and so are or will be, as applicable, subject to risks and uncertainties including but not limited to the risk factors discussed in this report, that could cause actual results to differ
materially from those anticipated in the forward-looking statements. We caution investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking
statements. Our views and the events, conditions and circumstances on which these future forward-looking statements are based, may change. All forward-looking statements are qualified in their entirety by this cautionary statement and we undertake
no obligation to revise or update any such statements to reflect events or circumstances after the date hereof.

SEQUENOM®, SpectroCHIP®, iPLEX®, SensiGene® and MassARRAY® are registered trademarks and SEQureDx, iSEQ, RetnaGene, and AttoSense are trademarks of Sequenom, Inc. This report may also refer to trade
names and trademarks of other organizations.

Sequenom, Inc. was incorporated in 1994 under the laws of the State of Delaware. As used in this
report, the words we, us, our, the Company, and Sequenom refer to Sequenom, Inc. and its wholly-owned subsidiaries on a consolidated basis, unless explicitly noted otherwise.

Overview

We are a molecular diagnostic
testing and genetics analysis company committed to providing products, services, applications, and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular
medicine applications, and agricultural, livestock, and other areas of research. Our development and commercialization efforts in various diagnostic areas include noninvasive womens health-related and prenatal diagnostics, ophthalmology,
oncology, infectious diseases, and other medical conditions, disorders and diseases.

Operating Segments

We operate our business on the basis of two reportable segments, Molecular Diagnostics and Genetic Analysis. A further description of the operations of
these segments is below. The following table sets forth revenues, and operating loss for our Molecular Diagnostic and Genetic Analysis segments for the three months ending March 31, 2011 and 2010 (in thousands):



|                      |  |                             |         |   |      |   |         |  
|--------------------- |  | --------------------------- | ------- | - | ---- | - | ------- | -
|                      |  | Three months endedMarch 31, |        
|                      |  | 2011                        |         |   | 2010 |  
|Revenues:             |  |                             |         |   |      |   |         |  
|Molecular Diagnostics |  | $                           | 1,666   |   |      | $ | 204     |  
|Genetic Analysis      |  |                             | 11,844  |   |      |   | 10,406  |  
|                      |  |                             |         |   |      |   |         |  
|Total revenues        |  | $                           | 13,510  |   |      | $ | 10,610  |  
|                      |  |                             |         |   |      |   |         |  
|Operating loss:       |  |                             |         |   |      |   |         |  
|Molecular Diagnostics |  | $                           | (7,390  | ) |      | $ | (8,958  | )
|Genetic Analysis      |  |                             | 3,906   |   |      |   | 2,107   |  
|Unallocated           |  |                             | (9,639  | ) |      |   | (10,069 | )
|                      |  |                             |         |   |      |   |         |  
|Total operating loss  |  | $                           | (13,123 | ) |      | $ | (16,920 | )
|                      |  |                             |         |   |      |   |         |  

We evaluate performance and allocate resources based on total segment revenue, operating expenses and operating profit or
loss exclusive of general and administrative expenses and other indirect overhead costs, which are not allocated to our segments for performance assessment by our chief operating decision maker. No evaluation of segment performance or allocation of
resources is done in consideration of segment assets. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. Intersegment revenues and transfers are immaterial.



18



---

##### Table of Contents

Molecular Diagnostics and SEQureDx Technology

We are committed to researching, developing and pursuing the commercialization of various noninvasive molecular diagnostic tests for prenatal genetic
disorders and diseases, womens health-related disorders and diseases, ophthalmology, oncology, infectious diseases, and other medical conditions, disorders and diseases. Currently, we are primarily focused on developing and commercializing
prenatal diagnostic tests using our foundational, patent-protected, noninvasive, circulating cell-free fetal, or ccff, nucleic acid-based assay technology, which we in-license from Isis Innovation Limited, or Isis. This technology uses a standard
maternal blood draw for a prenatal diagnosis or risk assessment in order to provide reliable information about the presence, amount or absence of fetal genetic material early in pregnancy. We have branded our diagnostic technology for prenatal
diagnostics under the trademark SEQureDx. Our efforts in molecular diagnostics are focused on developing noninvasive in vitro diagnostic tests using our proprietary MassARRAY system and/or nucleic acid sequencing platforms currently provided
by Illumina, Inc. We plan to conduct the development, validation, and other activities necessary to file submissions with the U.S. Food and Drug Administration, or FDA, seeking clearance or approval for commercialization of our in vitro
diagnostic tests in the United States. To that end, in 2010 we made a pre-investigational device exemption, or pre-IDE, submission to the FDA for an in vitro diagnostic test for fetal chromosome 21 aneuploidy, such as trisomy 21, and
have recently met with the FDA to discuss our proposed preclinical and clinical study design.

Sequenom Center for Molecular Medicine

Sequenom Center for Molecular Medicine, LLC, or Sequenom CMM, is our wholly-owned subsidiary, which operates a laboratory located in Grand
Rapids, Michigan, that is accredited by the College of American Pathology, or CAP, and compliant with the certification requirements for high complexity testing under the Clinical Laboratory Improvement Amendments, or CLIA, of 1988, as amended.
Sequenom CMM develops and validates laboratory developed tests, or LDTs, for use in and solely by Sequenom CMM as a testing service to physicians. Sequenom CMM utilizes our patented SEQureDx ccff technology in developing some of its LDTs. Sequenom
CMM has validated and offers to physicians two LDTs, the SensiGene Rhesus D fetal genotyping test and a DNA-based cystic fibrosis adult carrier screening test. Patient samples are collected by physicians and submitted to Sequenom CMM for testing and
the results are reported back to the ordering physician.

Sequenom CMM has established an additional laboratory in San Diego, California that
complies with the California Department of Public Health Title 17 California Code of Regulations applicable regulations for clinical laboratories. A California clinical laboratory license was issued by the state and a federal CLIA certification was
issued by the Centers for Medicare and Medicaid Services, or CMS, to the San Diego laboratory in late 2010. We have invested substantially in Sequenom CMMs information technology infrastructure to enhance the capabilities of the laboratory to
track samples and provide electronic ordering and reporting and are putting in place sample collection and transportation logistics that can be scaled as demand for Sequenom CMMs molecular diagnostic testing services increases. Sequenom CMM
continues to negotiate and enter into contracts with third-party payors to establish pricing for its LDTs and provide reimbursement recommendations.

Sequenom CMM is currently developing a potential LDT for assessing pregnant women who are at increased risk (by clinical indicators) of carrying a fetus with trisomy 21. The process employed in the LDT is
analysis of fetal DNA extracted from maternal blood samples utilizing next generation nucleic acid sequencing, known as massively parallel shotgun sequencing, or MPSS. With technological advances and projected instrument and reagent costs of MPSS
declining rapidly, Sequenom CMM believes that a trisomy 21 LDT on a MPSS platform is commercially feasible and potentially attractive compared to other platforms. The goal is to design a noninvasive test that has high specificity and sensitivity
compared to currently available serum biochemical screening tests, could be used during the first and second trimesters of pregnancy, has maximum ethnic coverage of the global population, and is a direct genetic test, not a surrogate marker. There
can be no assurance that Sequenom CMM will be able to achieve any of these objectives.

In November 2010, Sequenom CMM presented the results
from a pilot 96 patient study of a trisomy 21 test using MPSS at a meeting of the American Society of Human Genetics. Based on the results of this small study, Sequenom CMM started and completed a larger study that analyzed 480 patient samples
collected from pregnant women at increased risk for fetal chromosome 21 aneuploidy. A manuscript describing the results from this larger laboratory verification study was published online on February 10, 2011, in the American Journal of
Obstetrics & Gynecology, or AJOG. A hard copy publication is available in the March 2011 print edition of AJOG. There can be no assurance that Sequenom CMM will be able to repeat the study results in later studies.

Based on the results from these two studies, Sequenom CMM has undertaken the next major step in the SensiGene Trisomy 21 LDT development plan, a large
pivotal clinical validation study. The study is sponsored by Sequenom, but is designed, implemented, analyzed and reported by researchers at Women & Infants Hospital / Alpert School of Medicine of Brown University in Rhode Island, and is an
independent multi-center international collaboration. In this study, Sequenom CMM is testing patient samples that have been collected under an institutional review board-approved clinical study conducted under the auspices of the Women & Infants
Hospital in Rhode Island. We anticipate that the total number of patient samples in the clinical validation study will be approximately 2,000, of which approximately 200 will be positive for trisomy 21 based on laboratory confirmation of the
diagnosis performed on samples obtained from chorionic villus sampling, or genetic amniocentesis. The study design calls for approximately 100 positive samples in each of the first and second trimesters of pregnancy. Sequenom CMM is using
essentially the same assay process in the clinical validation study that was used in the 480 sample study with the exception of employing the higher throughput Illumina HiSeq 2000, a second generation sequencer, introduced in 2010. Sequenom CMM
scientists previously completed equivalency studies on the HiSeq



19



---

##### Table of Contents

2000 sequencer in preparation for this large clinical validation study. Sequenom CMM anticipates that it will complete the clinical validation study by the end of the second quarter of 2011 and
is planning to launch the SensiGene Trisomy 21 LDT by the end of 2011 or early 2012, after the publication of the clinical validation study results by our academic collaborators.

Sequenom CMM is also in the process of developing an LDT to predict genetic predisposition to late-stage age-related macular degeneration, or AMD, which is a prevalent, late onset, genetically linked
vision disorder that is the most common cause of legal blindness in the elderly. Supporting this initiative, in February 2010, we entered into a license agreement with Optherion, Inc., or Optherion, under which we and our affiliated companies were
granted an exclusive, worldwide, royalty-bearing license to know-how and a consolidated portfolio of patent rights that had been licensed to Optherion by a number of prominent academic institutions, for research and commercial use, including LDTs
and in vitro diagnostic tests, in conjunction with various types of technology platforms.

FDA Oversight of LDTs

Historically, the FDA has exercised enforcement discretion and exempted from regulation LDTs created and used by the same laboratory. During a public
meeting held in July 2010, the FDA explained that it is reconsidering its policy of enforcement discretion over LDTs. Citing a variety of safety concerns related to current LDTs, the FDA noted that the tests have become increasingly complex and
utilized for significant medical decisions, sometimes in place of similar tests that have been reviewed and approved by the FDA. As part of the FDAs evolving position on the regulation of LDTs, the FDA issued letters to a number of companies
in mid-2010 that primarily related to direct-to-consumer genetic testing. In these letters, the FDA expressed concern about consumers making medical decisions in reliance on genetic tests that have not undergone the FDAs premarket review.
However, no formal guidance has yet been issued discussing the nature of the changes the FDA may make with respect to the regulation of LDTs, nor the scope of potential regulation.

Although Sequenom CMM does not sell its testing services directly to consumers, we also received a letter from the FDA in July 2010. We responded to the FDA by letter in August 2010 and met with the FDA
in September 2010. We reiterated at that meeting that Sequenom CMMs LDTs are physician-ordered and neither we nor Sequenom CMM are involved in direct-to-consumer commercialization. The FDA indicated it had no further questions on the
direct-to-consumer issue at this time. We will continue to monitor potential changes as the FDAs LDT policy evolves to ensure Sequenom CMMs activities are consistent with the FDAs most current policy.

Prenatal Diagnostics Licenses

Isis License Agreement

We have
exclusively in-licensed from Isis patent rights (including U.S. Patent No. 6,258,540 and its foreign equivalents) to use ccff nucleic acids for diagnostic testing of serum and plasma samples obtained from pregnant women. These exclusive license
rights, which are platform independent and not limited to mass spectrometry, cover the general diagnostic use of ccff nucleic acids in territories that include the United States, Canada, Europe, Japan, Australia, and Hong Kong.

Subject to the license rights granted under the agreement with Isis, intellectual property rights created in connection with improvements made to the
licensed technology will belong to the party developing the improvements. We also granted a perpetual royalty-free license to the University of Oxford, which is the parent of Isis, to use and publish material relating to the licensed technology and
any of our improvements solely for non-commercial use. The University of Oxfords right to publish is subject to our right to delay publication of information to protect the licensed technology or our improvements.

We have agreed to make up-front payments to Isis and pay to Isis royalties on net sales of products developed or produced using the licensed patent
rights, including specified minimum royalty amounts, and milestone payments upon commercial events with respect to products for particular indications.

The agreement with Isis will remain in force for the life of any patent issued in connection with the patent application covering the licensed technology, subject to earlier termination by either party
upon uncured material breach or other specified circumstances. Isis may terminate the agreement if we file a petition to wind-up or dissolve or upon 30 days written notice if we were to challenge the validity of the patent rights covering the
licensed technology or fail to make the up-front payments as provided in the agreement. We may terminate the agreement for any reason with six months advance written notice. In the event we fail to achieve certain milestone requirements with
respect to particular indications, Isis may convert the exclusive license into a non-exclusive license with respect to those indications.

CUHK License Agreement

We have
also exclusively in-licensed patent rights from the Chinese University of Hong Kong, or CUHK, which cover the use of cell-free fetal nucleic acids from biological samples, including plasma, serum, whole blood and urine, for prenatal diagnostic
testing by MPSS. These exclusive license rights include pending United States patent application publication no. US2009/0029377A1, and its pending foreign equivalents in Australia, Brazil, Canada, China, Eurasia, Europe, Israel, India, Japan, Korea,
Mexico, New Zealand, Singapore and South Africa. Certain of our license rights, which are unrelated to prenatal diagnostic testing by MPSS sequencing, are non-exclusive.



20



---

##### Table of Contents

Under our license agreement with CUHK, CUHK maintains the right to use and develop any of the licensed
technology solely for academic, research and publication purposes, and with respect to one of the licensed patent applications, reserves the right to use the licensed application in accordance with its agreement with the Government of the Special
Administration Region of Hong Kong. In addition, CUHK has the right to grant to the Commissioner for Innovation and Technology, a non-exclusive, world-wide license to certain of our in-licensed patent rights, which do not relate to prenatal
diagnostic testing by MPSS.

Under the agreement with CUHK, we paid an upfront license fee to CUHK and are required to make milestone payments
upon commercial and regulatory events achieved with respect to products developed or produced using the licensed patent rights and to pay royalties on net sales of such products, including specified minimum royalty amounts. Subject to certain
limited circumstances, to maintain our licensed rights under the agreement we are required to assume the financial responsibility for the prosecution, defense and maintenance of all licensed patent applications and patents and are required to
provide CUHK with reasonable assistance for the prosecution, defense and maintenance of all licensed patent applications and patents at the request of CUHK.

The agreement with CUHK requires us to use all reasonable efforts and diligence to exploit the licensed patent rights and to proceed with the development, manufacture and sale of products developed or
produced using the licensed patent rights, and to diligently develop markets for such products. Under the terms of the agreement, we have agreed to indemnify CUHK from all losses incurred by CUHK relating to our manufacture, use, sale or any other
dealing with respect to products developed or produced using the licensed patent rights. CUHK has agreed to indemnify us from all losses incurred as a result of breaches of CUHKs representations and warranties under the agreement, subject to a
cap of two times the aggregate payments received by CUHK from us at the time of such breach.

The agreement with CUHK will remain effective
until the later of the life of any patent issued covering the licensed technology or September 16, 2028, subject to earlier termination by either party upon an uncured material breach. CUHK may terminate the agreement if we go into liquidation
or if a receiver is appointed for our assets or if we fail to make any payment as provided in the agreement or if we assign or transfer any rights under the agreement in violation of its terms or in the event of our cessation of our business
relating to the commercialization of the licensed technology. If we sublicense our rights under the agreement and our sublicensee fails to pay us as required under such sublicense agreement and as a result we fail to make requisite payments to CUHK
within 30 days, CUHK may terminate our agreement.

We may terminate the agreement with CUHK for any reason with 30 days advance written
notice. In the event we fail to achieve certain commercial milestone requirements with respect to products developed or produced using the licensed patent rights, CUHK may terminate the licensed patent rights with respect to such specific milestone.

Under the terms of the license agreement and other agreements with CUHK, we have rights in improvements to licensed technology when such
improvements are based upon and claim priority to existing patent applications that have been licensed by us. We also have a sole and exclusive option to obtain an exclusive license to research results generated by specific CUHK inventors, using a
sequencing platform purchased by us for CUHKs use, and which relate to MPSS to discover and analyze plasma, serum, blood or other bodily fluid-based markers for prenatal diagnosis, prenatal prognostication, construction of a whole genome
genetic map or complete genomic sequencing of the fetus or other prenatal analysis, cancer detection, cancer prognostication, or other analysis for the screening and management of cancer.

Genetic Analysis

Our proprietary MassARRAY system is comprised of hardware, software
applications, and consumable chips and reagents. It is a high performance (in speed, accuracy, and cost efficiency) nucleic acid analysis research use only platform that quantitatively and precisely measures genetic target material and variations.
Our system is widely accepted as a leading high-performance DNA analysis system for genotyping, somatic mutation analysis and fine mapping markets and continues to gain traction for applications, such as agricultural genomics and clinical research.
Our research customers include premier clinical research laboratories, bioagriculture, biotechnology and pharmaceutical companies, academic institutions, and various government agencies worldwide. To provide customer support for our expanding user
base, and in an effort to maximize market penetration, we have established direct sales and support personnel serving North America, Europe and Asia, in addition to distribution partners in several major countries throughout the world.

Our MassARRAY system provides reliable results for a wide range of DNA/RNA analysis applications, including single nucleotide polymorphism, or SNP,
genotyping, detection of mutations, analysis of copy number variants, and other structural genome variations. In addition, the system provides quantitative gene expression analysis, quantitative DNA methylation analysis, comparative sequence
analysis of haploid organisms, SNP discovery, and oligonucleotide quality control. These applications are provided through proprietary research use application software that operates on the MassARRAY system and through the purchase of consumable
chips and reagent sets. While the MassARRAY system is versatile across many applications, it is a robust and cost-effective genotyping and somatic mutation analysis solution enabled through our research use only iPLEX multiplexing assay, which
permits multiplexed SNP and somatic mutation analysis. In April 2010 we launched our next-generation research use only mass spectrometry system, the MassARRAY Analyzer 4. This new high performance nucleic acid analysis system has been designed to
meet customer demand for a bench top instrument with greater flexibility across multiple applications, improved reliability and faster performance and is designed to empower the basic and translational research community to advance findings from
discovery genetic and biomarker studies toward biomarker validation and clinical utility in diagnosis, prognosis and monitoring of diseases.



21



---

##### Table of Contents

Our research and development efforts in genetic analysis are committed to producing new and improved
components and applications for the MassARRAY system that deliver greater system versatility and higher data quality at a competitive price per data point. These research and development activities and new applications also serve to facilitate and
support our diagnostics initiatives.

Critical Accounting Policies and Estimates

Our condensed consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles, or GAAP. These accounting
principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments
and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods
presented. To the extent there are material differences between these estimates, judgments or assumptions and actual results, our financial statements will be affected. The accounting policies that reflect our more significant estimates, judgments
and assumptions and which we believe are the most critical to aid in fully understanding and evaluating our reported financial results include the following:



| |  |  | revenue recognition;
| | - |  | --------------------



| |  |  | goodwill and impairment evaluations of long-lived assets;
| | - |  | ---------------------------------------------------------



| |  |  | allowance for doubtful accounts;
| | - |  | --------------------------------



| |  |  | reserves for obsolete and slow-moving inventory;
| | - |  | ------------------------------------------------



| |  |  | income taxes; and
| | - |  | -----------------



| |  |  | stock-based compensation.
| | - |  | -------------------------

In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP and does not require managements judgment in
its application. There are also areas in which managements judgment in selecting among available alternatives would not produce a materially different result. Our senior management has reviewed these critical accounting policies and related
disclosures with the Audit Committee of our Board of Directors.

During the first three months of 2011, there were no significant changes in
our critical accounting policies and estimates. Please refer to Managements Discussion and Analysis of Financial Condition and Results of Operations contained in Part II, Item 7 of our Annual Report on Form 10-K for the year
ended December 31, 2010 for a more complete discussion of our critical accounting policies and estimates.



22



---

##### Table of Contents

Results of Operations for the Three Months Ended March 31, 2011 and 2010

Comparison of Three Months Ended March 31, 2011 and 2010

Revenues

Revenues are derived from sales of consumables, including our SpectroCHIP arrays
used with our iPLEX and other assays, MassARRAY systems, maintenance agreements, and sales and licensing of our proprietary software. Diagnostic revenues are from the sale of our cystic fibrosis carrier screening LDT, as well as our Rhesus D
genotyping LDT.



|                                           |  |                             |        |  |         |   |        |         |  |   |       |   |  |  |      |   
|------------------------------------------ |  | --------------------------- | ------ |  | ------- | - | ------ | ------- |  | - | ----- | - |  |  | ---- | --
|                                           |  | Three Months EndedMarch 31, |        |  | $Change |   |        | %Change | 
|                                           |  | 2011                        |        |  | 2010    |   |        |        
|                                           |  | (in thousands)              |        |  |         |   |        |         | 
|Consumables                                |  | $                           | 5,303  |  |         | $ | 5,143  |         |  | $ | 160   |   |  |  | 3    | % 
|MassARRAY system and other product related |  |                             | 5,843  |  |         |   | 4,776  |         |  |   | 1,067 |   |  |  | 22   | % 
|Contract research services                 |  |                             | 698    |  |         |   | 481    |         |  |   | 217   |   |  |  | 45   | % 
|Diagnostic                                 |  |                             | 1,666  |  |         |   | 204    |         |  |   | 1,462 |   |  |  | 717  | % 
|Research and other                         |  |                             |       |  |         |   | 6      |         |  |   | (6    | ) |  |  | (100 | %)
|                                           |  |                             |        |  |         |   |        |         |  |   |       |   |  |  |      |   
|Total revenues                             |  | $                           | 13,510 |  |         | $ | 10,610 |         |  | $ | 2,900 |   |  |  | 27   | % 
|                                           |  |                             |        |  |         |   |        |         |  |   |       |   |  |  |      |   

The increase in our consumables revenue is attributable to our larger installed base of MassARRAY systems against the
comparative period, as well as increased consumables orders from our customers in the biomedical research and agricultural biology markets against the comparative period.

The increase in our MassARRAY system and other product revenue was primarily due to an increase in MassARRAY system sales to $4.6 million for the three months ended March 31, 2011 from $3.5 million
for the same period in 2010. The increase in system sales revenue was related to the mix of MassARRAY system configurations sold during the current period as compared to the same period in 2010, which resulted in a higher average selling price.
Revenue from other product sales, which primarily represents MassARRAY system maintenance contract revenue, was $1.2 million and $1.3 million for the three months ended March 31, 2011 and 2010, respectively.

The increase of our contract research services revenue is attributable to increased volume of studies in the Asia Pacific region. Revenues from contract
research services have been dependent on particular contract terms of the work undertaken, as well as the particular market in which the services are being performed, the size of the projects and the pricing terms.

Diagnostic revenue is recognized upon cash collection as payments are received. The increase in our diagnostic revenue is attributable to an increase in
the number of tests performed in the three months ended March 31, 2011 compared to the same period in 2010. Diagnostic revenue going forward is uncertain and difficult to predict due to the lack of historical sales trends associated with our recent
commercial launches of these tests.

Research and other revenues, which consist of license and research grant payments, depends upon the
timing of our expenditures on grant research and our receipt of grant funding from sponsoring agencies. We expect license and grant revenue to be minimal going forward.

Our revenues have historically fluctuated from period to period and likely will continue to fluctuate substantially in the future based upon the unpredictable sales cycle for the MassARRAY system, general
economic conditions, revenue recognition criteria, the overall acceptance and demand for our new and existing commercial products and services, as well as the adoption rates of our cystic fibrosis carrier screening assay, Rhesus D genotyping assay,
and future assays.

Cost of Consumables and Products, Services and Diagnostic Revenues and Gross Margins

Gross margin consists of our revenues less cost of revenues. Cost of revenues consists of employee-related costs (salaries, bonus, fringe benefits, and
stock-based compensation) of our laboratory and manufacturing personnel, and other support personnel, as well as outside laboratory costs, laboratory and manufacturing supplies, logistic costs, depreciation, and administrative-related costs
allocated to cost of revenues.



|                             |  |                             |       |   |         |   |       |         |  |   |       |  |  |  |    |  
|---------------------------- |  | --------------------------- | ----- | - | ------- | - | ----- | ------- |  | - | ----- |  |  |  | -- | -
|                             |  | Three Months EndedMarch 31, |       |   | $Change |   |       | %Change | 
|                             |  | 2011                        |       |   | 2010    |   |       |        
|Gross margin (in thousands)  |  | $                           | 8,497 |   |         | $ | 5,353 |         |  | $ | 3,144 |  |  |  | 59 | %
|Gross margin (% of revenues) |  |                             | 63    | % |         |   | 50    | %       |  |   |       |  |  |  |    |  



23



---

##### Table of Contents

Cost of consumables and products related revenues for the three months ended March 31, 2011 and 2010
were $3.3 million and $4.0 million, respectively. Gross margins on consumables and products related sales for the three months ended March 31, 2011 were 70%, compared to 60% for the same period in 2010. Gross margins increased primarily due to
exclusively selling the MassARRAY 4 systems during the first quarter of 2011, which have a higher margin than the systems sold in the same period in 2010, plus higher consumable sales to the comparable period in 2010, which historically sell at
higher average gross margins.

Cost of contract research service revenues for the three months ended March 31, 2011 were $0.1 million, or
flat as compared to the same period in 2010. Gross margins were 80% during the quarter ended March 31, 2011, as compared to 76% for the quarter ended March 31, 2010. The improved margins in 2011 are attributable to our focus on higher
margin studies. Gross margins on contract research service revenues are dependent on the particular contract terms of the work undertaken in each quarter.

Costs of diagnostic revenues are recognized at the completion of testing and were $1.6 million and $1.2 million for the three months ended March 31, 2011 and 2010, respectively. Due to revenue being
recognized when cash is received, costs incurred in one period may relate to revenue recognized in a later period. Gross margins were 7% for the three months ended March 31, 2011 and negative for the three months ended March 31, 2010, as
we continued to build test volumes to cover costs associated with running our diagnostic tests, as well as other capacity related expenses. Gross margin on diagnostic tests were affected by test volumes, cash collected during the period, overall
reimbursement for the amount paid per test, and favorable laboratory operational costs.

We believe that gross margin in future periods will
be affected by, among other things, the selling price for systems and consumables, consumable sales per MassARRAY system sold, the mix of product sales and the type of services, competitive conditions, sales volumes, discounts offered, sales through
distributors, as well as the cost of goods sold, inventory reserves and obsolescence charges required, and royalty payment obligations on in-licensed technologies. Our gross margin will also be affected by the adoption rates of the diagnostic LDTs
we commercialize and the payor and other contracts we may enter into for laboratory developed or diagnostic tests.

Research and
development expenses

Research and development expenses consisted primarily of salaries and related personnel expenses, product development
costs, quality and regulatory costs, and expenses relating to work performed under research contracts.



|                                         |  |                             |        |   |         |   |        |         |  |   |      |   |  |  |    |   
|---------------------------------------- |  | --------------------------- | ------ | - | ------- | - | ------ | ------- |  | - | ---- | - |  |  | -- | --
|                                         |  | Three Months EndedMarch 31, |        |   | $Change |   |        | %Change | 
|                                         |  | 2011                        |        |   | 2010    |   |        |        
|Research and development (in thousands)  |  | $                           | 10,722 |   |         | $ | 11,191 |         |  | $ | (469 | ) |  |  | (4 | %)
|Research and development (% of revenues) |  |                             | 79     | % |         |   | 105    | %       |  |   |      |   |  |  |    |   

The decrease in research and development expenses for the three months ended March 31, 2011, as compared to
the same period in 2010 primarily related to lower clinical trial costs of $1.5 million associated with our trisomy and Rhesus D programs and the discontinued gender program, lower milestone payments of $0.4 million related to our licensing
agreement with Optherion, and lower restricted stock compensation expense of $0.1 million; offset by lower absorbed costs of $0.4 million due to decreased logistics costs in the current period, higher consulting costs of $0.5 million related to an
ongoing validation study, higher lab costs of $0.3 million due to an increase in sequencing activities, and higher labor costs of $0.3 million related to an increase in headcount and normal salary and wage increases.

We expect our research and development expenses to increase in 2011 compared to 2010, as we continue to expand our investment in the development of
noninvasive prenatal nucleic acid based tests, including a potential trisomy 21 LDT, and other noninvasive tests, and as we continue to invest in new products and applications for our MassARRAY system platform.

Selling and marketing expenses

Selling
and marketing expenses consisted primarily of salaries and related expenses for sales and marketing, customer support, and business development personnel and their related department expenses.



|                                      |  |                             |       |   |         |   |       |         |  |   |      |   |  |  |    |   
|------------------------------------- |  | --------------------------- | ----- | - | ------- | - | ----- | ------- |  | - | ---- | - |  |  | -- | --
|                                      |  | Three Months EndedMarch 31, |       |   | $Change |   |       | %Change | 
|                                      |  | 2011                        |       |   | 2010    |   |       |        
|Selling and marketing (in thousands)  |  | $                           | 6,060 |   |         | $ | 6,188 |         |  | $ | (128 | ) |  |  | (2 | %)
|Selling and marketing (% of revenues) |  |                             | 45    | % |         |   | 58    | %       |  |   |      |   |  |  |    |   

The decrease in selling and marketing expenses for the three months ended March 31, 2011 compared to the same
period in 2010 primarily was related to a decrease of $0.2 million associated with the reduction in consulting expenses within genetic analysis marketing programs and lower restricted stock compensation expense of $0.2 million; offset by higher
sales bonuses of $0.1 million, an increase in travel expenses of $0.1 million and an increase of $0.2 million in miscellaneous operating expenses.

We expect our sales and marketing expenses to increase in 2011 compared to 2010, as we expand our sales force and increase our marketing and commercial development teams in anticipation of
commercialization of our AMD and trisomy 21 LDTs.



24



---

##### Table of Contents

General and administrative expenses

General and administrative expenses consisted primarily of salaries and related expenses for executive, legal, finance, information technology, and human resource personnel, and their related department
expenses.



|                                           |  |                             |       |   |         |   |       |         |  |   |     |   |  |  |    |   
|------------------------------------------ |  | --------------------------- | ----- | - | ------- | - | ----- | ------- |  | - | --- | - |  |  | -- | --
|                                           |  | Three Months EndedMarch 31, |       |   | $Change |   |       | %Change | 
|                                           |  | 2011                        |       |   | 2010    |   |       |        
|General and administrative (in thousands)  |  | $                           | 4,838 |   |         | $ | 4,894 |         |  | $ | (56 | ) |  |  | (1 | %)
|General and administrative (% of revenues) |  |                             | 36    | % |         |   | 46    | %       |  |   |     |   |  |  |    |   

The decrease in general and administrative expenses for the three months ended March 31, 2011 from the same
period in 2010 was primarily due to a $0.3 million decrease in legal fees, lower restricted stock compensation expense of $0.1 million, and a $0.1 million decrease associated with lower insurance and other miscellaneous expenses. These decreases
were partially offset by an increase of $0.3 million in labor costs due to an increase in headcount and $0.1 million in other expenses.

We
expect general and administrative costs to decrease in 2011 compared to 2010, due to expected lower legal costs related to our ongoing investigations and litigation, offset by expansion in our infrastructure to support our anticipated growth.

Other income, net

Other
income, net, was approximately $404,000 and $5,000 for the three months ended March 31, 2011 and 2010, respectively. The increase was primarily due to $0.3 million related to the U.S. Governments Therapeutic Discovery Project Program,
favorable realized foreign currency translations and miscellaneous other income items.

Liquidity and Capital Resources

As of March 31, 2011, cash, cash equivalents and current marketable securities totaled $125.3 million, compared to $135.5 million at
December 31, 2010. Our cash equivalents and current marketable securities are held in certificates of deposit, mutual funds, corporate debt securities, and U.S. Government securities with ratings of AAA and repurchase agreements collateralized
by U.S. Government securities with ratings of AAA. Additional discussion with respect to the risks and uncertainties associated with our auction rate securities is included in the Risk Factors in Part II, Item 1A of this report, in
Quantitative and Qualitative Disclosures about Market Risk in Part I, Item 3 of this report and in the notes to our condensed consolidated financial statements included elsewhere in this report.

We have a history of recurring losses from operations and have an accumulated deficit of $730.8 million as of March 31, 2011. Our capital
requirements to sustain operations, including research and development projects, have been and will continue to be significant. As of March 31, 2011, we had working capital of $122.8 million. Other commitments and contingencies that may result
in contractual obligations to pay are described in the notes to our condensed consolidated financial statements included elsewhere in this report.

Based on our current plans, we believe our cash, cash equivalents and current marketable securities will be sufficient to fund our operating expenses and capital requirements into early 2013.

Cash Flows

We consider the
material drivers of our cash flow to be sales volumes, working capital, inventory management and operating expenses. Our principal sources of liquidity are our cash, cash equivalents and marketable securities. Cash used in operations for the three
months ended March 31, 2011, was $10.8 million, as compared to $13.4 million for the same period in 2010. The use of cash was primarily a result of the net loss of $12.7 million for the three months ended March 31, 2011, adjusted for
non-cash items of depreciation and amortization of $1.4 million, stock-based compensation, including restricted stock, of $2.6 million, offset by a non-cash change in deferred rent of $0.2 million. The changes in our operating assets and liabilities
primarily consisted of higher prepaid expenses and other assets, as well as lower accounts payable and accrued expense balances and other liabilities, which resulted in cash usages of $0.2 million and $2.7 million, respectively. The changes in
operating assets and liabilities were offset by lower accounts receivable and lower inventory balances representing our efforts to maximize working capital and an increase in our deferred revenue balance primarily associated with an increase in the
sale of maintenance contracts as compared to the three months ended March 31, 2010, which resulted in cash provisions of $0.2 million, $0.3 million, and $0.5 million, respectively. At our current and anticipated level of operating loss, we
expect to continue to incur an operating cash outflow for the next several years.

Net cash used in investing activities was $71.3 million for
the three months ended March 31, 2011, compared to cash provided of $15.2 million for the same period in 2010. For the three months ended March 31, 2011, the net change in our marketable securities used cash of $71.3 million, plus cash
usages for the purchases of capital equipment of $1.4 million, offset by cash provided by the release of restricted cash of $1.3 million. This is compared to cash used in investing activities in the comparative period in 2010, which consisted of a
net change in our marketable securities that provided cash of $15.5 million, offset by cash usages for the purchases of capital equipment that used $0.2 million.



25



---

##### Table of Contents

Net cash provided by financing activities was $0.3 million and $0.2 million for the three months ended
March 31, 2011 and 2010, respectively. Financing activities during the three months ended March 31, 2011, included the receipt of proceeds from the exercise of stock options and employee stock purchase plan purchases during the period of
$0.6 million, offset by cash used for repayments on our debt and capital lease obligation of $0.3 million. This activity is compared to cash provided from the exercise of stock options and employee stock purchase plan purchases of $0.6 million and
repayments on our debt and capital lease obligation of $0.4 million for the three months ended March 31, 2010.



26



---

##### Table of Contents

|Item 3. | Quantitative and Qualitative Disclosures About Market Risk
|------- | ----------------------------------------------------------

Marketable Securities and Fair Value Measurements

The primary objective of our investment
activities is to preserve principal while at the same time maximizing the income we receive from our investments without significantly increasing risk. Some of the securities that we invest in may have market risk. This means that a change in
prevailing interest rates may cause the fair value of the principal amount of the investment to fluctuate. For example, if we hold a security that was issued with a fixed interest rate at the then-prevailing rate and interest rates later rise, the
fair value of the principal amount of our investment will probably decline. To minimize this risk our current investment policy requires us to maintain our portfolio of cash equivalents and marketable securities in a variety of securities that are
represented by issuances from the U.S. Government, repurchase agreements collateralized by U.S. Government securities that have ratings of AAA or are fully guaranteed by the U.S. Government. Our investment policy also includes a minimum quality
rating for all new investments and the overall amount that may be invested with a single security. If an investment we hold falls below this level, we research the reasons for the fall and determine if we should continue to hold the investment in
order to minimize our exposure to market risk of the investment.

The appropriate classification of marketable securities is determined at the
time of purchase and reevaluated as of each balance sheet date. Based on this determination, as of March 31, 2011 and December 31, 2010, all of our investments in marketable securities were classified as available for sale and were
reported at fair value. We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is determined based
on observable market quotes or valuation models using assessments of counterparty credit worthiness, credit default risk or underlying security and overall capital market liquidity. Declines in fair value that are considered other-than-temporary are
charged to operations and those that are considered temporary are reported as a component of accumulated other comprehensive income in stockholders equity. We use the specific identification method of determining the cost basis in computing
realized and unrealized gains and losses on the sale of our available-for-sale securities.

Foreign currency rate fluctuations

We have foreign operations whose functional currencies are the Great British Pound (GBP), the Japanese Yen (Yen), the Indian Rupee (INR),
the Australian Dollar (AUD) and the Euro (EUR). The subsidiaries accounts are translated from the relevant functional currency to the United States Dollar (USD) using the current exchange rate in effect at the balance sheet date, for balance
sheet accounts, and using the average exchange rate during the period for revenues and expense accounts. The effects of translation are recorded as a separate component of stockholders equity. Our subsidiaries conduct their business with
customers in local currencies. Additionally, we occasionally invoice Australian customers in their local currency. Exchange gains and losses arising from these transactions are recorded using the actual exchange differences on the date of the
transaction. We have not taken any action to reduce our exposure to changes in foreign currency exchange rates, such as options or futures contracts, with respect to transactions with our subsidiaries or transactions with our customers where the
invoicing currency is not the USD.

The table below sets forth our currency exposure (i.e., those transactional exposures that give rise to
the net currency gains and losses recognized in the income and expenditure account) on our net monetary assets and liabilities. These exposures consist of our monetary assets and liabilities that are not denominated in the functional currency used
by us or our subsidiary having the asset or liability.



|                                  |     |                                                               |     |     |  |   |     | 
|--------------------------------- | --- | ------------------------------------------------------------- | --- | --- |  | - | --- | 
|Functional currency of operations |     | As of March 31, 2011Net foreign monetary assets/(liabilities) |    
|                                  | AUD |                                                               |     | EUR | 
|                                  |     | ($ in millions)                                               |    
|USD                               |     | $                                                             | 1.1 |     |  | $ | 0.8 | 

A movement of 10% in the USD to AUD
exchange rate would create an unrealized gain or loss of approximately $105,000. A movement of 10% in the USD dollar to EUR exchange rate would create an unrealized gain or loss of approximately $79,000.

We had no off balance sheet, or unrecognized, gains and losses in respect of financial instruments used as hedges at the beginning or end of the three
month period ended March 31, 2011. We had no deferred gains or losses during the period covered.

Inflation

We do not believe that inflation has had a material adverse impact on our business or operating results during the periods presented.



27



---

##### Table of Contents

|Item 4. | Controls and Procedures
|------- | -----------------------

We maintain
disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the timelines specified in the rules and forms of the
Securities and Exchange Commissions, or SEC, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding
required disclosure.

As required by Rule 13a-15(b) under the Exchange Act, we carried out an evaluation, under the supervision and with
the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the year covered by this
report. Based on the foregoing, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2011 to ensure that (a) the information required to be
disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SECs rules and forms, and (b) such information is accumulated and
communicated to our management, including our principal executive officer and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management does not expect that even our disclosure controls or our internal controls will prevent all error and all fraud. A control system, no
matter how well conceived, implemented and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of a control system must reflect the fact that there are resource constraints,
and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any,
have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Controls can be circumvented by the individual acts of some
persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any
design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because
of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Further,
management determined that as of March 31, 2011, there were no changes in internal control over financial reporting that occurred during the three months ended March 31, 2011 that have materially affected, or are reasonably likely to
materially affect, our internal control over financial reporting.



28



---

##### Table of Contents

PART II  OTHER INFORMATION



|Item 1. | Legal Proceedings
|------- | -----------------

IPO Litigation

In November 2001, we and certain of our current or former officers and directors were named as defendants in a class action shareholder
complaint filed by Collegeware USA in the U.S. District Court for the Southern District of New York (now captioned In re Sequenom, Inc. IPO Securities Litigation) Case No. 01-CV-10831. In the complaint, the plaintiffs allege that our
underwriters, certain of our officers and directors and we violated the federal securities laws because our registration statement and prospectus contained untrue statements of material fact or omitted material facts regarding the compensation to be
received by and the stock allocation practices of the underwriters. The plaintiffs seek unspecified monetary damages and other relief. Similar complaints were filed in the same District Court against hundreds of other public companies that conducted
initial public offerings of their common stock in the late 1990s and 2000 (the IPO Cases).

In October 2002, our officers and directors were
dismissed without prejudice pursuant to a stipulated dismissal and tolling agreement with the plaintiffs. In February 2003, the District Court dismissed the claim against us brought under Section 10(b) of the Exchange Act, without giving the
plaintiffs leave to amend the complaint with respect to that claim. The District Court declined to dismiss the claim against us brought under Section 11 of the Securities Act of 1933, as amended (the Securities Act).

In September 2003, pursuant to the authorization of a special litigation committee of our board of directors, we approved in principle a settlement offer
by the plaintiffs. In September 2004, we entered into a settlement agreement with the plaintiffs. In February 2005, the District Court issued a decision certifying a class action for settlement purposes and granting preliminary approval of the
settlement subject to modification of certain bar orders contemplated by the settlement. In August 2005, the District Court reaffirmed class certification and preliminary approval of the modified settlement. In December 2006, the U.S. Court of
Appeals for the Second Circuit vacated the District Courts decision certifying as class actions the six lawsuits designated as focus cases. Thereafter the District Court ordered a stay of all proceedings in all of the lawsuits
pending the outcome of plaintiffs petition to the Second Circuit for rehearing en banc. In April 2007, the Second Circuit denied plaintiffs rehearing petition, but clarified that the plaintiffs may seek to certify a more limited class in
the District Court. Accordingly, the settlement as originally negotiated was terminated pursuant to stipulation.

In February 2009, liaison
counsel for plaintiffs informed the District Court that a new settlement of all IPO Cases had been agreed to in principle, subject to formal approval by the parties and preliminary and final approval by the District Court. In April 2009, the parties
submitted a tentative settlement agreement to the District Court and moved for preliminary approval thereof. In June 2009, the District Court granted preliminary approval of the tentative settlement and ordered that notice of the settlement be
published and mailed to class members. In September 2009, the District Court held a final fairness hearing. In October 2009, the District Court certified the settlement class in each IPO Case and granted final approval to the settlement. Thereafter,
three shareholders filed a Petition for Permission to Appeal Class Certification Order, asserting that the District Courts certification of the settlement classes violates the Second Circuits earlier class certification decisions in the
IPO Cases and a number of shareholders also filed direct appeals, objecting to final approval of the settlement. If the settlement is affirmed on appeal, the settlement will result in the dismissal of all claims against us and our officers and
directors with prejudice, and our pro rata share of the settlement fund will be fully funded by insurance.

Securities and Shareholder
Derivative Litigation

In April 2009, we announced that the expected launch of our a test for trisomy 21 then under development by Sequenom
CMM had been delayed and that they were no longer relying on the previously announced test data and results for that test, as a result of inadequately substantiated claims, inconsistencies and errors and inadequate protocols and controls, which
included: the mischaracterization of tests as having been conducted in a blinded manner (i.e., that the tests had been performed by scientists who did not know the true outcomes for the samples tested before the test results had been determined);
the improper unblinding of true outcomes for samples being tested; the use of the unblinded true outcomes to alter and improve reported test results; the unsubstantiated reporting of test results for low-risk samples (i.e., samples from expectant
mothers who were less likely to be carrying a fetus with trisomy 21) without knowing the true outcomes for such samples; the failure to perform testing on those low-risk samples; the inadequate storage of serum samples resulting in breakdown of
nucleic acids; and other improper practices. Following the April 2009 announcement, several complaints were filed in the U.S. District Court for the Southern District of California against us and certain of our current and former officers and
directors on behalf of certain purchasers of our common stock. The complaints included claims asserted under Sections 10 and 20(a) of the Exchange Act and Sections 11 and 12(a)(2) of the Securities Act and were brought as shareholder class actions.
In general, the complaints alleged that we and certain of our officers and directors violated federal securities laws by making materially false and misleading statements regarding our test, thereby artificially inflating the price of our common
stock. In September 2009 the complaints were consolidated under the caption In re Sequenom, Inc. Securities Litigation, Master File No. 3:09-cv-00921 LAB-WMC and a lead plaintiff was appointed. In December 2009 we entered into a stipulation of
settlement with the lead plaintiff on behalf of the plaintiffs class. Pursuant to the terms of the stipulation, we paid $14 million, which



29



---

##### Table of Contents

was funded by insurance proceeds. We also agreed to issue to the plaintiffs class approximately 6.8 million shares of our common stock, and to adopt or continue our implementation of
changes and additions to certain corporate governance policies, protocols and practices. The court held a final settlement approval hearing in May 2010, following which the court approved the final settlement. The time for appeals lapsed without any
appeal. Of the 6.8 million shares of common stock to be issued in the settlement, 409,005 shares were issued in June 2010 to counsel for the plaintiffs class in accordance with the stipulation of settlement. Following completion of the
class action claim procedures, we issued the balance of 6,407,738 shares as of December 31, 2010.

In May 2009, a shareholder derivative
complaint was filed in the Superior Court of California for the County of San Diego against certain of our current and former directors and officers. Thereafter, a number of similar actions, also styled as shareholder derivative suits, were filed in
state court and were consolidated in a single court. In July 2009 the first of three shareholder derivative suits were filed in the U.S. District Court for the Southern District of California. The federal shareholder derivative actions were
consolidated before a single court under the caption In re Sequenom, Inc. Derivative Litigation, S.D. Cal. Case No. 09-CV-1341 LAB (WMc) and plaintiffs filed a single consolidated complaint. A separate federal derivative compliant, Ries, et al.
v. Stylli, et al, case no. 09-CV-2517 LAB (WMc), was filed thereafter and it was coordinated with the consolidated federal derivative action. The state and federal shareholder derivative actions are hereinafter collectively referred to as the
Derivative Actions. The complaints in the Derivative Actions allege breaches of fiduciary duties by the defendants and other violations of law. In general, the complaints allege that our directors and certain of our officers caused or
allowed for the dissemination of materially false and misleading statements regarding the trisomy 21 test then under development, thereby artificially inflating the price of our common stock. In May 2010, we entered into a stipulation of settlement
to resolve the Derivative Actions. The current and former directors and officers named as individual defendants in the Derivative Actions also entered into the stipulation of settlement. In exchange for a release of all claims by the plaintiffs and
a dismissal of the Derivative Actions, we agreed (i) to adopt or continue certain corporate governance measures and (ii) to pay the plaintiffs attorneys a total of $2.5 million, of which $1.0 million has been funded by insurance
proceeds. The U.S. District Court issued its final approval of the settlement in accordance with the terms of the stipulation of settlement in July 2010, and entered an order dismissing the federal shareholder derivative actions in July 2010. In
accordance with the terms of the stipulation of settlement, the parties in the state shareholder derivative actions filed a joint stipulation to dismiss the actions with prejudice in San Diego Superior Court in July 2010. In connection with the
final approval of settlement, we remitted a cash payment of $338,000 and issued 200,000 shares of our common stock at a fair value of $5.81 per share in payment of the portion of the plaintiffs attorneys fees not funded by insurance
proceeds.

SEC Investigation

In June 2009, we received written notification that the Enforcement staff of the Securities and Exchange Commission (SEC) has initiated an investigation
following our April 2009 announcement regarding the trisomy 21 test then under development. As part of this investigation, the SEC staff has also required us to produce information with respect to our announcement relating to our offer to acquire
EXACT Sciences, Inc. in January 2009. On March 7, 2011, the staff of the SEC advised us that it is considering recommending that the SEC bring a civil injunctive action against us alleging that we violated Sections 10(b) and 13(a) of the
Exchange Act of 1934 and Rules 10b-5, 12b-20, 13a-1 and 13a-11 thereunder. We have cooperated fully with the SEC in its investigation and will endeavor to negotiate an acceptable resolution with the staff, but any resolution that we may
negotiate with the staff will be subject to the approval of the SEC. There can be no assurance that such resolution will not have a material adverse effect on our business, results of operation or financial condition.

In June 2010, the SEC filed a complaint against Elizabeth Dragon, who was formerly our Senior Vice President, Research and Development. The complaint
alleged that between June 2008 and January 2009 Dr. Dragon made or allowed for the dissemination of materially false and misleading statements regarding the trisomy 21 test then under development, thereby inflating the price of our stock. The
SEC sought a permanent injunction against any future violations of the federal securities laws by Dr. Dragon, civil penalties, and imposition of an officer and director bar against her. On the same day, Dr. Dragon filed a consent to
judgment of permanent injunction and other relief. In the consent to judgment, Dr. Dragon, without admitting or denying the allegations in the SECs complaint, agreed to the permanent injunction against future violations of federal
securities laws, the director and officer bar, and civil penalties to be determined by the court. Prior to sentencing, Dr. Dragon passed away in February 2011.

DOJ and FBI Investigation

Following our September 2009 announcement regarding the work and
recommendations of a special committee of independent directors after it had completed its independent investigation of activity related to the trisomy 21 test, representatives of the Office of the U.S. Attorney for the Southern District of
California contacted us to inquire about the announcement. We intend to continue to cooperate fully with the U.S. Attorney and the Federal Bureau of Investigation (FBI) in this matter.

In June 2010, the U.S. Attorney filed a criminal information against Dr. Dragon. The criminal information charged Dr. Dragon with one count of conspiracy to commit securities fraud by conspiring
to disseminate materially false and misleading statements regarding the trisomy 21 test then under development. On the same day, Dr. Dragon pled guilty to the criminal information, and the magistrate judge assigned to this matter recommended
that the district court judge accept Dr. Dragons guilty plea. Prior to sentencing, Dr. Dragon passed away in February 2011.



30



---

##### Table of Contents

Former Employee Litigation

In August 2010, Paul Hawran, our former chief financial officer, sued the three directors who comprised the special committee that conducted the investigation of activity related to the trisomy 21 test,
alleging that they had defamed him, invaded his privacy, negligently and intentionally interfered with his prospective economic advantage, and committed unfair business practices under California Business and Professions Code Section 17200.
Mr. Hawran alleged in his complaint that he was asked to resign because he had raised concerns about the conduct of certain of our directors. The lawsuit, Hawran v. Hixson et al, case no. 37-2010-00058632-CU-DF-NC, was filed in the Superior
Court of California for the North County of San Diego. In September 2010, we were served with an amended complaint in this lawsuit, in which Mr. Hawran named us as a defendant in addition to the three individuals previously named and added
claims of breach of contract and intentional and negligent misrepresentation. In October 2010, the defendants filed a motion to strike the complaint under California Code of Civil Procedure Section 425.16 on the grounds that
Mr. Hawrans claims arise from acts in furtherance of the defendants right of petition or free speech under the United States or California Constitution in connection with a public issue and filed a demurrer to each and every cause
of action in the complaint. On January 3, 2011, the court issued a minute order dismissing some, but not all, of the claims alleged in the amended complaint. The defendants filed a notice of appeal regarding the minute order on January 11,
2011 and Mr. Hawran filed a cross-appeal regarding the same on January 31, 2011. The individual defendants and we intend to vigorously defend ourselves against the claims advanced.

In addition, from time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. These other matters are, in the opinion of management,
immaterial with respect to our consolidated financial position, liquidity, or results of operations.

Claim estimates that are probable and
can be reasonably estimated are reflected as liabilities of the Company. Because of the uncertainties related to the incurrence, amount and range of loss on any pending litigation, investigation, inquiry or claim, management is currently unable to
predict the ultimate outcome of any litigation, investigation, inquiry or claim, determine whether a liability has been incurred or make an estimate of the reasonably possible liability that could result from an unfavorable outcome. It is reasonably
possible that some of the matters, which are pending or may be asserted, could be decided unfavorably to the Company. An adverse ruling or outcome in any lawsuit involving us could materially affect our business, liquidity, consolidated financial
position or results of operations ability to sell one or more of our products or could result in additional competition. In view of the unpredictable nature of such matters, we cannot provide any assurances regarding the outcome of any litigation,
investigation, inquiry or claim to which we are a party or the impact on us of an adverse ruling of such matters.



31



---

##### Table of Contents

|Item 1A. | Risk Factors
|-------- | ------------

Before deciding to invest
in us or deciding to maintain or increase your investment, you should carefully consider the risks described below, in addition to the other information contained in this report and in our other filings with the SEC. The risks and uncertainties
described below and in our other filings are not the only ones facing us. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business. If any of these known or unknown risks or
uncertainties actually occurs, our business, financial condition and results of operations could be seriously harmed. In that event, the market price for our common stock could decline and you may lose your investment. The risk factors in this
report have been revised to incorporate changes to our risk factors from those included in our annual report on Form 10-K for the year ended December 31, 2010. The risk factors set forth below with an asterisk (*) next to the title are new
risk factors or risk factors containing changes, including any material changes, from the risk factors previously disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2010, as filed with the SEC.

*If we fail to obtain the capital necessary to fund our operations, our financial results, financial condition and our ability to
continue as a going concern will be adversely affected and we will have to delay or terminate some or all of our product development programs.

We expect to continue to incur losses for the foreseeable future and may have to raise substantial cash to fund our planned operations.

Our cash, cash equivalents and current marketable securities were $125.3 million as of March 31, 2011. Based on our current plans, we believe our cash, cash equivalents and current marketable
securities will be sufficient to fund our operating expenses and capital requirements into early 2013. Our announced plans for research and development activities to expand our diagnostic test menu can only be implemented if we are successful in
raising significant funds. In addition, there can be no assurances that our research and development activities will be successful. We need to collect a large number of patient samples in a timely manner in order to execute our molecular diagnostic
research and development activities. If we do not make sufficient research and development progress, this could adversely impact our ability to raise significant additional funds, which could adversely impact our ability to continue as a going
concern. The actual amount of funds that we will need and the timing of any such investment will be determined by many factors, some of which are beyond our control.

In September 2010, we filed a shelf registration statement with the SEC providing for the sale by us of up to $150 million of our equity and debt securities from time to time in one or more transactions.
This registration statement was declared effective by the SEC in October 2010 and is intended to provide us with the flexibility to take advantage of potential financing opportunities when and if deemed appropriate by our management. In December
2010, pursuant to this registration statement, we issued and sold 16,100,000 shares of our common stock at a price of $6.00 per share in a public offering that raised net proceeds of approximately $90.6 million. In addition to the capital we raised
in December 2010, we anticipate that we may need to raise additional funds in the future for the continued development and commercialization of our molecular diagnostic technology. We may need to sell equity or debt securities to raise significant
additional funds. However, it may be difficult for us to raise additional capital through the sale of equity or debt securities. The sale of additional securities will likely result in dilution to our stockholders. Additional financing may not be
available in amounts or on terms satisfactory to us or at all. We may be unable to raise additional funds due to a variety of factors, including our financial condition, the status of our research and development programs, the status of ongoing
litigation and pending governmental investigations and the general condition of the financial markets. If we fail to raise additional funds, we will have to delay or terminate some or all of our research and development programs, our financial
condition and operating results will be adversely affected and we may have to cease our operations.

The amount of additional funds we will
need depends on many factors, including:



| |  |  | the size of our future operating losses;
| | - |  | ----------------------------------------



| |  |  | our success and our distributors success in selling our MassARRAY system, ancillary reagents, software and services;
| | - |  | ---------------------------------------------------------------------------------------------------------------------



| |  |  | Sequenom CMMs success in generating revenues from its testing services for cystic fibrosis carrier screening and fetal Rhesus D genotyping and
the level of reimbursement it receives and its collections for those tests and future tests;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the terms and conditions of sales contracts, including extended payment terms;
| | - |  | ------------------------------------------------------------------------------



| |  |  | the level of our selling, general and administrative expenses;
| | - |  | --------------------------------------------------------------



| |  |  | our success and the extent of our investment in the research, development and commercialization of diagnostic technology, including genetic analysis
technology, molecular diagnostics and noninvasive prenatal diagnostic technology and the acquisition and/or licensing of third party intellectual property rights;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our success in obtaining sufficient quantities and quality of patient samples;
| | - |  | ------------------------------------------------------------------------------



| |  |  | our success in obtaining regulatory clearance or approval to market our diagnostic products in various countries, including the United States;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------



32



---

##### Table of Contents

| |  |  | our success in validating our diagnostic tests and the levels of clinical performance achieved;
| | - |  | -----------------------------------------------------------------------------------------------



| |  |  | our success either alone or in collaboration with our partners in launching and selling additional diagnostic products or services;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------



| |  |  | our success and the extent of our investment in the research and development in our genetic analysis business;
| | - |  | --------------------------------------------------------------------------------------------------------------



| |  |  | the extent to which we enter into, maintain, and derive revenues from licensing agreements, including agreements to out-license our noninvasive
prenatal analysis technology, research and other collaborations, joint ventures and other business arrangements;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the amount of our legal expenses and any fines or damages arising out of the matters that were the subject of an investigation by a special committee
of our board of directors in 2009, including such amounts associated with the investigations by the SEC, the Office of the U.S. Attorney for the Southern District of California and the FBI, none of which are currently covered by insurance;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the level of our legal expenses and any damages or settlement payments arising from the lawsuit filed by our former chief financial officer to the
extent our insurance coverage is insufficient;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the amount of any legal expenses, settlement payments, fines or damages arising from any future investigation or litigation and the extent to which any
of the foregoing is not covered by insurance;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the dilution from any issuance of securities, whether in connection with future capital-raising or acquisition transactions, the settlement of
litigation, or otherwise;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the extent to which we acquire, and our success in integrating, technologies or companies;
| | - |  | ------------------------------------------------------------------------------------------



| |  |  | the level of our expenses associated with the audit of our consolidated financial statements as well as compliance with other corporate governance and
regulatory developments or initiatives;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | regulatory changes by the FDA and other worldwide regulatory authorities; or
| | - |  | ----------------------------------------------------------------------------



| |  |  | technological developments in our markets.
| | - |  | ------------------------------------------

General market conditions, the market price of our common stock, uncertainty about the successful development and validation of the trisomy 21 test and other laboratory developed tests (LDTs) and
diagnostic tests, the uncertainty regarding the results of ongoing litigation matters and the investigations by the SEC, the U.S. Attorney and the FBI or other factors may not support capital raising transactions. In addition, our ability to raise
additional capital may depend upon obtaining stockholder approval. There can be no assurance that we will be able to obtain stockholder approval if it is necessary. If we are unable to obtain sufficient additional funds on a timely basis or on terms
favorable to us, we may be required to cease or reduce further commercialization of our products, to cease or reduce certain research and development projects, to sell, license or otherwise dispose of some or all of our technology or assets or
business units, to merge all or a portion of our business with another entity or we may not be able to continue as a going concern. If we raise additional funds by selling shares of our capital stock (or otherwise issue shares of our capital stock
or rights to acquire share of our capital stock), the ownership interest of our current stockholders will be diluted.

*Uncertainty
regarding the SensiGene Trisomy 21 Test and other planned tests could materially adversely affect our business, financial condition and results of operations.

Sequenom CMM is focusing its research and development efforts on a noninvasive trisomy 21 test that analyzes DNA samples utilizing massively parallel shotgun sequencing, or MPSS, instead of our
proprietary MassARRAY system. We and Sequenom CMM have limited experience developing and no experience commercializing sequencing-based technology and need to rely on collaborative partners and sequencing technology provided by others in order to
commercialize a test utilizing sequencing. We have no control over the manufacture of the sequencers and consumables that Sequenom CMM expects to use for the SensiGene Trisomy 21 Test, including whether such sequencers will meet our quality system
requirements to ensure quality and reliability for the sequencers and consumables, and can give no assurance that we will be able to obtain a reliable supply of the sequencers and consumables that we will need for such a test.

The launch of any diagnostic test will require the completion of certain clinical development and commercialization activities, including the efforts of
collaborative partners on which we rely, and the expenditure of additional cash resources. We can give no assurance that we will be able to successfully complete the clinical development of any test or that we will be able to establish or maintain
the collaborative relationships that are essential to our clinical development and commercialization efforts. We also can give no assurance that we will be able to reduce our expenditures sufficiently or otherwise mitigate the risks associated with
our business to raise enough capital to complete clinical development or commercialization activities. Clinical development requires large numbers of patient samples and we may not be able to use prior collected samples or collect a sufficient
number of appropriate samples in a timely manner in the future to complete clinical development for a trisomy 21 test or any other planned molecular diagnostic test. Failure to possess or to collect a sufficient number of appropriate samples in a
timely manner could prevent or significantly delay our ability to research, develop, complete clinical development and validation, obtain FDA approval as may be necessary, and launch, any of the planned tests. Our inability to use prior collected
samples or any failure to complete our on-going clinical studies or commercialization of the trisomy 21 test, as well as other planned screening and diagnostic tests could have material adverse effects on our business, operating results or financial
condition.



33



---

##### Table of Contents

*We are the subject of investigations by the SEC, the Office of the U.S. Attorney for the Southern
District of California and the FBI, each of which could further adversely affect our reputation, business prospects, operating results, or financial condition.

In June 2009, we received written notification that the staff of the SEC has initiated an investigation relating to our April 29, 2009 announcement regarding the trisomy 21 test then under
development. As part of this investigation, the SEC staff has also required us to produce information with respect to our announcements relating to our offer to acquire EXACT Sciences, Inc. in January 2009. We intend to continue to cooperate fully
with the SEC in its investigation. Following our announcement on September 28, 2009 regarding the completion of the independent investigation by the special committee of our board of directors, the Office of the U.S. Attorney for the Southern
District of California and the FBI contacted us to inquire about our announcement. We intend to continue to cooperate fully with the U.S. Attorney and the FBI.

In June 2010, the SEC filed a complaint against Elizabeth Dragon, who was formerly our senior vice president, research and development. The complaint alleges that between June 2008 and January 2009
Dr. Dragon made or allowed for the dissemination of materially false and misleading statements regarding the trisomy 21 test then under development, thereby inflating the price of our stock. The SEC sought a permanent injunction against any
future violations of the federal securities laws by Dr. Dragon, civil penalties, and imposition of an officer and director bar against her. On the same day, Dr. Dragon filed a consent to judgment of permanent injunction and other relief.
In the consent to judgment, Dr. Dragon, without admitting or denying the allegations in the SECs complaint, agreed to the permanent injunction against future violations of federal securities laws, the director and officer bar, and civil
penalties to be determined by the court. In June 2010, the U.S. Attorney filed a criminal information against Dr. Dragon. The criminal information charges Dr. Dragon with one count of conspiracy to commit securities fraud by
conspiring to disseminate materially false and misleading statements regarding the trisomy 21 test then under development. On the same day, Dr. Dragon pled guilty to the criminal information, and the magistrate judge assigned to this matter
recommended that the district court judge accept Dr. Dragons guilty plea. Prior to sentencing, Dr. Dragon passed away in February 2011.

On March 7, 2011, the staff of the SEC advised us that it is considering recommending that the SEC bring a civil injunctive action against us alleging that we violated Sections 10(b) and 13(a) of the
Exchange Act of 1934 and Rules 10b-5, 12b-20, 13a-1 and 13a-11 thereunder. We have cooperated fully with the SEC in its investigation and will endeavor to negotiate an acceptable resolution with the staff, but any resolution that we may
negotiate with the staff will be subject to the approval of the SEC. There can be no assurance that such resolution will not have a material adverse effect on our business, results of operation or financial condition.

The investigations by the SEC, the U.S. Attorney and the FBI have had an adverse impact on our reputation, and if they continue for a prolonged period of
time, they may have a further adverse impact on our reputation, business prospects, operating results or financial condition. There can be no assurance that we will be able to negotiate an acceptable resolution with the staff of the SEC or that the
SEC will approve any resolution that we negotiate with the staff or that any resolution of this matter will not have a material adverse effect on our reputation, business prospects, operating results or financial condition. In the event that the
investigations by the SEC, the U.S. Attorney or the FBI lead to action against us or additional action against any current or former officer or director, our reputation, business prospects, operating results or financial condition may be adversely
impacted. We have indemnification obligations to our current and former officers and directors, which require that we advance the expenses they incur, including the fees and costs of their attorneys in connection with these matters. These
matters are likely to result in the continued incurrence of significant legal expenses, which have exceeded our available insurance policy limits. These matters may result in the diversion of managements attention from our business and may
have a negative effect on employee morale.

We and certain of our current executive officers and directors have been named as defendants
in litigation that could result in substantial costs, divert managements attention and otherwise result in dilution to our stockholders.

In September 2010, we were served with a complaint in a lawsuit filed by our former chief financial officer. He has asserted various claims against us, our chief executive officer, our executive vice
president and one of our directors arising out of his resignation in September 2009. Although we intend to continue to vigorously defend such claims, there is no guarantee that we will be successful and we may be have to pay damages awards or
otherwise may enter into settlement arrangements in connection with such other claims. Any such payments or settlement arrangements could have material adverse effects on our business, operating results or financial condition. We may be required to
issue additional shares of our common stock or other securities convertible into or exchangeable for our common stock in connection with future settlements, which would result in additional dilution to our stockholders. Even if the pending claims
are not successful, litigation with respect to such claims could result in substantial costs and significant adverse impact on our reputation and divert managements attention and resources, which could have a material adverse effect on our
business, operating results or financial condition.



34



---

##### Table of Contents

*We have limited experience.

Sequenom CMMs noninvasive prenatal and other molecular diagnostic laboratory developed tests are in development or have just recently been launched. Additionally, we continue to develop new products
and create new applications for our products. We are also researching, developing and pursuing the commercialization of additional noninvasive molecular diagnostic tests for prenatal genetic disorders and other diseases and disorders for use on our
MassARRAY system and other platforms, and we have limited or no experience in these applications of our technology and operating and selling in these markets. We have limited experience developing and no experience commercializing sequencing-based
technology and rely on collaborative partners and sequencing technology provided by others in order to commercialize any test utilizing sequencing, including our noninvasive prenatal test for trisomy 21. Among other risks, using a platform provided
by another party presents potential manufacturing supply and reliability, quality compliance, and intellectual property infringement risks. Sequenom CMM has limited knowledge and experience regarding age-related macular degeneration, or AMD, and its
associated genetics and genetic factors and as a result, may be unable to conduct and complete adequate research and development activities in order to develop a commercially viable LDT for AMD. You should evaluate us in the context of the
uncertainties and complexities affecting an early stage company developing products and applications for the life science industries and experiencing the challenges associated with entering into new markets that are highly competitive. Based on our
limited experience in developing new products and applications, we may not:



| |  |  | effectively execute on or focus our research and development efforts;
| | - |  | ---------------------------------------------------------------------



| |  |  | properly model new opportunities to ensure appropriate resource allocation;
| | - |  | ---------------------------------------------------------------------------



| |  |  | create products that are appropriately developed to meet customer needs;
| | - |  | ------------------------------------------------------------------------



| |  |  | perform adequate and timely validation testing of such products and applications;
| | - |  | ---------------------------------------------------------------------------------



| |  |  | effectively assess and meet regulatory requirements in the United States and other countries;
| | - |  | ---------------------------------------------------------------------------------------------



| |  |  | ensure appropriate communication between different departments responsible for commercialization activities;
| | - |  | ------------------------------------------------------------------------------------------------------------



| |  |  | implement effective product launch or sales strategies;
| | - |  | -------------------------------------------------------



| |  |  | effectively design and manufacture products that achieve commercial success; or
| | - |  | -------------------------------------------------------------------------------



| |  |  | take other actions that ultimately lead to commercial success of any new products or applications that we develop.
| | - |  | ------------------------------------------------------------------------------------------------------------------

Sequenom CMM may face setbacks in the development and validation of noninvasive prenatal and other molecular diagnostic laboratory developed tests.

We need to make significant investments to ensure our diagnostic tests as well as our genetic analysis products and applications perform
properly and are cost-effective. We or our partners will likely need to apply for and obtain certain regulatory approvals to sell certain of our products under development for diagnostic applications, and it is uncertain whether such approvals will
be granted. Even if we develop products for commercial use and obtain all necessary regulatory approvals, we may not be able to develop products that are accepted or satisfy customers in the genomic, diagnostic, noninvasive prenatal, clinical
research, pharmaceutical, or other markets or the emerging field of molecular medicine and that can be marketed and sold successfully.

*We may not be able to generate significant revenue from noninvasive prenatal diagnostic tests or any other tests we may develop.

Our business is substantially dependent on our ability to develop and launch and obtain reimbursement for our diagnostic tests and
Sequenom CMM laboratory developed tests. Sequenom CMM has committed significant research and development resources for the development and validation of laboratory developed tests and Sequenom has likewise invested significant research and
development resources. There is no guarantee that Sequenom CMM will successfully generate significant revenues from any of its testing services that Sequenom CMM has launched or plans to launch in the future. In September 2009, Sequenom CMM launched
a testing service for cystic fibrosis carrier screening. In early 2010, Sequenom CMM launched a testing service for noninvasive prenatal Rhesus D. Sequenom CMM is pursuing the development and launch of a testing service for assessment of risk for
progressing from early to late AMD, as well as a testing service for noninvasive prenatal risk assessment for trisomy 21 and additional testing services in the future. However, there is no guarantee that Sequenom CMM will be able to successfully
launch any of these or any other diagnostic testing services on anticipated timelines or at all. We have limited experience in licensing, manufacturing, selling, marketing or distributing our SEQureDx technology, or diagnostic or other tests. If we,
or our partners, are not able to successfully market or sell noninvasive prenatal diagnostic tests or other tests we may develop for any reason, including the failure to obtain any required regulatory approvals, we will not generate any revenue from
the sale of such tests or Sequenom CMMs laboratory developed testing services. Even if we are able to develop noninvasive prenatal diagnostic or other tests for sale in the marketplace, a number of factors could impact our ability to sell such
tests or generate any significant revenue from the sale of such tests or testing services, including the following:



| |  |  | the outcome of the investigations by the SEC, the Office of the U.S. Attorney for the Southern District of California and the FBI and private
litigation;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------



35



---

##### Table of Contents

| |  |  | the effectiveness of the remedial measures recommended by the special committee following its independent investigation and our ability to implement
additional controls and risk management measures as appropriate;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our ability to establish and maintain sufficient intellectual property rights in our products;
| | - |  | ----------------------------------------------------------------------------------------------



| |  |  | intellectual property rights held by others, including United States Patent No. 7,888,017 titled Non-invasive Fetal Genetic Screening by
Digital Analysis assigned to Stanford University, and parties infringing our intellectual property rights;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the availability of adequate study samples for validation studies for any diagnostic tests we develop;
| | - |  | ------------------------------------------------------------------------------------------------------



| |  |  | reliance on Sequenom CMM, which is subject to routine governmental oversight and inspections for continued operation pursuant to Clinical Laboratory
Improvement Amendments, or CLIA, to process tests ordered by physicians;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Sequenom CMMs ability to establish and maintain adequate infrastructure to support the commercial launch of its testing services of its LDTs,
including establishing adequate laboratory space, information technology infrastructure, sample collection and tracking systems, electronic ordering and reporting systems and other infrastructure and hiring adequate laboratory and other personnel;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the level of success of the validation studies for Sequenom CMMs LDTs under development and its ability to continue to publish study results in
peer-reviewed journals;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the availability of alternative and competing tests or products and technological innovations or other advances in medicine that cause our technologies
to be less competitive;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | compliance with federal, state and foreign regulations governing laboratory testing on human specimens;
| | - |  | -------------------------------------------------------------------------------------------------------



| |  |  | the sale and marketing of research use only or other tests, including noninvasive prenatal tests;
| | - |  | -------------------------------------------------------------------------------------------------



| |  |  | the accuracy rates of such tests, including rates of false negatives and/or false positives;
| | - |  | --------------------------------------------------------------------------------------------



| |  |  | concerns regarding the safety and effectiveness or clinical validity of noninvasive prenatal or other tests;
| | - |  | ------------------------------------------------------------------------------------------------------------



| |  |  | changes in the regulatory environment affecting health care and health care providers, including changes in laws regulating laboratory testing and/or
device manufacturers and any laws regulating prenatal testing;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the extent and success of Sequenom CMMs sales and marketing efforts and ability to drive adoption of its diagnostic testing services;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------



| |  |  | coverage and reimbursement levels by government payors and private insurers;
| | - |  | ----------------------------------------------------------------------------



| |  |  | the level of physician adoption of any diagnostic tests we or Sequenom CMM develops;
| | - |  | ------------------------------------------------------------------------------------



| |  |  | pricing pressures and changes in third-party payor reimbursement policies;
| | - |  | --------------------------------------------------------------------------



| |  |  | general changes or developments in the market for womens and/or prenatal health diagnostics, or diagnostics in general;
| | - |  | ------------------------------------------------------------------------------------------------------------------------



| |  |  | ethical and legal issues concerning the appropriate use of the information resulting from noninvasive prenatal diagnostic tests or other tests;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the refusal by women to undergo such tests for moral, religious or other reasons, or based on perceptions about the safety or reliability of such
tests;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our ability to provide effective customer support; or
| | - |  | -----------------------------------------------------



| |  |  | our ability to promote and protect our SEQureDx patented technology and our other technologies.
| | - |  | -----------------------------------------------------------------------------------------------



36



---

##### Table of Contents

Our operating results may fluctuate significantly.

Our revenues and results of operations may fluctuate significantly, depending on a variety of factors, including the following:



| |  |  | our ability to manage costs and expenses and effectively implement our business strategy;
| | - |  | -----------------------------------------------------------------------------------------



| |  |  | our ability to raise additional capital;
| | - |  | ----------------------------------------



| |  |  | our success and our distributors success in marketing and selling, and changes in the demand for, our products and services, including our
MassARRAY system and iPLEX multiplex genotyping application and other applications and related consumables, and demand for products and services for genotyping, DNA methylation (epigenetic analysis) and QGE (gene expression analysis) applications;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Sequenom CMMs success in providing its cystic fibrosis carrier screening and fetal Rhesus D genotyping testing services and the level of
reimbursement Sequenom CMM receives and its collections for those tests;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our success in manufacturing, marketing and selling the MassARRAY Analyzer 4;
| | - |  | -----------------------------------------------------------------------------



| |  |  | the pricing of our products and services and those of our competitors;
| | - |  | ----------------------------------------------------------------------



| |  |  | our success in collecting payments from customers and collaborative partners, variations in the timing of these payments and the recognition of these
payments as revenues;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our success in responding to customer complaints effectively and managing relationships with our customers;
| | - |  | -----------------------------------------------------------------------------------------------------------



| |  |  | the timing and cost of any new product or service offerings by us;
| | - |  | ------------------------------------------------------------------



| |  |  | our ability to identify and develop in a cost-efficient manner new applications and products, such as noninvasive prenatal or other diagnostic assays
and other diagnostic technologies, our ability to improve current products to increase demand for such products and the success of such applications, products and improvements;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our ability to establish and maintain sufficient intellectual property rights in our products;
| | - |  | ----------------------------------------------------------------------------------------------



| |  |  | the potential need to acquire licenses to new technology, including genetic markers that may be useful in diagnostic applications, or to use our
technology in new markets, which could require us to pay unanticipated license fees and royalties in connection with licenses we may need to acquire;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our research and development progress and how rapidly we are able to achieve technical milestones;
| | - |  | --------------------------------------------------------------------------------------------------



| |  |  | the cost, quality and availability of the MassARRAY Analyzer 4, consumable chips, also known as SpectroCHIP arrays, oligonucleotides, DNA samples,
tissue samples, reagents and related components and technologies;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | material developments in our customer and supplier relationships, including our ability to successfully transition to new technologies;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Sequenom CMMs ability to validate any potential noninvasive prenatal or other LDTs;
| | - |  | ------------------------------------------------------------------------------------



| |  |  | our ability to obtain regulatory clearance or approval of any potential diagnostic product;
| | - |  | -------------------------------------------------------------------------------------------



| |  |  | the level of our legal expenses and any fines or damages arising out of the matters that were the subject of an investigation by a special committee of
our board of directors in 2009, including the investigations by the SEC, and the Office of the U.S. Attorney for the Southern District of California and the FBI, none of which are covered any longer by insurance; or
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the level of our legal expenses and any fines, damages or settlement payments arising from the lawsuit filed by our former chief financial officer or
any future investigation or litigation and the extent to which any of the foregoing is not covered by insurance.
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Further,
our revenues and operating results are difficult to predict because Sequenom CMMs testing services have only recently been launched and we do not have sufficient history to forecast revenues reliably for those tests, and also because our
revenues and operating results depend on the number, timing, and type of MassARRAY system placements that we make during the year and the quantity and timing of consumables sales for the installed base of systems. Changes in the relative mix of our
MassARRAY system and consumables sales, as well as service agreements can have a significant impact on our gross margin, as consumable sales and service agreements typically have margins significantly different than MassARRAY system sales. Our
international revenues and operating results are also difficult to predict because they depend upon the activities of our distributors in some countries. The absence of or delay in generating revenues will have a significant adverse effect on our
operating results from period to period and result in increased operating losses.



37



---

##### Table of Contents

We believe that period-to-period comparisons of our financial results will not necessarily be meaningful.
You should not rely on these comparisons as an indication of our future performance. If our operating results in any future period fall below the expectations of securities analysts and investors, our stock price will likely fall.

A reduction in revenues from sales of MassARRAY systems would harm our business.

We expect that sales of MassARRAY systems and consumables will account for most of our total revenues throughout 2011 and perhaps thereafter, unless and until our noninvasive prenatal or Sequenom
CMMs testing services begin to generate significant revenues. The following factors, among others, would reduce the demand for MassARRAY systems and services:



| |  |  | our success in manufacturing, marketing and selling the MassARRAY Analyzer 4;
| | - |  | -----------------------------------------------------------------------------



| |  |  | our ability to maintain necessary quality standards and specifications for the MassARRAY Analyzer 4;
| | - |  | ----------------------------------------------------------------------------------------------------



| |  |  | unstable, weak, or deteriorating economic conditions and fiscal policies or changes in fiscal policies that negatively impact customer buying
decisions;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | uncertainty about our ability to supply products and services to customers;
| | - |  | ---------------------------------------------------------------------------



| |  |  | competition from other products and service providers or failure of our products or applications or services; or
| | - |  | ----------------------------------------------------------------------------------------------------------------



| |  |  | negative publicity or evaluations, particularly with respect to product warranty and repair and troubleshooting services provided to existing
customers, or with respect to the investigations by the SEC, the Office of the U.S. Attorney for the Southern District of California or the FBI, or the lawsuit filed by our former chief financial officer or other private litigation, developments or
events in our prenatal diagnostic and other programs.
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Our revenues are subject to risks faced by our customers and
potential customers.

We expect that our revenues throughout 2011 and perhaps thereafter, unless and until our noninvasive prenatal and
Sequenom CMMs testing services begin to generate significant revenues, will be derived primarily from MassARRAY systems provided to academic institutions and other research institutions. Our operating results could fluctuate substantially due
to reductions and delays in research and development expenditures by these customers. These reductions and delays could result from factors such as:



| |  |  | changes in economic conditions and possible country-based boycotts;
| | - |  | -------------------------------------------------------------------



| |  |  | changes in government programs that provide funding for these customers;
| | - |  | ------------------------------------------------------------------------



| |  |  | other factors affecting research and development spending; or
| | - |  | -------------------------------------------------------------



| |  |  | uncertainty about our ability to continue as a going concern and fund operations and supply products and services to customers.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------

None of these factors are within our control. We have broadened the markets to which we sell our products and applications
and continue to develop new applications and products for use in new markets. We are targeting customers in clinical research and clinical marker validation, the emerging field of molecular medicine, genetic service laboratories, and animal testing
laboratories and diagnostic testing markets. We have limited or no experience operating in certain of these potential markets and, as a result, may be unable to develop products and applications that allow us to penetrate these markets or
successfully generate any revenue from sales in these markets. We have limited ability to forecast demand for our products and applications in these markets.

*We depend on sales of our consumable chips and other MassARRAY consumables for a significant portion of our revenues.

Sales of our consumable chips and other consumables for the MassARRAY system are an important source of revenue. Revenues from MassARRAY consumables totaled approximately 39% of our total revenues for the
quarter ended March 31, 2011, compared to 48% of our total revenues for the quarter ended March 31, 2010. Factors which may limit the use of our consumable chips and other consumables or otherwise adversely affect our revenues from
consumables include:



| |  |  | the extent of our customers level of utilization of their MassARRAY systems;
| | - |  | -----------------------------------------------------------------------------



| |  |  | our ability to provide timely repair services and our ability to secure replacement parts, such as lasers, for our MassARRAY systems;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the extent to which customers increase multiplexing levels using iPLEX applications;
| | - |  | ------------------------------------------------------------------------------------



| |  |  | the availability and adoption of new technologies and applications provided by our competitors;
| | - |  | -----------------------------------------------------------------------------------------------



| |  |  | a failure to sell additional MassARRAY systems;
| | - |  | -----------------------------------------------



| |  |  | the termination of contracts with or adverse developments in our relations with suppliers of our consumables;
| | - |  | -------------------------------------------------------------------------------------------------------------



| |  |  | the training of customer personnel in the use of our products;
| | - |  | --------------------------------------------------------------



| |  |  | the acceptance of our technology by our customers;
| | - |  | --------------------------------------------------



38



---

##### Table of Contents

| |  |  | any negative publicity with respect to the investigations by the SEC, the Office of the U.S. Attorney for the Southern District of California or the
FBI, the lawsuit filed by our former chief financial officer or other private litigation or developments or events in our prenatal diagnostic and other programs;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | uncertainty about our ability to fund operations and supply products and services to customers;
| | - |  | -----------------------------------------------------------------------------------------------



| |  |  | our ability to maintain necessary quality standards and specifications for our SpectroCHIP arrays; or
| | - |  | -----------------------------------------------------------------------------------------------------



| |  |  | our ability to maintain suppliers for components for the MassARRAY Analyzer 4.
| | - |  | ------------------------------------------------------------------------------

Our wholly-owned subsidiary, Sequenom CMM, has limited experience operating a CLIA-certified laboratory. Its ability to successfully develop and
commercialize LDTs will depend on its ability to successfully operate its CLIA-certified laboratory and maintain required regulatory licensures.

Sequenom CMM, our wholly-owned CLIA-certified laboratory located in Grand Rapids, Michigan, has developed, validated and commercialized three LDTs. We acquired Sequenom CMM in 2008 and as a result have
limited experience operating a CLIA-certified laboratory. For future tests, if Sequenom CMM is unable to successfully develop and validate any new LDTs or other testing services that it intends to commercialize it may not be able to successfully
commercialize such tests on the anticipated timelines or at all. Although we have invested substantially in Sequenom CMMs infrastructure, it is possible that they may not have adequate infrastructure in place to meet demand for its currently
launched testing services or for the demand of future LDTs that it develops. In 2010 we established an additional Sequenom CMM laboratory in San Diego and a California clinical laboratory license was issued by the state to the San Diego laboratory
in October 2010. A federal CLIA certification was issued by CMS. Sequenom CMMs ability to successfully develop and validate LDTs will depend on its ability to successfully operate and maintain required regulatory licensure. We cannot provide
assurances that we or Sequenom CMM will have sufficient resources to successfully build or qualify an additional CLIA-certified laboratory.

CLIA is designed to ensure the quality and reliability of clinical laboratories by mandating specific standards in the areas of personnel qualifications,
administration and participation in proficiency testing, patient test management, quality control, quality assurance and inspections. The sanction for failure to comply with CLIA requirements may be suspension, revocation or limitation of a
laboratorys CLIA certificate, which is necessary to conduct business, as well as significant fines and/or criminal penalties. Laboratories must undergo on-site surveys at least every two years, which may be conducted by the Federal CLIA
program or by a private CMS approved accrediting agency such as the College of American Pathologists, among others. Sequenom CMM is also subject to regulation of laboratory operations under state clinical laboratory laws as will be any new
CLIA-certified laboratory that we establish or acquire. State clinical laboratory laws may require that laboratories and/or laboratory personnel meet certain qualifications, specify certain quality controls or require maintenance of certain records.
Certain states, such as California, Florida, Maryland, New York, Pennsylvania and Rhode Island, each requires that laboratories obtain licenses to test specimens from patients residing in those states and additional states may require similar
licenses in the future. If we are unable to obtain and maintain a license from these states, we will not be able to process any samples from patients located in those states. Only Washington and New York States are exempt under CLIA, as these states
have established laboratory quality standards at least as stringent as CLIAs. Potential sanctions for violation of these statutes and regulations include significant fines and the suspension or loss of various licenses, certificates and
authorizations, which could adversely affect our business and results of operations.

We may not successfully obtain regulatory approval
of any noninvasive prenatal or other product which we or our licensing or collaborative partners develop.

Products that we or our
collaborators develop in the molecular diagnostic, noninvasive prenatal diagnostic, or other markets, depending on their intended use, may be regulated as medical devices by the FDA and other worldwide regulatory authorities. In the United States
our products may require either a premarket approval application, or PMA, or a premarket notification, or 510(k), from the FDA, prior to marketing. The 510(k) notification process usually takes from three to six months from submission to clearance,
but can take significantly longer. The premarket approval process is much more costly, lengthy, uncertain, and generally takes from nine to eighteen months or longer from submission to approval. In addition, commercialization of any diagnostic or
other product that we or our licensees or collaborators develop would depend upon successful completion of non-clinical testing and clinical studies. Preclinical and clinical studies can be long, expensive, and uncertain processes and we do not know
whether we, our licensees, or any of our collaborators, would be permitted or able to undertake clinical studies of any potential products. It may take us or our licensees or collaborators many years to complete any such testing, and failure could
occur at any stage. Results from preliminary studies do not necessarily predict final results, and acceptable results in early studies may not be repeated in later studies. A number of companies in the diagnostics industry, including biotechnology
companies, have suffered significant setbacks in clinical studies, even after promising results in earlier studies. Delays or rejections of potential products may be encountered based on changes in regulatory policy for product approval during the
period of product development and regulatory agency review. If our projects reach clinical studies, we or our licensees or collaborators could decide to discontinue development of any or all of these projects at any time for commercial, scientific,
or other reasons.



39



---

##### Table of Contents

The FDA currently regulates in vitro diagnostic devices as products that assess human specimens and
are intended for use in the diagnosis of diseases or other conditions, under the authority of Section 321(h) of the Federal Food, Drug, and Cosmetic Act. Historically the FDA has exercised enforcement discretion and exempted from regulation
LDTs created and used within a single laboratory. LDTs have included a broad range of test types, from routine blood tests to complex genomic assays that seek to predict disease risk or a patients response to treatment. The FDA has emphasized
that its policy was to regulate LDTs in a way that would not inhibit the development of such tests or diminish the contribution they make to public health. Although LDTs to date have not been subject to FDA regulation, certification of the
laboratory is required under CLIA to ensure the accuracy and reliability of all laboratory testing through a quality assurance program, which includes standards in the areas of personnel qualifications, administration and participation in
proficiency testing, patient test management and quality control procedures. In addition, state laboratory licensing and inspection requirements may also apply. Although LDT testing is currently solely under the purview of CMS and state agencies who
provide oversight of laboratories, the FDA has been reviewing their approach to the oversight of LDTs, and the regulations may undergo change in the future.

In July 2010, the FDA held a two day public meeting to discuss the regulatory oversight of LDTs, which may result in new oversight in the future. We and Sequenom CMM may not be able to meet such new
regulatory oversight requirements and Sequenom CMM may be forced to stop offering LDTs until any such new regulatory requirements have been met, which would have a material adverse effect on our business. We cannot predict the extent of the
FDAs future regulation and policies with respect to LDTs in general or our diagnostic tests in particular. If Sequenom CMM is unable to successfully launch any LDTs or if it is otherwise required to obtain FDA premarket clearance or approval
prior to commercializing any testing service, its ability to generate revenue from the sale of such testing services may be delayed and it may never be able to generate significant revenues from sales of diagnostic products.

The FDA has recently expressed specific concern regarding direct-to-consumer genetic tests, and may require that such tests be offered only under
510(k) clearance or PMA and not as laboratory developed tests.

As part of the FDAs evolving position on the regulation of LDTs,
the FDA issued letters to a number of companies in mid-2010 that primarily related to direct-to-consumer genetic testing. In these letters, the FDA expressed concern about consumers making medical decisions in reliance on genetic tests that have not
undergone the FDAs premarket review. However, no formal guidance has yet been issued discussing the nature of the changes the FDA may make with respect to the regulation of LDTs, nor the scope of potential regulation.

Although Sequenom CMM does not sell its testing services directly to consumers, we also received a letter from the FDA in July 2010. We responded to the
FDA by letter in August 2010 and met with the FDA in September 2010. We reiterated at that meeting that Sequenom CMMs LDTs are physician ordered and neither we nor Sequenom CMM are involved in any direct-to-consumer commercialization of any
kind. The FDA indicated it had no further questions on the direct-to-consumer issue at this time. We will continue to monitor potential changes as the FDAs LDT policy evolves to ensure Sequenom CMMs activities are consistent with the
FDAs most current policy. Although the FDA has exercised enforcement discretion in the past for LDTs, we cannot assure you that the FDA will abstain from such action in the future against us, which would have material adverse effects on our
business.

*The results of preclinical and clinical studies are not necessarily predictive of future results, and our current diagnostic
products and product candidates may not have favorable results in later studies.

We intend to publish results of certain of our
studies, including studies of Sequenom CMMs SensiGene Trisomy 21 LDT currently under development, and there can be no assurance that such results will be viewed favorably by clinicians, patients or investors when published. For example, a
manuscript describing the results from our laboratory verification study was published online on February 10, 2011, in the American Journal of Obstetrics & Gynecology, or AJOG. A hard copy publication is available in the March 2011
print edition of AJOG. In addition, Sequenom CMMs scientific collaborators and other third parties may also publish results relating to their own studies. There can be no assurance that the results of their studies when published will be
viewed favorably. If such results are not viewed favorably after publication, it could have a negative impact on the perception of our technology and prospects. Additionally, there can be no assurance that the results of others studies are
indicative of our own future study results or of our ability to develop and commercialize noninvasive molecular diagnostic tests.

To date
performance data has not yet been demonstrated in large clinical validation studies for any of our diagnostic products. Favorable results in early studies may not be repeated in later studies that would be required to obtain either PMA approval or
510(k) clearance from the FDA. Our diagnostic products may fail to demonstrate positive results in clinical studies despite having progressed through earlier-stage validation studies. Limited results from earlier-stage studies may not predict
results from studies in larger numbers of subjects drawn from more diverse populations over a longer period of time. Unfavorable results from ongoing preclinical and clinical studies could result in delays, modifications or abandonment of ongoing or
future clinical studies, or abandonment of a product development program or may delay, limit or prevent regulatory approvals or commercialization.



40



---

##### Table of Contents

Because we exclusively licensed our noninvasive prenatal diagnostic testing rights from Isis any
dispute with Isis may adversely affect our and Sequenom CMMs ability to develop and commercialize diagnostic tests based on these licensed rights.

In October 2005, we entered into an exclusive license to noninvasive prenatal diagnostic rights (United States Patent No. 6,258,540 and foreign equivalents) with Isis, which we amended in October
2006 and in November 2007 to also include exclusive rights to intellectual property for noninvasive prenatal gender determination testing for social and lifestyle purposes. In November 2009, we entered into a third amendment to modify certain
time-based commercial launch milestones relating to aneuploidy and other products. We and Sequenom CMM are using and intend to continue to use the rights that we acquired under the license to develop and commercialize noninvasive prenatal nucleic
acid based tests. If there is any dispute between us and Isis regarding our rights under the license agreement, or we do not achieve the commercial launch milestones, as modified, in a timely manner, our and Sequenom CMMs ability to
exclusively commercialize these diagnostic tests and LDTs may be adversely affected and could delay or completely terminate our product development and commercialization efforts for these tests.

We and our licensees and collaborators may not be successful in developing or commercializing diagnostic products, and LDTs, diagnostic assays
including noninvasive prenatal diagnostic products, or other products using our products, services, or discoveries.

Development of
diagnostic or other products by us or LDTs developed by Sequenom CMM, our licensees, or our collaborators are subject to risks of failure inherent in the development and commercial viability of any such product, such as demand for such product.
These risks further include the possibility that such product would:



| |  |  | be found to be ineffective, unreliable, inadequate or otherwise fail to receive regulatory approval;
| | - |  | ----------------------------------------------------------------------------------------------------



| |  |  | be difficult or impossible to manufacture on a commercial scale;
| | - |  | ----------------------------------------------------------------



| |  |  | be uneconomical to market or otherwise not be effectively marketed;
| | - |  | -------------------------------------------------------------------



| |  |  | fail to be successfully commercialized if adequate reimbursement from government health administration authorities, private health insurers, and other
organizations for the costs of such product is unavailable;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | be impossible to commercialize because such product infringes on the proprietary rights of others or competes with products marketed by others that are
superior; or
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | fail to be commercialized prior to the successful marketing of similar products by competitors.
| | - |  | -----------------------------------------------------------------------------------------------

If a licensee discovers or develops diagnostic or other products or we or Sequenom CMM or a collaborator, discover or develop diagnostic or other
products using our technology, products, services, or discoveries, we may rely on that licensee or collaborator (hereafter referred to as partner) for product development, regulatory approval, manufacturing, and marketing of those
products before we can realize revenue and some or all of the milestone payments, royalties, or other payments we may be entitled to under the terms of the licensing or collaboration agreement. If we are unable to successfully achieve milestones or
our partners fail to develop successful products, we will not earn the revenues contemplated and we may also lose exclusive (as in the case of our license agreement with Isis, under which we in-license our fundamental noninvasive prenatal diagnostic
technology, and our license agreement with the Chinese University of Hong Kong) or non-exclusive license rights to intellectual property that are required to commercialize such products. Our agreements may allow our partners significant discretion
in electing whether to pursue any of these activities. We cannot control the amount and timing of resources our partners may devote to our programs or potential products. As a result, we cannot be certain that our partners will choose to develop or
commercialize any products or will be successful in doing so. In addition, if a partner is involved in a business combination, such as a merger or acquisition, or changes its business focus, its performance under its agreement with us may suffer
and, as a result, we may not generate any revenues or only limited revenues from the royalty, milestone, and similar payment provisions contained in our agreement with that partner.

Our ability to compete in the market may decline if we lose some of our intellectual property rights or are unable to obtain other intellectual property rights.

Our success will depend on our ability to obtain and protect patents on our technology, to protect our trade secrets, and to maintain our rights to
licensed intellectual property or technologies, including United States Patent No. 6,258,540 and foreign equivalents, which we have licensed from Isis for noninvasive prenatal diagnostics and noninvasive prenatal gender determination testing
for social and lifestyle purposes. Our patent applications or those of our licensors may not result in the issue of patents in the United States or other countries. Our patents or those of our licensors may not afford meaningful protection for our
technology and products. Others may challenge our patents or those of our licensors in litigation or by proceedings such as interference, oppositions and reexaminations, as is the case with the appeal pending before the European Patent Office with
respect to the European patent equivalent of United States Patent No. 6,258,540 (European Patent No. 994963). As a result, our patents or those of our licensors could be narrowed or invalidated or become unenforceable or lose priority to
other patents, which could adversely affect our ability to successfully commercialize any of our diagnostic products that are dependent upon such patents. With respect to the SensiGene Trisomy 21 test under development, Sequenom CMM is currently
focusing its efforts on a test that analyzes DNA samples utilizing MPSS instead of our proprietary MassARRAY system. While we believe our exclusive license to United States Patent No. 6,258,540 provides us



41



---

##### Table of Contents

substantial rights with respect to prenatal diagnostic products independent of platform and we are also the licensee of a patent application that contains claims regarding the use of MPSS in
prenatal diagnostics, we are also aware of other patent applications that contain the same claims and similar claims and are owned or controlled by a potential competitor. The issuance by the U.S. Patent and Trademark Office of a patent with respect
to any of these applications could result in an interference proceeding, which would be expensive and there can be no assurance that we would prevail in such a proceeding. If we do not prevail in any such proceeding, the prevailing party may obtain
superior rights to our claimed inventions and technology, which could adversely affect our ability to successfully commercialize the SensiGene Trisomy 21 test under development. For example, on February 15, 2011, Stanford University was issued
United States Patent No. 7,888,017 titled Non-invasive Fetal Genetic Screening by Digital Analysis which includes patent claims purportedly covering methods for the noninvasive detection of fetal aneuploidy. We believe a competitor
may have licensed rights to the 017 patent. If we are forced to challenge the validity of the 017 patent and defend against claims of infringement of that patent, or if we are forced to defend against any other asserted intellectual
property right, we will face costly litigation and diversion of managements attention and resources. As a result of such disputes, we may have to develop costly non-infringing technology or enter into licensing agreements. These agreements, if
necessary, may be unavailable on terms acceptable to us, which could seriously harm our business and financial condition.

Competitors may
develop products similar to ours that do not conflict with our patents or patent rights. Others may develop products, technologies or methods, including noninvasive prenatal tests or other diagnostic tests in violation of our patents or those of our
licensors, or by operating around our patents or license agreements, which could reduce sales of our consumables or reduce or remove our noninvasive prenatal and other diagnostic commercialization opportunities. To protect or enforce our patent
rights, we may initiate interference proceedings, oppositions, reexaminations or litigation against others. However, these activities are expensive, take significant time and divert managements attention from other business concerns. We may
not prevail in these activities. If we are not successful in these activities, the prevailing party may obtain superior rights to our claimed inventions and technology, which could adversely affect our ability to successfully commercialize any of
our diagnostic products that are dependent upon such technologies. The patent position of biotechnology companies generally is highly uncertain and involves complex legal and factual questions that are often the subject of litigation. No consistent
policy has emerged from the U.S. Patent and Trademark Office, the offices of foreign countries or the courts regarding the breadth of claims allowed or the degree of protection afforded under biotechnology patents. There is a substantial backlog of
biotechnology patent applications at the U.S. Patent and Trademark Office and of the equivalent offices around the world and the approval or rejection of patent applications may take several years.

Claims by other companies that we infringe their intellectual property rights or that patents on which we rely are invalid could adversely affect
our business.

From time to time, companies have asserted, and may again assert, patent, copyright and other intellectual proprietary
rights against our products or products using our technologies. These claims have resulted and may in the future result in lawsuits being brought against us. We may not prevail in any lawsuits alleging patent infringement given the complex technical
issues and inherent uncertainties in intellectual property litigation. If any of our products, technologies or activities, in particular our iPLEX products and our MassARRAY system (including the MassARRAY Analyzer 4), from which we derive a
substantial portion of our revenues, or Sequenom CMMs SensiGene Trisomy 21 or AMD LDTs under development, were found to infringe on another companys intellectual property rights, we could be subject to an injunction that would force the
removal of such product from the market or we could be required to redesign such product, which could be costly. We could also be ordered to pay damages or other compensation, including punitive damages and attorneys fees to such other
company. A negative outcome in any such litigation could also severely disrupt the sales of our marketed products to our customers or their customers, which in turn could harm our relationships with our customers, our market share and our product
revenues. Even if we are ultimately successful in defending any intellectual property litigation, such litigation is expensive and time consuming to address, will divert our managements attention from our business and may harm our reputation.

Other companies or entities also may commence actions seeking to establish the invalidity of our patents. In the event that one or more of
our patents are challenged, a court may invalidate the patent(s) or determine that the patent(s) is not enforceable, which could harm our competitive position. If one or more of our patents are invalidated or found to be unenforceable, or if the
scope of the claims in any of these patents is limited by a court decision, we could lose certain market exclusivity afforded by patents owned or in-licensed by us and potential competitors could more easily bring products to the market that
directly compete with our own. Such adverse decisions may negatively impact our revenues.

The rights we rely upon to protect the
intellectual property underlying our products may not be adequate, which could enable others to use our technology and reduce our ability to compete with them.

We require our employees, consultants, advisors, and collaborators to execute confidentiality agreements and in certain cases, assignment or license agreements. We cannot guarantee that these agreements
will provide us with adequate intellectual property ownership or protection against improper or unauthorized use or disclosure of confidential information or inventions. In some situations, these agreements may conflict with or be subject to the
rights of others with whom our employees, consultants, advisors, or collaborators have prior employment or consulting relationships. In some situations, as is the case with our employees in Germany, these types of agreements or relationships are
subject to foreign law, which provides us with less favorable rights or treatment than under United States law. Others may gain access to our inventions, trade secrets or independently develop substantially equivalent proprietary materials,
products, information, and techniques.



42



---

##### Table of Contents

Our business and industry are subject to complex and costly regulation and if government regulations
are interpreted or enforced in a manner adverse to us, we may be subject to enforcement actions, penalties, exclusion, and other material limitations on our operations.

We are subject to various federal, state and local laws targeting fraud and abuse in the health care industry, including anti-kickback and false claims laws. The Federal Anti-Kickback Statute prohibits
persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for
which payment may be made under a federal health care program, such as Medicare or Medicaid. The definition of remuneration has been broadly interpreted to include anything of value, including, for example, gifts, discounts, the
furnishing of free supplies, equipment or services, credit arrangements, payments of cash and waivers of payment. The recently enacted Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability
Reconciliation Act (collectively, the PPACA), among other things, amends the intent requirement of the federal anti-kickback and criminal health care fraud statutes. A person or entity no longer needs to have actual knowledge of this
statute or specific intent to violate it. In addition, the PPACA provides that the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim
for purposes of the false claims statutes.

The Anti-Kickback Statute is broad and prohibits many arrangements and practices that are lawful
in businesses outside of the health care industry. Recognizing that the Anti-Kickback Statute is broad and may technically prohibit many innocuous or beneficial arrangements, Congress authorized the U.S. Department of Health & Human
Services Office of Inspector General, or OIG, to issue a series of regulations, known as safe harbors. These safe harbors set forth requirements that, if met in their entirety, will assure health care providers and other parties that
they will not be prosecuted under the Anti-Kickback Statute. The failure of a transaction or arrangement to fit precisely within one or more safe harbors does not necessarily mean that it is illegal, or that prosecution will be pursued. However,
conduct and business arrangements that do not fully satisfy each applicable safe harbor may result in increased scrutiny by government enforcement authorities, such as the OIG. Many states have adopted laws similar to the Anti-Kickback Statute. Some
of these state prohibitions apply to referral of patients for health care items or services reimbursed by any payor, not only the Medicare and Medicaid programs, and do not contain identical safe harbors. Government officials have focused their
enforcement efforts on marketing of health care services and products, among other activities, and have brought cases against numerous companies and certain sales and marketing personnel for allegedly offering unlawful inducements to potential or
existing customers in an attempt to procure their business.

Another development affecting the health care industry is the increased use of
the federal civil False Claims Act and, in particular, actions brought pursuant to the False Claims Acts whistleblower or qui tam provisions. The False Claims Act imposes liability on any person or entity who, among
other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal health care program. The qui tam provisions of the False Claims Act allow a private individual to bring actions on behalf of the
federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary recovery. In recent years, the number of suits brought by private individuals has increased dramatically. In addition,
various states have enacted false claim laws analogous to the False Claims Act. Many of these state laws apply where a claim is submitted to any third-party payor and not merely a federal health care program. When an entity is determined to have
violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties of $5,500 to $11,000 for each separate false claim. There are many potential bases for liability under
the False Claims Act. Liability arises, primarily, when an entity knowingly submits, or causes another to submit, a false claim for reimbursement to the federal government. The False Claims Act has been used to assert liability on the basis of
inadequate care, kickbacks and other improper referrals, improper use of Medicare numbers when detailing the provider of services, and allegations as to misrepresentations with respect to the services rendered. Our activities relating to the sale
and marketing of our products may be subject to scrutiny under these laws. We are unable to predict whether we would be subject to actions under the False Claims Act or a similar state law, or the impact of such actions. However, the costs of
defending such claims, as well as any sanctions imposed, could significantly adversely affect our financial performance.

Federal law
prohibits any entity from offering or transferring to a Medicare or Medicaid beneficiary any remuneration that the entity knows or should know is likely to influence the beneficiarys selection of a particular provider, practitioner or supplier
of Medicare or Medicaid payable items or services, including waivers of copayments and deductible amounts (or any part thereof) and transfers of items or services for free or for other than fair market value. Entities found in violation may be
liable for civil monetary penalties of up to $10,000 for each wrongful act. Although we believe that our sales and marketing practices are in material compliance with all applicable federal and state laws and regulations, relevant regulatory
authorities may disagree and violation of these laws, or, our exclusion from such programs as Medicaid and other governmental programs as a result of a violation of such laws, could have a material adverse effect on our business, results of
operations, financial condition and cash flows.



43



---

##### Table of Contents

We have a history of generating a large percentage of our revenue at the end of each quarterly
accounting period.

Due to the manner in which many customers in target markets for our MassARRAY systems allocate and spend their
budgeted funds for acquisition of our products, a large percentage of our sales are booked at the end of each quarterly accounting period. Because of this timing of our sales, we may not be able to reliably predict order volumes and our quarterly
revenues. A sales delay of only a few days may significantly impact our quarter-to-quarter comparisons. If our quarterly or year-end revenues fall below the expectations of securities analysts and investors, our stock price may decline. Similarly,
if we are unable to ship our customer orders on time, or if extended payment terms are required, there could be a material adverse effect on revenues for a given quarter.

If our customers are unable to adequately prepare samples for our MassARRAY system, the overall market demand for our products may decline.

Before using the MassARRAY system, customers must prepare samples by following several steps that are subject to human error, including DNA isolation and
DNA amplification. If DNA samples are not prepared appropriately, or the proposed assays are too complex, the MassARRAY system may not generate a reading or a correct reading. If our customers experience these difficulties, they might achieve lower
throughput levels than specified for the system. If our customers are unable to generate expected levels of throughput, they might not continue to purchase our consumables, they could express their discontent with our products to others, or they
could collaborate with others to jointly benefit from the use of our products. Any or all of these actions would reduce the overall market demand for our products. From time to time, we have experienced customer complaints regarding data quality and
difficulty in processing more complex assays.

The sales cycles for our MassARRAY systems are lengthy, and we may expend substantial
funds and management effort with no assurance of successfully selling our products or services.

The sales cycles for our MassARRAY
system products are typically lengthy. Our sales and licensing efforts require the effective demonstration of the benefits, value, and differentiation and validation of our products and services, and significant education and training of multiple
personnel and departments within a customer organization. We may be required to negotiate agreements containing terms unique to each prospective customer or licensee which would lengthen the sales cycle. We may expend substantial funds and
management effort with no assurance that we will sell our products or services. In addition, this lengthy sales cycle makes it more difficult for us to accurately forecast revenue in future periods and may cause revenues and operating results to
vary significantly in such periods.

We may not be able to successfully adapt or maintain our products for commercial applications.

A number of potential applications of our MassARRAY technology and potential products, including research use only and diagnostic
applications for noninvasive prenatal and other molecular testing, may require significant enhancements in our core technology or the in-licensing of intellectual property rights or technologies. In connection with developing new products and
applications, we may not effectively deploy our research and development efforts in a cost-efficient manner or otherwise in a manner that leads to the successful commercialization and scale-up of such products and applications. If we are unable to
complete the development, introduction, or scale-up of any product, or if any of our products or applications, such as gene expression analysis, epigenetic analysis or iPLEX multiplexing, do not achieve a significant level of market acceptance, our
business, financial condition and results of operations could be seriously harmed. Achieving market acceptance will depend on many factors, including demonstrating to customers that our technology and products are cost competitive or superior to
other technologies and products that are available now or that may become available in the future. We believe that our revenue growth and profitability will substantially depend on our ability to overcome significant technological and other
challenges and successfully introduce our newly developed products, applications, and services into the marketplace.

We have limited
commercial production capability and experience and may encounter production problems or delays, which could result in lower revenue.

We partially assemble the MassARRAY system and partially manufacture our consumable chips and MassARRAY kits. The MassARRAY Analyzer 4 requires more
outsourcing of component manufacturing and more internal assembly. To date, we have only produced our current products in moderate quantities. We may not be able to maintain acceptable quality standards as we ramp up production of the MassARRAY
Analyzer 4. To achieve anticipated customer demand levels, we will need to transition and scale-up our production capability and maintain adequate levels of inventory while manufacturing our products at a reasonable cost. We may not be able to
produce sufficient quantities to meet market demand or manufacture our product at a reasonable cost. If we cannot achieve the required level and quality of production, we may need to abandon or reduce our internal efforts and fully outsource
production or rely on licensing and other arrangements with third parties. This reliance could reduce our gross margins and expose us to the risks inherent in relying on others. We might not be able to successfully outsource our production or enter
into licensing or other arrangements with these third parties, which would adversely affect our business. Also, from time to time we have experienced quality issues on some of our chips. We may not be able to maintain acceptable quality standards
for production of our chips, which could harm our business and result in lower revenue.



44



---

##### Table of Contents

We depend on third-party products and services and limited sources of supply to develop and
manufacture our products.

We rely on outside vendors to supply certain products and the components and materials used in our products.
Many of these products, components and materials are obtained from a single supplier or a limited group of suppliers and some have lead-times of several months. The MassARRAY Analyzer 4 is comprised of numerous components each provided to us from a
single source and some of which have lead times of several months. Regarding other elements of our MassARRAY system, we also have sole suppliers for our chips, our pins for our nanodispenser and our liquid handling device. Our consumables also
include components provided by sole suppliers. In the event of any adverse developments with these vendors, our product supply may be interrupted and obtaining substitute components could be difficult or require us to re-design our products and
assays which would have an adverse impact on our business. In the past, we have experienced quality problems with and delays in receiving components used to produce our consumable chips and quality issues with our chips, and also had technical
difficulties with our pin-tool nanoliter dispenser device. We have also experienced software and operational difficulties with our MassARRAY system. Our reliance on outside vendors generally, and a sole or a limited group of suppliers in particular,
involves several risks, including:



| |  |  | the inability to obtain an adequate supply of properly functioning, required products, components, and materials due to capacity constraints, product
defects, a discontinuance of a product by a supplier, or other supply constraints;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | reduced control over quality and pricing of products, components, and materials; or
| | - |  | -----------------------------------------------------------------------------------



| |  |  | delays and long lead times in receiving products, components, or materials from vendors.
| | - |  | ----------------------------------------------------------------------------------------

We depend on third-party products and services for our current and planned laboratory developed tests.

We rely on outside vendors to supply certain products and the components and materials used for laboratory developed tests currently provided by Sequenom
CMM and we will also rely on outside vendors for laboratory developed tests that Sequenom CMM plans to offer in the future. Many of these products, components and materials are obtained from a single supplier or a limited group of suppliers and
some have lead times of several months. For example, we are relying solely on Illumina, Inc. for sequencers and reagents for Sequenom CMMs planned laboratory developed tests for trisomy 21. Also, the MassARRAY Analyzer 4 mass
spectrometry system that is currently used for Sequenom CMMs cystic fibrosis carrier screen and fetal Rhesus D tests, is comprised of numerous components, each provided to us from a single source and some of which have lead times of several
months. Regarding other elements of our MassARRAY system, we also have sole suppliers for our chips, our pins for our nanodispenser and our liquid handling device.

Our consumables also include components provided by sole suppliers. In the event of any adverse developments with these vendors, our product supply may be interrupted and obtaining substitute components
could be difficult or require Sequenom CMM to re-design and/or re-validate its laboratory developed tests, which would have an adverse impact on our business, including Sequenom CMMs ability to offer or to continue to offer laboratory
developed tests. In the past, we have experienced quality problems with and delays in receiving components used to produce our consumable chips and quality issues with our chips, and also had technical difficulties with our pin-tool nanoliter
dispenser device. We have also experienced software and operational difficulties with our MassARRAY system. Our reliance on outside vendors generally, and a sole or a limited group of suppliers in particular, involves several risks, including:



| |  |  | the inability to obtain an adequate supply of properly functioning, required products, components, and materials due to capacity constraints, product
defects, a discontinuance of a product by a supplier, or other supply constraints;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | reduced control over quality and pricing of products, components, and materials;
| | - |  | --------------------------------------------------------------------------------



| |  |  | delays and long lead times in receiving products, components, or materials from vendors; and
| | - |  | --------------------------------------------------------------------------------------------



| |  |  | Sequenom CMMs inability to provide laboratory developed tests or to maintain or increase its capacity to do so.
| | - |  | ----------------------------------------------------------------------------------------------------------------

*If the validity of an informed consent from a subject was to be challenged, we could be forced to stop using some of our resources, which would
hinder our diagnostic product development efforts.

We have measures in place to ensure that all clinical data and genetic and other
biological samples that we receive from our clinical collaborators have been collected from subjects who have provided appropriate informed consent for the data and samples provided for purposes which extend to include commercial diagnostic product
development activities. We have measures in place to ensure that data and samples that have been collected by our clinical collaborators are provided to us on a subject de-identified basis. We also have measures in place to ensure that the subjects
from whom our data and samples are collected do not retain or have conferred on them any proprietary or commercial rights to the data or any discoveries derived from them. Our clinical collaborators are based in a number of different countries, and,
to a large extent, we rely upon our clinical collaborators for appropriate compliance with the subjects informed consent provided and with local law and international regulation. That our data and samples come from and are collected by
entities based in different countries results in complex legal questions regarding the adequacy of informed consent and the status of genetic material under a large number of different legal systems. The subjects informed consent obtained in
any



45



---

##### Table of Contents

particular country could be challenged in the future, and those informed consents could prove invalid, unlawful or otherwise inadequate for our purposes. Any findings against us, or our clinical
collaborators, could deny us access to or force us to stop using some of our clinical samples, which would hinder our diagnostic product development efforts. We could become involved in legal challenges, which could consume our management and
financial resources.

If we cannot obtain licenses to patented SNPs and genes relevant to our diagnostic areas of interest, we could be
prevented from obtaining significant revenue or becoming profitable.

The U.S. Patent and Trademark Office has issued and continues to
issue patents claiming single SNP and gene discoveries and their related associations and functions. If certain SNPs and genes are patented, we will need to obtain rights to those SNPs and genes to develop, use, and sell related assays and other
types of products or services utilizing such SNPs and genes. Required licenses may not be available on commercially acceptable terms. If we were to fail to obtain licenses to certain patented SNPs and genes, we might never achieve significant
revenue from our diagnostic product development.

If the medical relevance of SNPs is not demonstrated or is not recognized by others,
we may have less demand for our products and services and may have less opportunity to enter into diagnostic product development and commercialization collaborations with others.

Some of the products we hope to develop involve new and unproven approaches or involve applications in markets that we are only beginning to explore. They are based on the assumption that information
about genes and SNPs may help scientists better understand conditions or complex disease processes. Scientists generally have a limited understanding of the role of genes and SNPs in diseases, and few products based on gene discoveries have been
developed. We cannot be certain that genetic information will play a key role in the development of diagnostics or other products in the future, or that any genetic-based findings would be accepted by diagnostic, pharmaceutical, or biotechnology
companies or by any other potential market or industry segment. If we or our customers or collaborators are unable to generate valuable information that can be used to develop diagnostics or other products, the demand for our products, applications,
and services will be reduced and our business will be harmed.

We may not be able to form and maintain the collaborative relationships
or the rights to third-party intellectual property and technologies that our business strategy requires and such relationships may lead to disputes over technology rights or product revenue, royalties, or other payments.

We form research collaborations and licensing arrangements with collaborators to operate our business successfully. To succeed, we will have to maintain
our existing relationships and establish additional collaborations and licensing arrangements. Our current strategy includes pursuing partnering opportunities with larger companies interested in or involved in the development of pharmaceutical and
diagnostic products. Our strategy also includes obtaining licenses to third-party intellectual property rights and technologies, such as our exclusive license to noninvasive prenatal analysis rights that we acquired from Isis (United States Patent
No. 6,258,540 and foreign equivalents) and other rights we have acquired for the use of fetal nucleic acids obtained from maternal urine for noninvasive prenatal diagnostics and to pursue development of a test for assessment of risk for
developing AMD, to potentially expand our product portfolio and generate additional sources of revenue. If we do not achieve certain milestones in a timely manner, particularly with respect to the planned test for trisomy 21, we risk losing our
exclusive license rights from Isis and may also lose rights under our other licenses if we do not adequately pursue commercialization in the manner specified in those licenses. In the case of the Isis license, we have satisfied all milestone
obligations under the license agreement regarding Sequenom CMMs development of a fetal Rhesus D genotyping LDT and a fetal sex determination LDT, and provided Sequenom CMM meets its anticipated launch for a trisomy 21 LDT and we meet our U.S.
FDA submission date for a trisomy 21 test, we will have satisfied all milestone obligations under the license agreement regarding that test and the license would no longer be convertible to a non-exclusive license. Disputes may also arise in
connection with these collaborations and licensing arrangements, which may result in liability to us or may result in the loss of acquired technology that may adversely affect our business.

We cannot be sure that we will be able to establish any additional research collaborations, licensing arrangements, or other partnerships necessary to develop and commercialize products or that we can do
so on terms favorable to us. If we are unable to establish these collaborations or licensing arrangements, we may not be able to successfully develop any diagnostic or other products or applications including the Sequenom CMM SensiGene Trisomy 21
Test under development, or generate any milestone, royalty, or other revenue from sales of these products or applications. If our collaborations or licensing arrangements are not successful or we are not able to manage multiple collaborations
successfully, our programs will suffer and we may never generate any revenue from sales of products based on licensed rights or technologies or under these collaborative or licensing arrangements. If we increase the number of collaborations or
licensing agreements, it will become more difficult to manage the various relationships successfully and the potential for conflicts among the collaborators and licensees or licensors will increase. Conflicts with our collaborators, licensees or
licensors, or other factors may lead to disputes over technology or intellectual property rights or product revenue, royalties, or other payments, which may adversely affect our business.

In addition, our government grants provide the government certain license rights to inventions resulting from funded work. Our business could be harmed if the government exercises those rights.



46



---

##### Table of Contents

If we do not succeed in obtaining development and marketing rights for products developed in
collaboration with others, our revenue and profitability prospects could be substantially harmed.

Our business strategy includes, in
part, the development of noninvasive prenatal diagnostic and other products in collaboration with others, or utilizing the technology of others, and we intend to obtain commercialization or royalty rights to those products or technologies. If we are
unable to obtain such rights, or are unable to do so on favorable financial terms, our revenue and profitability prospects could be substantially harmed. To date, we have initiated limited activities towards commercializing products developed in
collaboration with, or utilizing the technology of, others. Even if we obtain commercialization rights, commercialization of products may require resources that we do not currently possess and may not be able to develop or obtain, or
commercialization may be financially unattractive based upon the revenue-sharing terms offered by potential licensors or provided for in the relevant agreement.

Ethical, privacy, or other concerns about the use of genetic information could reduce demand for our products and services.

Genetic testing, including gender determination and trisomy 21 testing, has raised ethical issues regarding privacy and the appropriate uses of the resulting information. For these reasons, governmental
authorities may limit or otherwise regulate the use of genetic testing or prohibit testing for genetic predisposition to certain conditions, particularly for those that have no known cure. Such concerns may lead individuals to refuse to use genetics
tests even if permitted. Any of these scenarios could reduce the potential markets for our products and services, which would seriously harm our business, financial condition, and results of operations.

If we breach any of the terms of our license or supply agreements, or these agreements are otherwise terminated or modified, the termination or
modification of such agreements could result in our loss of access to critical components and could delay or suspend our commercialization efforts.

We have sourced or licensed components of our technology from other parties. Our failure to maintain continued supply of such components, particularly in the case of sole suppliers, or the right to use
these components would seriously harm our business, financial condition, and results of operations. As a result, in the event that demand for our products declines or does not meet our forecasts, we could have excess inventory or increased expenses
or our margins could decrease which could have an adverse impact on our financial condition and business. In the event of any adverse developments with these vendors, our product supply may be interrupted, which would have an adverse impact on our
business. Changes to or termination of our agreements or inability to renew our agreements with these parties or enter into new agreements with other suppliers could result in the loss of access to these aspects of our technology or other
intellectual property rights or technologies that we may acquire from time to time and could impair, delay, or suspend our commercialization efforts. While we negotiate for agreement periods or notice of termination periods that provide us
reasonable periods of time to secure alternative supplies, and require that such agreements may not be terminated without advance notice arbitrarily or without good reason, such as uncured breach or insolvency, these negotiations are often
unsuccessful or such provisions may not provide us with adequate time to secure alternative supplies, provide us with access to alternative technologies on commercially acceptable terms, or otherwise provide us with adequate protection.

We may not successfully complete the acquisition of businesses or technologies that we desire to acquire.

We may acquire additional businesses or technologies, or enter into other strategic transactions.

Managing future acquisitions entails numerous operational and financial risks, including:



| |  |  | the inability to retain key employees of any acquired businesses or hire enough qualified personnel to staff any new or expanded operations;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the impairment of relationships with key customers of acquired businesses due to changes in management and ownership of the acquired businesses;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the inability to sublease on financially acceptable terms excess leased space or terminate lease obligations of acquired businesses that are not
necessary or useful for the operation of our business;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the exposure to federal, state, local and foreign tax liabilities in connection with any acquisition or the integration of any acquired businesses;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the exposure to unknown liabilities or disputes with the former stakeholders or management or employees of acquired businesses;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------



| |  |  | higher than expected acquisition and integration expenses that would cause our quarterly and annual operating results to fluctuate;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------



| |  |  | increased amortization expenses if an acquisition results in significant intangible assets;
| | - |  | -------------------------------------------------------------------------------------------



| |  |  | combining the operations and personnel of acquired businesses with our own, which would be difficult and costly;
| | - |  | ----------------------------------------------------------------------------------------------------------------



| |  |  | disputes over rights to acquired technologies or with licensors or licensees of those technologies; or
| | - |  | ------------------------------------------------------------------------------------------------------



47



---

##### Table of Contents

| |  |  | integrating or completing the development and application of any acquired technologies, which would disrupt our business and divert managements
time and attention.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------

We may also attempt to acquire businesses or technologies or attempt to enter into strategic
transactions that we are unable to complete. If we are unable to complete such transactions, we may expend substantial resources and ultimately not successfully complete the transaction. Such transactions may also distract management and result in
other adverse effects on our business and operations. These transactions may also involve the issuance of shares of our capital stock, which may result in dilution to our stockholders.

We may not be able to successfully compete in the biotechnology and diagnostic industries.

The biotechnology and diagnostic industries are highly competitive. We expect to compete with a broad range of companies in the United States and other countries that are engaged in the development and
production of products, applications, services, and strategies to analyze genetic information and strategies to develop and commercialize diagnostic, noninvasive prenatal diagnostic, and other products for customers in the clinical research and
clinical marker validation and molecular medicine fields as well as diagnostic service laboratories, animal testing and food safety labs, and customers in other markets. They include:



| |  |  | biotechnology, pharmaceutical, diagnostic, chemical, and other companies;
| | - |  | -------------------------------------------------------------------------



| |  |  | academic and scientific institutions;
| | - |  | -------------------------------------



| |  |  | governmental agencies; or
| | - |  | -------------------------



| |  |  | public and private research organizations.
| | - |  | ------------------------------------------

Many of our competitors have much greater financial, technical, research, marketing, sales, distribution, service, and other resources than we do. Our competitors may offer broader product lines and
services and have greater name recognition than we do. Several companies are currently making or developing products that compete with our products. Our competitors may develop or market technologies or products that are more effective or
commercially attractive than our current or future products that may render our technologies or products obsolete or that have superior intellectual property rights. The delay in the development and launch of a trisomy 21 test, as well as
developments in the investigations by the SEC, the Office of the U.S. Attorney for the Southern District of California and the FBI, and the lawsuit filed by our former chief financial officer or other pending private litigation may adversely affect
our competitive position and the market acceptance of any tests that we may commercialize and may affect our ability to maintain and recruit key personnel.

We may potentially compete with our customers, which may adversely affect our business.

We have sold MassARRAY systems worldwide to pharmaceutical and biotechnology companies, academic research centers, and government laboratories. Some of our customers use our DNA analysis products to
perform contract research services, or to perform genetics studies on their own disease populations for potential diagnostic applications and drug target identification in the same or similar manner as we have done. Although there are many potential
contract research services opportunities and disease areas and diagnostic applications, our customers may seek service work or develop diagnostic assays or may target diseases areas that may overlap with those that we have chosen to pursue. In such
cases we may potentially compete against our customers. Competition from our customers may adversely affect our services business or our ability to successfully commercialize diagnostic products.

If we cannot attract and retain highly-skilled personnel, our growth might not proceed as rapidly as we intend and our business may be adversely
affected.

The success of our business will depend on our ability to identify, attract, hire, train, retain, maintain, and motivate
highly skilled personnel, particularly sales, scientific, medical, and technical personnel, for our future success. Competition for highly skilled personnel is intense, and we might not succeed in attracting and retaining these employees. If we
cannot attract and retain the personnel we require, we would not be able to expand our business as rapidly as we intend. Our announcements in 2009 of the delay in the launch of the trisomy 21 test then under development and the results of the
investigation by the special committee may have had a negative effect on employee morale and may have affected our ability to retain and recruit key personnel. When we seek to hire personnel to fill open positions, we may be unable to hire qualified
replacements for the positions that we need to fill, and there may be significant costs associated with the recruiting, hiring and retention of officers and employees for the open positions. If we lose additional key employees, scientists, physician
collaborators or if our management team is not able to effectively manage us through these events, our business, financial condition, and results of operations may be adversely affected. We do not carry key person insurance covering any
of our officers or other employees.



48



---

##### Table of Contents

If we do not effectively manage our business as it evolves, it could affect our ability to pursue
opportunities and expand our business.

Evolution in our business, particularly our attempted transition to developing and
commercializing molecular diagnostic tests, has placed and may continue to place a significant strain on our personnel, facilities, management systems, information technology infrastructure, disclosure controls, internal controls and resources. We
have implemented the remedial measures recommended by the special committee of our board of directors following its independent investigation, including:



| |  |  | the introduction of a number of standard operating procedures regarding study design planning and review, including clear identification of whether a
study is blinded or unblinded, raw data storage at multiple locations, independent third-party review of blinded clinical data, and a redundancy review of clinical study design by our oversight committee and of blinded clinical data by the science
committee of our board of directors, our clinical group and our biostatistician;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the creation of the science committee to oversee our research and development strategy and activities, including our evaluation of cross-functional
training for personnel in all areas associated with research and development, covering: (i) the proper conduct of test studies, (ii) the proper and timely disclosure of any problems with test studies, and (iii) the proper handling of
data and results of test studies;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the hiring of a full-time biostatistician and engagement of an external consultant on an as needed basis as a clinical biostatistician;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the formalization of the role of our oversight committee and the appointment of project leaders to oversee and manage each of our products in
development;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the amendment of our new hire orientation program, employee handbook and code of business conduct and ethics and enhancement of our training programs
concerning ethics, scientific processes, public disclosures and professional e-mail conduct;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the revision of our policy concerning the storage of clinical samples, including requiring that samples be stored in third-party storage facilities,
bar-coding samples for electronic tracking and auditing, creating formal procedures for obtaining a sample, and limiting access to our sample storage freezer;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the requirement that the known outcomes of all samples to be used in any blinded experiment must be conveyed to the third party storage provider and
are only revealed to us after the results of the blinded experiment have been finalized;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the amendment and restatement of our disclosure committees charter;
| | - |  | --------------------------------------------------------------------



| |  |  | the adoption of a comprehensive new policy on corporate disclosure controls and procedures, a set of disclosure controls and procedures and a corporate
disclosure policy;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the reduction in the number of direct reports to our chief executive officer; and
| | - |  | ---------------------------------------------------------------------------------



| |  |  | the engagement of an external consultant to assist and advise the audit committee in developing an enterprise risk management process.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------

These remedial measures are designed to prevent the use of inadequate protocols and controls in our clinical studies and
the recurrence of the other errors discovered in the special committees investigation by:



| |  |  | establishing a procedural framework for the conduct of future clinical studies;
| | - |  | -------------------------------------------------------------------------------



| |  |  | inserting internal controls consistent with that framework;
| | - |  | -----------------------------------------------------------



| |  |  | augmenting our companys expertise in conducting clinical studies;
| | - |  | ------------------------------------------------------------------



| |  |  | reinforcing management oversight of the conduct of clinical studies;
| | - |  | --------------------------------------------------------------------



| |  |  | educating employees on the proper conduct of clinical studies and their responsibilities in such activities;
| | - |  | ------------------------------------------------------------------------------------------------------------



| |  |  | establishing control over the samples used in our clinical studies;
| | - |  | -------------------------------------------------------------------



| |  |  | establishing additional levels of responsibility for the development of new products;
| | - |  | -------------------------------------------------------------------------------------



| |  |  | enhancing our organizational structure to distribute management responsibility appropriately;
| | - |  | ---------------------------------------------------------------------------------------------



| |  |  | reinforcing our disclosure controls and procedures to prevent the dissemination of inadequately vetted information by our company; and
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------



| |  |  | improving our risk assessment and management in general.
| | - |  | --------------------------------------------------------

While we feel that the remedial measures that we have implemented have made our controls and procedures more effective, any controls and procedures, no matter how well designed and operated, can provide
only reasonable assurance of achieving the desired control objectives and no evaluation of controls and procedures can provide absolute assurance that all control issues have been detected. We will need to continue to improve our operational and
financial systems and managerial controls and procedures and train and manage our workforce and transition our business to execute on the commercialization of molecular diagnostic tests. If we fail to effectively manage the evolution of our business
and the transition to also being a provider of diagnostic products, including the



49



---

##### Table of Contents

effective implementation these remedial measures and additional changes to our corporate governance policies, protocols and practices, or fail to take other necessary action to maintain close
coordination among our various departments, our ability to execute on our business plan, rebuild credibility, pursue business opportunities, expand our business, and sell our products and applications in new markets may be adversely affected.

Certain of our molecular diagnostic tests may not be eligible for reimbursement by payors which may limit the demand for these tests by
physicians and their patients. We may incur additional financial risk related to collections and reimbursement in connection with the commercialization of our molecular diagnostic tests.

In September 2009, Sequenom CMM commercially launched its testing service for cystic fibrosis carrier screening and in early 2010 it launched its testing
service for noninvasive fetal Rhesus D genotyping, and it intends to continue launching additional molecular diagnostic testing services in the future. Because these LDTs have only recently been launched, demand for and reimbursement by payors of
these tests is uncertain. Because certain of the molecular diagnostic LDTs Sequenom CMM has launched or intends to launch as a testing service may not be medically necessary or may otherwise not be subject to reimbursement by payors, it is difficult
to know how much demand there will be for such tests by physicians. Sequenom CMM generally bills third-party payors for its testing services and pursues case-by-case reimbursement where policies are not in place for a particular test it has very
limited experience in billing and pursuing reimbursement and payment for molecular diagnostic tests. As a result of this lack of experience and uncertainty with respect to reimbursement, Sequenom CMM may also face an increased risk in its collection
efforts, including potential write-offs of doubtful accounts and long collection cycles for accounts receivable related to its testing service, which could adversely affect our business, results of operations and financial condition.

We must be in compliance with security and privacy regulations under the Health Insurance Portability and Accountability Act of 1996, or HIPAA, and
other state regulations, which may increase our operational costs.

The HIPAA privacy and security regulations establish comprehensive
federal standards with respect to the uses and disclosures of protected health information, or PHI, by health plans and health care providers, in addition to setting standards to protect the confidentiality, integrity and availability of electronic
PHI. The regulations establish a complex regulatory framework on a variety of subjects, including:



| |  |  | the circumstances under which uses and disclosures of PHI are permitted or required without a specific authorization by the patient, including but not
limited to treatment purposes, to obtain payments for services and health care operations activities;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | a patients rights to access, amend and receive an accounting of certain disclosures of PHI;
| | - |  | --------------------------------------------------------------------------------------------



| |  |  | the content of notices of privacy practices for PHI; and
| | - |  | --------------------------------------------------------



| |  |  | administrative, technical and physical safeguards required of entities that use or receive PHI electronically.
| | - |  | --------------------------------------------------------------------------------------------------------------

As Sequenom CMM launches additional commercial diagnostic tests, they must continue to implement policies and procedures related to compliance with the
HIPAA privacy and security regulations, as required by law, which may increase their operational costs. Furthermore, the privacy and security regulations provide for significant fines and other penalties for wrongful use or disclosure of PHI,
including potential civil and criminal fines and penalties. Although the HIPAA statute and regulations do not expressly provide for a private right of damages, Sequenom CMM also could incur damages under state laws to private parties for the
wrongful use or disclosure of confidential health information or other private personal information.

We incur significant costs as a
result of operating as a public company and our management expects to continue to devote substantial time to public company compliance programs.

As a public company, we incur significant legal, accounting and other expenses due to our compliance with regulations and disclosure obligations applicable to us, including compliance with the
Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well as rules implemented by the SEC and The NASDAQ Stock Market. The SEC and other regulators have continued to adopt new rules and regulations and make additional changes to existing
regulations that require our compliance. In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the
Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as say on pay and proxy access. Stockholder activism, the current political environment and the current high level of government
intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact (in ways we cannot currently anticipate) the manner in which we operate our business. Our
management and other personnel devote a substantial amount of time to these compliance programs and monitoring of public company reporting obligations and as a result of the new corporate governance and executive compensation related rules,
regulations and guidelines prompted by the Dodd-Frank Act and further regulations and disclosure obligations expected in the future, we will likely need to devote additional time and costs to comply with such compliance programs and rules. These
rules and regulations will continue to cause us to incur significant legal and financial compliance costs and will make some activities more time-consuming and costly.



50



---

##### Table of Contents

The U.S. health care reform law could adversely affect our business, profitability and stock price.

Comprehensive health care reform legislation has been signed into law in the United States. Although we cannot fully predict the many
ways that health care reform might affect our business, the law imposes a 2.3% excise tax on certain transactions, including many U.S. sales of medical devices, which we expect will include U.S. sales of Sequenoms systems and
consumables. This tax is scheduled to take effect in 2013. It is unclear whether and to what extent, if at all, other anticipated developments resulting from health care reform, such as an increase in the number of people with health insurance and
an increased focus on preventive medicine, may provide us additional revenue to offset this increased tax. If additional revenue does not materialize, or if our efforts to offset the excise tax through price increases, spending cuts or other actions
are unsuccessful, the increased tax burden would adversely affect our financial performance, which in turn could cause the price of our stock to decline.

*We are subject to risks associated with our foreign operations.

We expect that a
significant portion of our genetic analysis segment sales will continue to be made outside the United States. Approximately 59% of our genetic analysis segment sales were made outside of the United States during the quarter ended March 31,
2011, compared to 58% for the quarter ended March 31, 2010. A successful international effort will require us to develop relationships with international customers and collaborators, including distributors. We may not be able to identify,
attract, retain, or maintain suitable international customers or collaborators. Expansion into international markets will require us to establish and grow foreign operations, hire additional personnel to run these operations, and maintain good
relations with our foreign customers and collaborators or distributors. International operations including many of the same risks to our business that affect our domestic operations, but also involve a number of risks not typically present in
domestic operations, including:



| |  |  | currency fluctuation risks;
| | - |  | ---------------------------



| |  |  | changes in regulatory requirements;
| | - |  | -----------------------------------



| |  |  | costs and risks of deploying systems in foreign countries;
| | - |  | ----------------------------------------------------------



| |  |  | licenses, tariffs, and other trade barriers;
| | - |  | --------------------------------------------



| |  |  | political and economic instability and possible country-based boycotts;
| | - |  | -----------------------------------------------------------------------



| |  |  | difficulties in staffing and managing foreign operations;
| | - |  | ---------------------------------------------------------



| |  |  | potentially adverse tax consequences;
| | - |  | -------------------------------------



| |  |  | the burden of complying with a wide variety of complex foreign laws and treaties; or
| | - |  | ------------------------------------------------------------------------------------



| |  |  | different rules, regulations, and policies governing intellectual property protection and enforcement.
| | - |  | ------------------------------------------------------------------------------------------------------

Our international operations are also subject to the risks associated with the imposition of legislation and regulations relating to the import or export
of high technology products. We cannot predict whether tariffs or restrictions upon the importation or exportation of our products will be implemented by the United States or other countries.

If our production and laboratory facilities are damaged, our business would be seriously harmed.

Our only manufacturing facility for research use only genetic analysis products is located in San Diego, California, where we also have laboratories. Sequenom CMM also has laboratory facilities in San
Diego, California and Grand Rapids, Michigan. Damage to our facilities due to war, fire, natural disaster, power loss, communications failure, terrorism, unauthorized entry, or other events could prevent us from conducting our business for an
indefinite period, could result in a loss of important data or cause us to cease development and production of our products. We cannot be certain that our limited insurance to protect against business interruption would be adequate or would continue
to be available to us on commercially reasonable terms, or at all.

Responding to claims relating to improper handling, storage or
disposal of hazardous chemicals, and radioactive and biological materials which we use could be time consuming and costly.

We use
controlled hazardous and radioactive materials in the conduct of our business, as well as biological materials that have the potential to transmit disease. The risk of accidental contamination or injury from these materials cannot be completely
eliminated. If an accident with these substances occurs, we could be liable for any damages that result, which could seriously harm our business. Additionally, an accident could damage our research and manufacturing facilities and operations,
resulting in delays and increased costs. Such damage and any expense resulting from delays, disruptions, or any claims may not be covered by our insurance policies.

We may not have adequate insurance if we become subject to product liability or other claims.

Our business exposes us to potential product liability and other types of claims and our exposure will increase as we and Sequenom CMM and our partners and collaborators prepare to commercialize research
use only or other molecular tests, including LDTs and diagnostics for prenatal and other diseases, disorders and medical conditions. We have product and general liability insurance that covers us against specific product liability and other claims
up to an annual aggregate limit of $20.0 million and $2.0 million,



51



---

##### Table of Contents

respectively. Any claim in excess of our insurance coverage would have to be paid out of our cash reserves, which would have a detrimental effect on our financial condition. It is difficult to
determine whether we have obtained sufficient insurance to cover potential claims. Also, we cannot assure you that we can or will maintain our insurance policies on commercially acceptable terms, or at all.

The uncertainty of the current economic and political conditions could harm our revenues and operating results.

Current domestic and global economic conditions are uncertain and have continued to be volatile over the past few years. The recent turmoil in the
economic environment in many parts of the world may continue to put pressure on global economic conditions. Our revenues and operating results may be affected by uncertain or changing economic and market conditions. If global economic and market
conditions, or economic conditions in the United States or other key markets, remain uncertain or persist, spread, or deteriorate further, we may experience material impacts on our business, operating results, and financial condition.

Our stock price has been and may continue to be volatile, and your investment could suffer a decline in value.

The trading price of our common stock has been volatile and could be subject to wide fluctuations in price in response to various factors, many of which
are beyond our control, including but not limited to:



| |  |  | our ability to raise additional capital and continue as a going concern;
| | - |  | ------------------------------------------------------------------------



| |  |  | actual or anticipated variations in quarterly and annual operating results;
| | - |  | ---------------------------------------------------------------------------



| |  |  | announcements regarding technological innovations, intellectual property rights, research and development progress or setbacks, or product launches by
us or our competitors;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our success in entering into, and the success in performing under, licensing and product development and commercialization agreements with others;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the success of the validation studies for Sequenom CMMs LDTs under development and its ability to continue to publish study results in
peer-reviewed journals;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our success in and the expenses associated with researching, developing and commercializing diagnostic products, alone or in collaboration with our
partners and obtaining any required regulatory approval for those products and services;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the status of litigation against us and certain of our former executive officers and directors;
| | - |  | -----------------------------------------------------------------------------------------------



| |  |  | the dilution from the issuance of securities in connection with the settlement of litigation;
| | - |  | ---------------------------------------------------------------------------------------------



| |  |  | our ability to successfully implement the remedial measures recommended by the special committee following our independent investigation and the
effectiveness of those measures;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the status, duration, scope and outcome of the investigations by the SEC, the Office of the U.S. Attorney for the Southern District of California and
the FBI; or
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | securities analysts earnings projections or securities analysts recommendations; or general market conditions, including the recent crisis
in global financial markets.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The stock market in general, and The NASDAQ Global Market and the market for life sciences
companies in particular, have experienced extreme price and volume fluctuations that may have been unrelated or disproportionate to the operating performance of the listed companies. There have been dramatic fluctuations in the market prices of
securities of biotechnology companies. These price fluctuations may be rapid and severe and may leave investors little time to react. Broad market and industry factors may seriously harm the market price of our common stock, regardless of our
operating performance. Sharp drops in the market price of our common stock expose us to further securities class-action litigation.



|Item 5. | Other Information
|------- | -----------------

On May 3, 2011 we
entered into a License Agreement (the License Agreement) with The Chinese University of Hong Kong (the University) pursuant to which the University granted us an exclusive, worldwide (excluding Hong Kong), royalty-bearing license to use, and to
sublicense, certain intellectual property covered by patent applications owned by the University for prenatal diagnostics, prognostics, and analysis for research and commercial purposes. The License Agreement covers intellectual property rights
relating to size-based genomic analysis. Pursuant to the License Agreement we agreed to pay the University $1,500,000 within 30 days and another $1,500,000 within one year. We are obligated to pay royalties on sales of products incorporating
the licensed intellectual property and amounts we receive from any sublicensees. We are also obligated to pay additional amounts to the University upon the accomplishment of certain commercialization and development milestones. If we fail
to achieve certain commercialization and development milestones within specified timeframes, the University may terminate the License Agreement. In accordance with the



52



---

##### Table of Contents

License Agreement, the University will prosecute, defend and maintain certain patent applications relating to the licensed intellectual property at our expense. The License Agreement will
expire on the later of 20 years or the expiration of the last patent, if any patent is issued, relating to the licensed intellectual property, unless terminated earlier pursuant to the terms of the License Agreement. We may terminate the
License Agreement at any time after one year on 30 days written notice to the University.

Pursuant to the License Agreement, on May 3,
2011 we issued to the Chinese University of Hong Kong Foundation Limited (an affiliate of the University) a warrant to purchase up to 200,000 shares of our common stock at a price of $7.00 per share, the closing price of our common stock on
May 3, 2011 as reported by The Nasdaq Global Market (the Warrant). The Warrant is immediately exercisable and has a term of seven years.

We relied on the exemption from registration contained in Section 4(2) of the Securities Act, and Rule 506 of Regulation D thereunder, for the issuance of the Warrant and the shares of common stock
issuable pursuant to the Warrant (the Warrant Shares). The Chinese University of Hong Kong Foundation Limited represented that it was an accredited investor as defined in Regulation D of the Securities Act and that the Warrant
and the Warrant Shares were being acquired solely for investment for its own account and not with a view to, or for resale in connection with, any distribution thereof in violation of the Securities Act.



53



---

##### Table of Contents

|Item 6. | Exhibits
|------- | --------



|(a) | Exhibits
|--- | --------



|              |  |                                                                                                                           
|------------- |  | --------------------------------------------------------------------------------------------------------------------------
|ExhibitNumber |  | Description of Document                                                                                                   
|3.1 (1)       |  | Restated Certificate of Incorporation of the Registrant.                                                                  
|              | 
|3.2 (2)       |  | Restated Bylaws of Registrant, as amended.                                                                                
|              | 
|3.3 (3)       |  | Registrants Certificate of Designation of Series A Junior Participating Preferred Stock.                                 
|              | 
|4.1 (1)       |  | Specimen common stock certificate.                                                                                        
|              | 
|4.2 (3)       |  | Rights Agreement dated as of March 3, 2009, between the Registrant and American Stock Transfer and Trust Company, LLC.    
|              | 
|4.3 (3)       |  | Form of Right Certificate.                                                                                                
|              | 
|10.1 #        |  | New-Hire Equity Incentive Plan                                                                                            
|              | 
|10.2          |  | Employment Agreement dated October 22, 2009 between the Registrant and Dirk van den Boom, Ph.D.                           
|              | 
|31.1          |  | Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a).                          
|              | 
|31.2          |  | Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a).                      
|              | 
|32.1          |  | 18 U.S.C. Section 1350 Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|              | 
|32.2          |  | 18 U.S.C. Section 1350 Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.



|# | Management contract or compensatory plan
|- | ----------------------------------------

|(1) | Incorporated by reference to the Registrants Current Report on Form 8-K (No. 000-29101) filed June 6, 2006.
|--- | ------------------------------------------------------------------------------------------------------------

|(2) | Incorporated by reference to the Registrants Current Report on Form 8-K (No. 000-29101) filed January 15, 2010.
|--- | ----------------------------------------------------------------------------------------------------------------

|(3) | Incorporated by reference to the Registrants Current Report on Form 8-K (No. 000-29101) filed March 4, 2009.
|--- | -------------------------------------------------------------------------------------------------------------

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.



|                   |  |  |  |                |  |                        
|------------------ |  |  |  | -------------- |  | -----------------------
|                   |  |  |  | Sequenom, Inc.
|                   |  |  | 
|Dated: May 5, 2011 |  |  |  | By:            |  | /s/ PAUL V. MAIER      
|                   |  |  |  |                |  | Paul V. Maier          
|                   |  |  |  |                |  | Chief Financial Officer



54